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ABSTRACT 
Type I collagen is the predominant collagen within the stroma and plays an important role 
in the processes of tumour cell invasion and metastasis during which the collagens within 
the stroma is degraded. Total RNA was extracted from different stages of breast cancer 
and adjacent normal tissue for analysis of collagen gene expression by Northern blot 
hybridisation. Stage I breast tumours had increased al(I) and a2(1) collagen mRNA, 
whereas stages II and III tumours had decreased mRNA levels when compared to the 
adjacent normal tissue. This stage-specific change in collagen gene expression was 
confirmed by non-radioactive in situ hybridisation and the results indicated that a 1 (I) and 
a2(1) collagen mRNA was produced by the stromal fibroblasts and not the tumour cells. 
To determine whether this altered collagen gene expression was manifested in other 
cancers, a 1 (I) and a2(1) collagen mRN A· levels were analysed in colorectal carcinoma 
samples by in situ hybridisation. Colon cancer as in the case of breast cancer, also showed 
stage specific changes in collagen gene expression. Dukes C and D colon cancer samples 
had decreased collagen mRNA levels compared to Dukes A and B. Mutated Ras has bee·n 
shown to affect collagen mRNA levels in vitro (Slack et al, 1992), therefore the colon 
samples were analysed for Ras mutations in an attempt to correlate Ras mutations with the 
decreased levels of al(I) and a2(1) collagen mRNA. Co!~rectal DNA samples were 
screened for Ras mutations by SSCP and direct sequence analysis. No possible association 
was found between the presence of Ras mutations and the decreased collagen gene 
expression. 
To gain greater insight into exactly how tumour cells modulate the collagen produced by 
normal fibroblasts, primary breast fibroblasts (prepared from breast tissue) were co-
cultured with various breast tumour cell lines. The fibroblasts were also incubated with 
conditioned media prepared from the tumour cells. Collagen production was analysed 
using the collagenase assay and the results showed that co-cultured tumour cells, as well 
as growth in the presence of tumour cell conditioned media, resulted in decreased type I 
collagen production by the fibroblasts. Type III collagen is often produced in conjunction 
xiii 
with type I collagen and we have found that the breast tumour cells modulated type III 
collagen in the same way as type I collagen. These results demonstrated that a factor( s) 
was secreted by the tumour cells which affected collagen production. This factor was 
further shown to stimulate the fibroblasts to produce type I collagenase as analysis of the 
medium from co-cultured fibroblasts and tumour cells indicated the presence of 
collagenases. The tumour cell conditioned media was subsequently shown by Western blot 
analysis to contain a protein of similar molecular weight to the tumour cell derived 
collagenase stimulatory factor (known as EMMPRIN or extracellular matrix 
metalloproteinase inducer) which stimulates fibroblasts to secrete collagenases and has 
been shown to play a crucial role in tumour invasion (Biswas 1982, 1984 and Biswas et al, 
1995). 
In order to determine whether fibroblasts of different origins reacted similarity when co-
cultured with breast tumour cell lines, WI-38 lung fibroblasts and FGo skin fibroblasts 
were co-cultured with breast tumour cells. WI-38 fibroblasts responded in the same way 
as breast fibroblasts (having decreased collagen production), FGo fibroblasts had no effect 
or slightly elevated collagen production, depending on the tumour cell line. These results 
suggested that the response to tumour cells is tissue specific. 
The decrease in type I collagen produced by the fibroblasts when incubated with the 
tumour cell conditioned media was not due to a decrease in al(I) and a2(1) collagen 
mRNA as shown by Northern hybridisation. Type III collagen mRNA was affected 
differently, the levels were either decreased or increased depending on the tumour cell line 
being used. We postulate that the fibroblasts and tumour cells required contact for type I 
collagen mRNA to be decreased. Northern hybridisation showed that types I and III 
collagen mRNA levels were decreased when tumour cells were co-cultured with the 
fibroblasts. To demonstrate that specific contact was in fact required, the tumour cells 
were separated from the fibroblasts by a diffusible membrane and the levels of collagen 
mRNA were not adversely affected. 
xiv 
Tumour cells, therefore can modulate collagen production by normal fibroblasts in two 
ways I); cause the fibroblasts to secrete collagenases which will degrade the collagen and 
2); decrease collagen mRNA. Both of these mechanisms would aid the tumour in invasion 
and metastasis. 
1 
CHAPTER ONE 
INTRODUCTION 
Cancer has been described as the invasion of host tissue by a select group of tumour cells. 
In order for the tumour cells to invade host tissues, they have to cross certain extracellular 
matrix barriers of which collagen is a major component. The biosynthesis and degradation 
of collagen is extremely important during the processes of tumour cell invasion and 
metastasis, it is not yet quite sure whether it actually acts as a barrier to tumour cell 
growth or whether it facilitates the invasion. The main focus of this thesis was to examine 
changes in collagen gene expression in two types of cancers; breast and colon carcinomas. 
An in vitro system was set up to study collagen gene expression and to provide us with a 
greater understanding of the relationship between fibroblasts and epithelial cells. 
1.1 BREAST CANCER 
In most countries, the incidence of breast cancer has increased over the past twenty years 
and appears to be the most common cancer amongst women. This increase in incidence 
could be due to improved screening techniques, increased frequency of mammography, 
clinical breast examinations and general breast cancer awareness, so that previously 
undetected cancers are now registered. In the United States, 185, 700 new ~ases will be 
diagnosed in 1997 (including 1,400 among men) of which 44,560 deaths are expected 
(including 260 men) (Rennie 1996). In South Africa, 1 out of 15 white women and 1 out 
of60 black women are affected by this disease (Sitas et al,1990 and 1991). This might be 
an under-representation due to the fact that breast cancer screening is expensive and not 
affordable to all races and therefore screened mainly in the white population. Other factors 
to consider would be differences in life style, risk factors, and differences in breast cancer 
awareness between the population groups. In the United States more white women are 
also affected by this cancer than black women and it therefore appears a major affliction to 
women of affluence (Swanson et al, 1993). On the basis of incidence rates for 1983 
through 1987 and mortc1lity rates for 1987 in the United States, 12% of all women will be 
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diagnosed with breast cancer of which 3.5% will die of the disease (Harris et al, 1992). 
The incidence increases rapidly during the fourth decade and beco~es substantial before 
the age of 50, thus creating .a need for continuous screening and encouragement of all 
races to participate in breast cancer awareness. Due to the fact that the incidence of breast 
cancer is increasing world-wide, especially among postmenopausal women, it has become 
clear that extra efforts are required to obtain more information . about this disease. 
Valuable information such as the identification of family members at risk, and whether the 
risk factors are genetic or sporadic is needed in order to recommend participation in a 
screenmg program. 
1.1.1. Risk factors 
Factors that are generally agreed to increase the risk of breast cancer include early 
menarche, late menopause, late age at first pregnancy, obesity, history of benign breast 
disease, a high animal fat and protein diet, exposure to ionizing radiation,' use of oral 
contraceptives, hormone replacement therapy and a positive family history of breast 
cancer (Lynch et al, 1991; Harris et al, 1992). 
1.1.1.1 Hereditary Breast Cancer 
The greatest identified risk factor for hereditary breast cancer is having a family history of 
the disease, particularly when the diagnosis has been made in a mother or a sister at a 
young age. Those patients with hereditary breast cancer have been defined as having a 
positive family history for breast cancer, and sometimes, also of related cancers ( eg 
ovarian) and a distribution that is consistent with an autosomal dominant, highly penetrant 
cancer susceptibility factor (Lynch et al, 1991). Studies indicate that the presence ofbreast 
cancer in a first degree relative increases a women's risk of developing breast cancer by 
two or three fold (Lynch et al, 1991; Hall et al, 1990). 
Those individuals with inherited breast cancer have been shown to have mutations in the 
BRCAl breast cancer susceptibility gene, which has been localised to chromosome l 7q21 
and is thought to code for a transcription factor (Miki et al, 1994). The BRCAl protein . 
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has two ring finger domains near the NH2-terminus and an acidic COOR-terminal domain 
(Chen et al, 1995). BRCAl mutations or deletions occur in most families with multiple 
cases of both early-onset breast 3:nd ovarian cancer and about 45% of families with breast 
cancer alone (Wooster et al, 1994). BRCAl therefore appears to confer a high risk of 
early-onset breast cancer in females and does not play a role in sporadic, nonhereditary 
forms of breast cancer, which account for 95% of breast cancer cases (Vogelstein and 
Kinzler 1994). 
Another breast cancer susceptibility gene, BRCA2, has been localised to chromosome 
13q 12-13. BRCA2 confers a high risk of breast cancer alone, unlike BRCAl which 
confers a high risk to both breast and ovarian cancers (Wooster et al, 1994). Whether 
BRCA2 is involved in sporadic breast cancer still remains to be assessed. It is more than 
likely that sporadic breast cancer may involve several genes and not only one. Studies on 
LOH in sporadic breast tumours have shown loss of heterozygosity in chromosomes 1, 3, 
6, 7, 8, 9, 11, 13, 15, 16, 17, 18 and 22 (Coles et al, 1992; Osborne et al, 1991 and 
Thompson et al, 1992). This suggests that a number of tumour suppressor genes could be 
involved, for example mutations in the p53 gene have been found to occur frequently in 
sporadic breast tumours (Thompson et al, 1992; Coles et al, 1992). Several oncogenes 
such as myc, neu and int2 have also been implicated in the development of breast cancer 
(Coles et al, 1992; Tandon et al, 1989). 
1.1.2 Types of Breast Cancer 
Breast tumours are heterogenous and contain a mixture of several biologically distinct 
clones of cancer cells, each capable of self replication or clonal growth (Isaacs 1986; 
Fidler and Hart 1982). There are basically two types of breast carcinomas, those that do 
not degrade the basement membrane and do not enter the stroma, thus remaining in situ 
and those that degrade the basement membrane to enter the stroma and become invasive. 
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1.1.2.1 In Situ Carcinomas 
1.1.2.1.1 In situ Ductal Carcinomas 
In situ ductal carcinomas are classified as pre-invasive lesions with histological features of 
proliferating tumour cells within the ducts which have not invaded the surrounding stromal 
tissue (Harris et al, 1992; Radford et al, 1993). Morphologically, in situ ductal carcinomas 
have been divided into several subtypes: noncomedocarcinomas; the most common being 
cribiform (sievelike), micropapillary, solid and comedocarcinoma, although mixtures of the 
various types have been seen (Pierson and Wilkinson 1991). Comedocarcinomas are 
classified. by large pleomorphic nuclei (irregular shapes), with numerous mitotic figures 
and necrotic cellular debris in the centre of the ducts. In contrast the noncomedo subtype 
is characterised by monomorphic nuclei (of similar shapes), few if any mitoses and the 
absence of necrosis (Harris et al, 1992). The subtypes also differ according to nuclear 
grade; the comedo is a high nuclear grade (more advanced stage) and more likely to recur 
after excision than the low nuclear grade (less advacned stage) noncomedo variety. In 
addition, the comedo subtype is often associated with areas of microinvasion (Radford et 
al, 1993). The critical, but unanswered question regarding· these breast carcinomas, is 
whether they will progress to invasive cancer. In most cases a mastectomy is performed 
which results in a cure rate of 98 to 99 percent. However, it is apparently difficult to 
recommend the mastectomy as routine procedure due to the trauma involved as well as 
the expense, especially on small lesions, and . therefore more data is required about the 
tumour's invasive potential (Harris et al, 1992). 
1.1.2.1.2 In Situ Lobular Carinomas 
These lesions are characterised by a solid mass of small epithelial cells within breast 
lobules, with uniform, round-to-oval nuclei and distinct cell borders. 
1.1.2.2 Invasive Breast Carcinomas 
1.1.2.2.1 Infiltrating Ductal Carcinomas 
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Infiltrating ductal carcinomas, account for 75% of invasive breast tumours, and are the 
most common type of breast tumour. They are characterised by the absence of any specific 
histological features (Pierson and Wilkinson 1991 ). They are generally known as 
infiltrating ductal carcinomas, "not otherwise specified" or scirrhous carcinomas of the 
breast. Upon palpation they have a stony hardness and when transected are "gritty" in 
texture. The presence of excess stroma, consisting of collagen types I, III and V and 
elastin, is often detected within and around these neoplasms and is known as desmoplasia 
(Harris et al, 1992 ; Hewitt et al, 1993). 
1.1.2.2.2 Infiltrating Lobular Carcinomas 
Invasive infiltrating lobular carcinomas have been described as being distinctly linear, with 
a target-like growth pattern as well as having a desmoplastic stroma termed Indian filing 
(Pierson and Wilkinson 1991). These tumours vary in their gross appearance from being 
clinically inapparent, microscopic lesions to replacing the entire breast with a poorly 
defined, firmer lesion. The tumour may mimic inflammatory and benign disease in many 
instances. Histopathological features include charateristic small cells with rounded nuclei, 
inconspicuous nucleoli and scanty indistinct cytoplasm. There is controversy concerning 
the prognosis of infiltrating lobular carcinomas but the overall prognosis appears to be the 
same as that for infiltrating ductal carcinomas of equivalent stage (Pierson and Wilkinson 
1991). 
Infiltrating lobular carcinomas account for 5 to IO percent of breast tumours, presenting as 
an ill-defined thickening in the breast. Generally, infiltrating lobular and ductal carcinomas 
show lymph node involvement, however ductal carcinomas metastasize to bone, lung, liver 
or brain, whereas lobular carcinomas metastasize to meningeal and serosal surfaces (Harris 
et al, 1992). 
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1.2 COLORECTAL CANCER 
Cancer of the colon is a common malignant neoplasm in Western countries and is thought 
to be diet related. In the United States,· colon cancer is the second highest cause of 
mortality in men (after lung cancer) and the third highest cause in women (after lung and 
breast cancer). 133,500 new cases are expected to be diagnosed in the United States this 
year (1997) of which 54,900 will succumb to the disease (Crissman and Barwick, 1993; 
Rennie 1996). 
1.2.1 Familial Adenomatous Polyposis (FAP) 
A genetic alteration which is inherited in F AP is allelic deletion of chromosome Sq, 
encompassing the APC gene (Fearon and Vogelstein 1990). FAP is inherited as an 
autosomal dominant trait with high penetrance. It is characterised by the presence of 
thousands of adenomatous polyps in the colon by the age of 20 and if not treated will 
progress to colon cancer (Eng and Ponder 1993). FAP accounts for approximately 1% of 
colon cancers in the Western world (Peltomaki et al, 1993). A germline mutation in the 
APC gene is thought to be the first hit in the two hit hypothesis of Knudson's model (Eng 
and Ponder 1993). In some adenomas from patients with polyps, however, no allelic 
deletions of chromosome 5 have been detected, whereas the deletions were common in 
adenomas from patients without polyposis. This finding ·is not compatible with the 
Knudson model for a tumour suppressor gene which, at the cellular level, functions in a 
recessive manner so that in order for a tumour to occur, both alleles require inactivation 
(Vogelstein et al, 1988). It has been hypothesised that deletions in the APC gene induce an 
increase in proliferation leading to the fonnation of the adenoma in F AP patients. The 
mutation in one of the alleles inactivates the APC gene, causing a decrease in nonnal gene 
expression and inefficient control of cellular proliferation, even when the other allele 
remains unaffected. In some patients without F AP, the somatic loss of one allele would 
also cause nonnal epithelial cells to proliferate, providing them with a selective growth 
advantage. Inactivation of the other allele would increase the proliferative effect, but there 
is still another event which should occur to promote the transition of the abnormal 
epithelium to the adenoma and this ·event is not the loss of the wild type allele. This second 
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event is unknown, but could be a decrease in DNA methylation (Vogelstein et al, 1988; 
Eng and Ponder 1993). 
1.2.2 Hereditary Non-Polyposis Colorectal Cancer 
A second form of colon cancer that shows familial aggregation is hereditary non-polyposis 
colorectal cancer (HNPCC) which is more common than FAP, accounting for 4 to 13% of 
colon cancers (Peltomaki et al, 1993). Unlike patients with sporadic colon cancer, patients 
with HNPCC have a mean age of diagnosis of 44 years with 72% of first colon cancers 
located in the right colon (Eng and Ponder 1993). HNPCC patients are defined as 
individuals who have at least three relatives in two generations having colorectal cancer, 
with one of the relatives having been diagnosed at less than 50 years of age (Peltomaki et 
al, 1993; Eng and Ponder 1993). 
1.2.3 DNA mismatch Repair Genes in HNPCC 
Genetic linkage analysis has been performed on families with HNPCC to identify the 
existence of a familial colon cancer gene(s) responsible for this disease. Close linkage 
using microsatellite markers on chromosome 2 have been demonstrated in two large 
families (Peltomaki et al, 1993). This gene is not a typical tumour suppressor gene but is 
the human homolog of the bacterial MutS and S. cerevisiae MSH proteins, and was thus 
called hMSH2 which maps to chromosome 2p22-21, near the locus implicated in HNPCC 
(Fishel et al, 1993). 
It has therefore been suggested that hMSH2 plays a role in the development of colon 
cancer. A second mismatch repair gene (hMutL), homologous to the bacterial mismatch 
repair gene was located on chromosome 3p21.3-23 and has been identified as playing a 
role in HNPCC (Bronner et al, 1994). These two genes can therefore be used as markers 
to identify HNPCC patients (Nicolaides et al, 1994). It is also possible that other mismatch 
repair genes may be involved in HNPCC, and sporadic colon cancer. 
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1.2.4 Genetic Mutations associated with Colon Cancer 
Colon cancer has been described as a multistep process which progresses from an 
adenoma to a carcinoma and eventually metastasis occurs (Fearon and Vogelstein 1990). 
I 
Genetic alterations occur and accumulate as the tumour progresses and may be used as 
markers to identify the stage of the cancer. Four alterations have been described; first is a 
mutation on chromosome Sq causing a change in the normal epithelium, aiding its 
progression to an adenoma. Mutation of the Ki-Ras oncogene is the second known gene 
alteration, which could be the initiating event, allowing for the progression of the adenoma 
to the carcinoma stage and is therefore involved in the early stages of the disease. The 
remaining alterations occur in the tumour suppressor genes DCC and p53 which are 
associated with late adenoma and carcinoma stages respectively. The exact order of these 
mutations seems not to be the key factor, but it is the accumulation which is important 
(Fearon and Vogelstein 1990). 
1.2.4.1 Ras Gene Mutations in Colon Cancer 
The incidence of Ras mutations in colorectal cancer has been reported to be higher when 
compared to breast, stomach and bladder cancers. The reason for this is unknown but 
could be due to different pathogenic mechanisms (Bos et al, 1987). A mutation in the Ki-
Ras gen~ is an early event in the adenoma stage. The Ras family of genes consists of three 
members, Ha-Ras, Ki-Ras and N-Ras, and point mutations in these genes have been 
shown to occur in about 50% of all human malignancies (Bos et al, 1987). Mutations 
occur primarily in codons 12, 13 and 61, resulting in amino acid substitutions that reduce 
or abolish intrinsic GTPase activity (Finkelstein et al, 1993). In colon cancer, mutations in 
codon 12 of the Ki-Ras gene are more common than mutations in codons 13 and 61 (Bos 
et al, 1987). The exact role and functional significance of Ki-Ras in tumourigenesis was 
closely analysed in two human colon cancer cell lines and it was found that cells 
constitutively active for Ki-Ras were morphologically altered, lost the capacity for 
anchorage dependent growth, grew slowly in nude mice and showed reduced expression 
of c-Myc (Shirasawa et al, 1993). It was therefore concluded that activated Ki-Ras plays a 
key role in.tumourigenesis through altered cell growth and differentiation. Transfection of 
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a mutated Ras gene into nonnal cells has been shown to confer neoplastic properties 
(Barbacid 1987; Weinberg 1989; Thorgeirsson et al, 1985). Transfonnation of rat 
fibroblasts with mutant Ha-Ras VAL2 resulted in cell transformation and a reduction of the 
levels of a I (I) and a2(1) collagen mRNA of which the exact mechanism is unknown but 
has been shown to be regulated at both transcriptional and post-transcriptional levels 
(Slack et al, 1992). The AP-I site in the first intron of the a I (I) collagen gene has been 
implicated in the loss of transcription (Slack et al, 1995). The authors relate this decrease 
in gene expression to the presence of oncogen.ic Ras which would increase the metastatic 
potential of the cell. 
1.3 TUMOUR INVASION AND METASTASIS 
1.3.1 Invasion of the Extracellular Matrix 
The extracellular matrix (ECM) acts as a three-dimensional support scaffold that mediates 
cell attachment and determines tissue architecture (Liotta 1992). It also provides selective 
permeability for the transport of proteins as well as other molecules between cells, across 
blood vessel walls and during filtration of the kidney. It influences cytodifferentiation, 
mitogenesis and morphogenesis. The interstitial matrix, with stromal fibroblasts and 
myofibroblasts contains predominantly type I collagen as well as collagen typ~s II and III, 
fibronectin and specific glycoproteins and proteoglycans. The basement membrane, on the 
other hand, (which separates organ parenchyma cells from the interstitial stroma) contains 
type IV collagen, Jamin.in, entactin and BMI proteoglycan. Type V collagen has been 
identified in the basement membrane and the interstitial matrix, depending on the tissue 
type (Liotta 1992). 
During the process of invasion, the tumour cell(s) must traverse the ECM as they cross 
tissue boundaries. During the transition from in situ to invasive carcinoma, tumour cells 
penetrate the basement membranes and subsequently enter the interstitial stroma (Liotta et 
al, 1983). From the stroma, the tumour cells disseminate further by gaining access to the 
lymphatics and blood vessels. lntravasation and extravasation through the capillary walls 
require penetration of the basement membrane by the tumour cells. In the target organ, 
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where metastases are initiated, the extravasated tumour cells migrate through the 
perivascular interstitial stroma before tumour colony growth can . occur in the organ 
parenchyma. Therefore the ECM is invaded several times during metastasis (Liotta et al, 
1982 and 1983). The ability of tumour cells to invade the ECM is not unique to tumour 
cells, but also performed by normal .cells. For example, trophoblasts, invade the 
endometrial stroma and blood vessels to establish contact with the maternal circulation 
during development of the hemocorial placenta (Stetler-Stevenson et al, 1993). Similarily 
endothelial cells invade basement membranes as well as the interstitial stroma during 
angiogenesis. The main difference between normal and tumour cells is that tumour cells 
have lost control over the invasive phenotype expressed by normal cells. 
The ECM has often been described as a mechanical barrier to tumour cell invasion and the 
loss of basement membrane has become a marker for invasive carcinomas which may be 
due to decreased synthesis or assembly of secreted products (Liotta et al, 1983). Normal 
epithelial cells require a basement membrane for attachment and growth, whereas actively 
invading carcinoma cells do not have this requirement. The tumour cell must interact with 
the basement membrane at all tissue boundaries and the loss of the basement membrane 
has been depicted as a fundamental difference between malignant and benign tumours 
(Liotta et al, 1982). Tumour cell interaction with the basement membrane has been defined 
as the critical event that signals the initiation of the metastatic cascade (Stetler-Stevenson 
et al, 1993). Other lines of evidence that do not substantiate and support the fact that 
basement membrane acts as a barrier against tumour cell invasion have also been 
presented. Many invading carcinomas retain their basement membranes in both primary 
and secondary sites and the loss of the tumour basement membrane is not always 
associated with tumour invasion (Nakanishi et al, 1992). It has also been reported that in 
some tumours, the tumour basement membrane appears to mediate tumour invasion and 
metastasis where it was shown that more highly metastatic clones had a more highly 
integrated basement membrane than low metastatic cells (Nakanishi et al, 1991 and 1992). 
It was speculated that attachment of tumour cells to the vascular basement membrane 
results in intravasation (Nakanishi et al, 1992). Work done by Hewitt et al, (1994) 
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demonstrated that colorectal carcinoma metastases tended to have more continuous 
epithelial basement membranes than corresponding primary tumours and could be 
explained by local tissue environmental factors having an influence on basement membrane 
continuity. These results argue against the metastases dogma which infers that metastases 
arise preferentially from more aggressive tumour cell sub-populations, and being a 
selective process, more discontinuous basement membranes might be expected in 
secondary rather than in primary tumours. Metastases are thought to arise from more 
aggressive tumour cell populations, however, Hewitt et al, (1994) argue that resulting 
metastases tend to show a less aggressive phenotype than the primary tumour of origin. 
The authors hypothesize that epithelial basement membrane breaks are associated with 
invasive activity determined by the local tissue environment at the site of primary tumours 
and their metastases. These studies demonstrate that the function of basement membrane 
can be questioned and possibly vary from not only study to study but also from carcinoma 
type to carcinoma type. 
The exact function of tumour basement membrane, whether it aids invasion· or acts as a 
barrier, must still therefore be determined, but its importance in the processes of tumour 
cell invasion and metastasis cannot be undermined. As already mentioned most of the 
steps in the metastatic process require that the tumour cells interact with the basement 
membrane in order to invade and metastasize. A three-step hypothesis was proposed by 
Liotta and colleagues which describes the sequence of events occuring during invasion of 
the ECM; first step is attachment or adhesion of the tumour cell to the matrix; followed by 
the second step which is degradation of the matrix by tumour-cell associated proteases; 
the third step is tumour cell locomotion or motility into the region of the matrix modified 
by proteolysis (Liotta et al, 1983; Stetler-Stevenson et al, 1993). 
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1.3.1.1 Adhesion to the Matrix 
A number of specific cell-surface-associated molecules that modulate cell-matrix and cell-
cell interaction have been identified, such as the integrins, a 67 Kd laminin binding protein, 
cadherins, lg (immunoglobin) superfamily and CD44 (Stetler-Stevenson et al, 1993). 
The integrins, of which twenty have been identified so far, are a family of cell-surface 
receptors that mediate cell attachment and therefore play a role in tumourigenesis, 
invasion and metastasis. They are formed by various noncovalent associations of fourteen 
ex. and eight P subunits and were originally identified as receptors for collagens, 
fibronectin, laminin and vitronectin. There is redundancy at the level of both receptor and 
ligand because it has been found that integrin receptors can bind to more than one type of 
extracellular matrix protein and individual matrix proteins can be recognised by more than 
one integrin receptor (Stracke et al, 1996). lntegrins recognize the arginine-glycine-
aspartic acid (RGD) sequence which is the recognition site of many adhesion proteins such 
as collagen, fibronectin and thrombospondin (Vezediris 1993). Binding of some integrins 
to the ECM induces their aggregation into focal adhesions which can then activate many 
signal transduction molecules (Judware and Culp 1996). On the cytoplasmic side of focal 
adhesions, integrins combine with cytoskeletal components such as talin and vinculin 
which induces the condensation of actin into F-actin filament bundles, resulting in 
phosphorylation of both the focal adhesion kinase (FAK) and the P-subunit of the integrin. 
Intracellular pH increases due to activation of a Na+ -H+ antiport, [Ca2+] also increases and 
c-Src undergoes activation in the presence of phosphorylated F AK. Protein kinase C 
becomes activated, translocates to the cell membrane, and active NF-kB is liberated which 
translocates to the nucleus. In the nucleus NF-kB can promote transcription of many 
genes such as c-Fos, c-Jun, IL-I, MAD-6 and CSF-1 (Judware and Culp 1996). It has 
been shown that the first intron of the human ex.I collagen gene contains an AP-I motif 
which is able to bind a heterologous complex composed of members of the F os and Jun 
transcription factor families (Slack et al, 1993). In this way activation of the signal 
transduction pathway which activates NF-kB to promote transcription of Fos and Jun-
related transcription factors can modulate the collagen gene. 
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Laminin is involved in normal cell attachment, spreading, migration, tissue remodelling, 
embryogenesis as well as tumour invasion and metastases (Stracke et al, 1996). Laminin 
forms a bridge between the 67 Kd laminin receptor and type IV collagen (Liotta et al, 
1983; Liotta 1986). Breast and colon carcinomas have been found to have a large number 
of exposed laminin receptors compared to benign epithelium. The laminin receptors of 
normal epithelium may be polarised at the basal surface and occupied with laminin in the 
basement membrane. This is different to the invading tumour cells, where the receptors 
may be distributed over the entire surface and be unoccupied, due to absence of basement 
membrane (Liotta 1986; Stetler-Stevenson et al, 1993). 
Recent studies have implied an inhibitory role for cell adhesion molecules (CAMS) of the 
cadherin family. Cadherins are Ca2+ dependent CAMS that mediate cell-cell 
binding/adherence. Three sub-types (E, N and P-cadherins) have been well characterised 
and are distinguished by their tissue distribution. Other cell adhesion molecules include the 
lg superfamily members, such as N-CAM and VCAM-1, which incorporates a number of 
proteins that all share the immunoglobulin homology unit consisting of 70 to 110 amino 
acids organised into 7-9 f3-sheets. Family members include molecules involved in cellular 
immunity, signal transduction and cell adhesion, which makes the exact role of these 
molecules in tumour invasion difficult to understand. VCAM-1 (also known as INCM-
110) was identified on endothelial cells as a cytokine-inducible receptor for the VLA-4 
(a4f31) integrin. VLA.-4 is found primarily on white blood cells and functions in mediating 
leukocyte-endothelial cell attachment. Malignant melanoma cells may also express VLA-4, 
and VCAM-1 therefore may act as a tumour adhesion receptor, facilitating interaction of 
circulating melanoma cells with the endothelium in advance of tumour cell extravasation 
(Stetler-Stevenson et al, 1993; Stracke et al, 1996). Attachment to the matrix is only one 
of the qualities which a tumour cell(s) requires for tumour invasion, and tumour cells that 
are more adherent (either to a substrate or to other tumour cells) are less tumourigenic, 
less motile and less invasive. On the other hand receptor function studies ( eg, fibronectin, 
laminin) have indicated that inhibition of tumour cell adhesion to the ECM also results in 
less aggressive behaviour (Stetler-Stevenson et al, 1993; Stracke et al, 1996). 
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1.3.1.2 Proteolysis of the Extracellular Matrix 
The discovery that proteolytic enzymes play a role in tumour invasi~n and that inhibitors 
of metalloproteinases block invasion of the ECM indicated that invasion is not merely a 
passive growth process but requires active biochemical mechanisms (Liotta et al, 1983). 
The secretion of matrix metalloproteinases (MMPs) and the tissue inhibitors of matrix 
metalloproteinases (TIMPs) needs to be balanced and is not a property unique to tumour 
cells (Stetler-Stevenson et al, 1993; Liotta et al, 1982 and 1983). Proteolysis is utilised 
during trophoblast implantation, embryo morphogenesis, tissue remodelling, parasitic and 
bacterial invasion and angiogenesis (Liotta et al, 1991 ). Lysis of cell membranes is a 
tightly controlled mechanism used by tumour cells in conjunction with continued 
attachment and detachment, thus enabling the tumour cell to move. There is now 
substantial evidence that MMPs are directly involved in tumour invasion and metastasis. 
The tumour cell secretes proteolytic enzymes or factors which stimulate host cells to 
secrete these enzymes to locally degrade the matrix proteins. Degradation takes place in a 
higWy localised region close to the tumour cell surface where there is more active enzyme 
than natural protease inhibitors. Higher levels of proteolytic enzymes have been associated 
with malignant tumours when compared with normal or benign cells (Stetler-Stevenson et 
al, 1993). 
Connective tissue destruction has been described as an irreversible process, which is why 
MMP inhibitors constitute viable strategies for interfering with the processes of tumour 
invasion and metastasis. Several approaches, such as the use ofTIMPs or TIMP fragments 
as selective inhibitors of MMP activation or activity, peptide inhibitors, which mimic the 
amino terminal MMP motif and maintains the enzyme in a latent state, as well as synthetic 
compounds which compete for the substrate or bind to the active site, have been described 
(Kohn and Liotta 1995). An example of a synthetic MMP inhibitor is compound BB94 
which has been shown to be active in vitro with a 50% inhibitory concentration of 20 nM 
for stromelysin and 4 nM for gelatinase A. BB94 inhibited growth of a primary tumour, 
caused a reduction in the incidence of tumour invasion of local tissue and reduced the 
number of spontaneous metastases (Kohn and Liotta 1995). 
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1.3.1.3 Locomotion or tumour cell motility through the matrix 
Tumour cells have been found to migrate in response to a number of different stimuli, 
these include host-derived scatter factors, growth factors, components of the ECM, 
hyaluronan and tumour-secreted factors (Stracke et al, 1996). Motility stimulated by each 
of these factors can be either random (chemokinesis) or directed (chemotaxis). In the 
absence of soluble attractant, tumour cells can also migrate in a directional manner, 
towards substratum-bound, insoluble ECM proteins and this is called haptotaxis (Stracke 
et al, 1996; Stetler-Stevenson et al, 1993). Cultured human A2058 melanoma cells 
produce autocrine motility factors (AMF) which stimulate random and directed motility. 
Cells in the primary tumour may therefore secrete AMF until the concentration rises 
sufficiently to stimulate motility via receptors on the responding cells (Stetler-Stevenson et 
al, 1993). Only two growth factors, hepatocyte growth factor/scatter factor (HGF/SF) and 
insulin-like growth factor II (IGF-11) and the 125 Kd glycoprotein autoxin (ATF) have 
been purified to homogeneity and cloned. AMFs are not specific for a given type of cancer 
cell, but have a wide spectrum of activity on many types of cancer cells. Autocrine motility 
was based on the hypothesis that certain tumour cells exert autocrine control over their 
own migration, in this way AMFs would allow tumour cells to initiate, sustain and 
regulate migration of tumour cells during the processes of tumour cell invasion and 
metastasis (Stracke et al, 1996). 
Tumour cell migration in response to certain matrix proteins has been found to correlate 
with the in vivo invasive and metastatic potential of melanoma and carcinoma cell lines. 
Vitronectin, fibronectin, laminin, type I and IV collagen and thrombospondin are all 
capable of stimulating locomotion in tumour cells. ECM proteins stimulate different types 
of motility responses, depending on their mode of presentation to the cells; the response 
will be chemotaxis when they are in solution and haptotaxis when they are insoluble or 
bound to the substrate. Both types of stimulation appear to act through different cell 
surface receptors and post-receptor signal transduction pathways (Stracke et al, 1996). It 
is not clear how the stimulation of tumour cell motility by ECM proteins plays a role in 
metastasis but it has been hypothesised that during the initial phases of metastasis, 
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insoluble matrix proteins provide tumour cells with a means of activation thus allowing the 
tumour cells to track through stromal tissues and along basement membranes. Proteolytic 
enzymes (eg type IV and interstitial collagenase, cathepsin B, plasminogen activator) 
could then result in pools of soluble or partially degraded matrix proteins which could 
provide an additional chemotactic stimulus to motility (Stracke et al, 1996). 
Tumour cell locomotion is the third step in the invasion process and has been described as 
the protrusion of pseudopodia (ameboid false feet) into the zone of proteoysis, followed 
by migration of the tumour cell (Liotta 1992). The tumour has two fronts, an advancing 
one which activates enzymes and a rear one which remains attached to the ECM. Once the 
path for the tumour cell has been cleared, it advances forward. The invading tumour cell 
attaches to the matrix in the direction of movement, pulls itself forward and releases any 
attachments at the rear of the cell. Tumour cells, unlike normal cells which stop once the 
stimulus for movement has been removed, migrate and penetrate tissue barriers and only 
stop when the host dies (Liotta 1992; Weiss and Ward 1983; Vezeridis 1993; Strauli and 
Haemmerli 1984). 
Even though the three steps of tumour invasion are linked and much is known about them, 
we still do not know how each step is controlled. If the genes that control the different 
stages of tumour invasion and metastasis could be determined, this would contribute to a 
better understanding of these two processes. 
1.3.2 Metastasis 
Simplistically, metastasis is the process · by which tumour cells break away from the 
primary tumour, enter the host stroma and travel to distant sites, where secondary 
tumours are formed. Metastasis has been defined as the transfer of disease from one organ 
to another not directly connected with it (Fidler 1978). It is due to this process that 
individuals with cancer die, because in most cases by the time the cancer has been 
diagnosed, metastasis has already occurred. Early diagnosis, surgical removal, general 
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patient care, local and systemic adjuvant therapies do not prevent metastas~s from taking 
place and most cancer deaths are due to metastases that are resistant to conventional 
therapies (Fidler 1990). The major barrier or hindrance to the treatment of metastases is 
the biological heterogeneity of cancer cells in primary and secondary tumours. 
1.3.2.1 Biological Heterogeneity of Tumour Cells 
The term biological heterogeneity is used to describe cells within a tumour cell population 
where they have different cell surface receptors, enzymes, karyotypes, cell morphologies, 
growth properties, sensitivities to therapeutic agents and the ability to invade and 
metastasize (Fidler 1978). Only 0.1 % of tumours survive the metastatic process, indicating 
that metastasis is an inefficient process, carried out only by certain tumour cells which 
have the ability to do so (Fidler and Kriepe 1977). Studies on a B 16 melanoma cell line 
showed that unique metastatic tumour cells are present in the original tumour population 
and that cells of both low and high metastatic potential exist in the primary tumour. 
Nicolson and Custead (1982) showed that these metastatic properties did not arise during 
metastasis by a process of adaption to local environmental conditions. A cell that acquires 
an increased ability to survive all the facets of the metastatic process has an increased 
metastatic potential which enables that cell to "land" in organs with a suitable environment 
permitting their growth (Fidler and Kriepe 1977). It has now been established that tumour 
cell invasion and metastasis are not passive processes and a new hypothesis consisting of 
three principles has evolved which encompasses all aspects of these processess: 1) 
metastasis is not random, but selective~ 2) tumours are not uniform entities and contain 
cells with heterogeneous metastatic capabilities and 3) the outcome of metastasis depends 
on properties of tumour cells as well as host factors (Fidler and Balch 1987). 
The influence of the environment on the growth of tumour cells was originally proposed in 
Paget's "seed and soil" hypothesis (Gutman et al, 1995). Experimental data have 
subsequently shown that the organ environment can also influence tumourigenesis, 
production of degradative enzymes, angiogenic factors as well as other activities. For 
example IL-8 enhances the growth of malignant melanomas and melanoma cells growing 
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in the skin produced high levels of IL-8, whereas those in the liver expressed low levels 
(Gutman et al, 1995). This differential expression was found to be due to adaptation to the 
local organ environment and regulation by different cytokines expressed in the specific 
environment. 
The cellular heterogeneity of a tumour population is not unique to neoplastic cells. Normal 
cells and tissues are also heterogeneous for certain characteristics such as cell surface 
antigens and enzymes. Malignant cells, however, are more heterogeneous than benign or 
normal tissue. Tumour heterogeneity, therefore, is a normal characteristic and is exploited 
by tumour cells, enabling them to survive the metastatic process (Nicolson 1987). 
Phenotypic instability is a cellular phenomenon that appears to contribute to normal and 
tumour cell diversification and heterogeneity (Nicolson 1987). This property includes 
epigenetic and micro-environmental changes that can result in tumour cell diversity. The 
micro-environments of tumour cells can be a determining factor in their phenotypic 
stabilities. Differences in tissue inervation, stroma, nutrients, growth factors, oxygen; 
hormones, enzymes, inducers, ions and other tumour regulators may play roles in 
destabilising tumour cells and determining their susceptibilities to genetic and epigenetic 
changes (Nicolson 1988). The extracellular micr<:>-environment of tumours is determined 
by the matrix synthesised by normal and tumour cells. The host stromal components or 
infiltrating host fibroblasts and other cells also determine the type of tumour matrix. 
Modulation in the extracellular elements synthesised by parenchymal cells, endothelial 
cells, mesothelial cells, fibroblasts and other host cells could lead to altered gene 
expression and cell phenotype (Nicolson 1987; 1988). 
1.3.2.2 The Metastatic Process 
The metastatic process consists of a senes of sequential, interrelated steps such as 
angiogenesis, motility, invasion, survival in the circulation, adhesion, extravasation and 
proliferation (Fidler 1990; Ellis and Fidler 1995). The major steps after the initial 
transforming event are the growth of the neoplastic cells, followed by extensive 
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vascularisation caused by the synthesis and secretion of angiogenic factors which allow the 
tumour mass to exceed 2mm in diameter. The host stroma is degraded by proteolytic 
enzymes and subsequently invaded by malignant tumour cells from the primary tumour. 
The tumour cells, either as single cells or multiple cell emboli can then penetrate lymph 
nodes or blood vessels, known as intravasation. While in the circulation, the tumour cells 
must survive mechanical trauma such as blood turbulence and evade host defenses such as 
lymphocytes, complement, antibodies, natural killer cells and phagocytes. The tumour cells 
are then transported to distant sites in the body whereby those tumour cells which have 
survived in the circulation will arrest in the capillary beds of distant organs. Certain 
tumour cells exit from the capillaries, adhere to endothelial cells or exposed basement 
membranes and extravasate into the surrounding parenchyma of the tissue. These cells will 
proliferate, if the environment is suitable for their growth, thus completing the metastatic 
process (Fidler and Paste 1985; Fidler 1990). To complete the process, tumour cells 
develope a vascular network, evade the host immune system and respond to specific 
factors that influence their growth. Failure to complete any of the above steps in the 
metastatic process leads to the elimination of the desseminating tumour cell (Fidler and 
Paste 1985). 
1.3.2.2.1 Angiogenesis 
Angiogenesis is the process of generating new blood capillaries resulting in 
neovascularisation. The onset of angiogenesis permits rapid growth of a tumour 
population and is a normal process which occurs during embryonic development, 
ovulation, wound healing, and in nonmalignant diseases ( ocular neovascularisation, 
psoriasis/hypervascular skin lesions, arthritis) and cancer (Folkman 1974a; Folkman 1989; 
Folkman 1995). 
Some tumours can remain in situ for extended periods without neovascularisation and 
become vascularised by switching to an angiogenic phenotype. In the prevascular stage, 
the tumour is rarely bigger than 2-3mm and may contain a million or more cells, and can 
remain dormant but proliferate until the cells reach an equilibrium and die (Folkman 1995). 
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The switch to the angiogenic phenotype involves a change in the local equilibrium, 
whereby tumour cells may start overexpressing one or more of the positive regulators of 
angiogenesis as well as bring about down-regulation of inhibitors of angiogenesis. The 
angiogenic phenotype could then cause a benign tumour to become malignant and is 
influenced by the interaction of stimulatory and inhibitory molecules produced by the 
tumour cells as well as the organ specific enviroment (Singh et al, 1995). There are 12 
known angiogenic proteins, of which basic fibroblast growth factor (bFGF) and vascular 
permeability growth factor (VEGF) are the most common in tumours. Other factors 
include angiogenin, TGF-a. and TGF-P, TNF-a. and IL-8 (Folkman 1995). 
Thrombospondin-1, TIMP-1, 2 and 3 and angiostatin are a few examples of negative 
regulators of endothelial-cell proliferation. Removal of a primary Lewis lung carcinoma 
tumour in mice resulted in increased growth of lung metastases, and the presence of the 
primary tumour was therefore synonymous with potent anti-angiogenic activity, in the 
form of angiostatin which inhibited growth of the Lewis lung metastases (Holmgren et al, 
1995). Angiostatin is clearly a potential therapy against tumours, in fact, it has been 
systemically administered and found to inhibit growth of human breast, colon and 
prostrate cancers (O'Reilly et al, 1996). This inhibition was observed without detectable 
toxicity or resistance and the tumours were found to regress to microscopic dormant foci 
in which tumour proliferation was balanced by apoptosis · in the presence of blocked 
angiogenesis. This was the first demonstration of dormancy therapy, whereby malignant 
tumours are prevented from growing by inhibition of angiogenesis (Ellis and Fidler 1995; 
O'Reilly et al, 1996). 
1.4 COLLAGEN 
The largest group of ECM molecules is represented by the collagen family (Judware and 
Culp 1996). Collagens are large glycoproteins (about 300 Kd for the basic unit) that 
comprise 30% of the total body protein mass and their primary function is to maintain the 
three-dimensional shape of tissues. The word collagen derives from the Greek word kolla 
meaning glue and the term "glue former" was originally used in the 19th Century for the 
component in skin, bone, cartilage and tendon, which when boiled, produced glue (Weiss 
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and Ayad 1982). There are now at least 19 different collagens, and at least another 10 
have collagen-like domains (Prockop and Kivirikko 1995). Mature collagens are 
composed of three a chains that intertwine into a triple-helical conformation. 
Type I collagen, a fibrillar protein, is the most common form of collagen making up 90% 
of the total collagen found in the body. Collagenous domains (found predominantly in the 
fibrillar collagens I, II, II, V and XI) are characterised by a distinct tri-peptide repeat 
within the three a chains, Gly-X-Y, where X and Y is usually lysyl-hydroxylysine and/or 
prolyl-hydroxyproline (Prockop et al, 1979). These amino- acids allow for crosslinking 
which confers greater rigidity to the collagen fibrils and a necessary support to tissues, 
organs, tendons and ligaments (Judware and Culp 1996; Prockop and Kivirikko 1995). 
Each a chain is coiled into a left-handed helix with three amino acids per turn (Prockop et 
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al, 1979). The three helical chains are subsequently twisted into a right-handed super helix 
to form a rigid-rope like structure. The conformation of the triple helix places the amino 
acid side chain in the X- and Y- positions on the surface of the molecule, thus allowing 
collagen to polymerise (Prockop and Kivirikko 1995). 
The fibril-forming collagens have a more selective tissue distribution than the other 
collagens (Prockop and Kivirikko 1995). Type I collagen is found in most connective 
tissues, as is type III collagen, except that type III collagen is located in only the soft 
connective tissue matrix, whereras type I collagen is also found in mineralised bone 
(Prockop and Kivirikko 1995; Zhu et al, 1993). The ratio of these two collagens varies 
from tissue to tissue and also changes in various tissues during development. The ratio of 
type III collagen to type I collagen in cultured fibroblasts is roughly 1 :4 (Liau et al, 1985). 
1.4.1. Regulation of type I collagen synthesis 
Regulation of collagen production, and thus the formation of a functional collagenous 
matrix, can occur at the level of transcription, translation, or at some step prior to 
secretion (Paglia et al, 1979; Aycock et al, 1_986). 
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1.4.1.1. Transcriptional Regulation 
The transcriptional mechanisms which regulate collagen gene expression are generally 
poorly understood (Slack et al, 1993). The al and a2 collagen genes are co-ordinately 
expressed, and this is probably mediated by interactions between tightly regulated 
transcription factors and cis -acting DNA elements. The cis elements include TATA and 
CCAA T sequences and the trans-acting factors include a CCAA T box binding factor 
(CBF), which binds to both promoters and appears to be related to, or identical to, other 
CCAA T binding factors. In addition to factors which activate the collagen promoter, 
repressors also interact with them, and in the case of the a2(1) collagen promoter, there 
are overlapping binding sites for activators and repressors suggesting tight control in the 
regulation of these genes (Collins 1994). 
1.4.1.2. Regulation by Cytokines 
Fibroblasts are the predominant cells which produce type I collagen and they are 
continuously exposed to extracellular signaling molecules such as Transforming Growth 
Factor-Pl (TGF-Pl), Interleukin-I (IL-I), Tumour Necrosis Factor a (TNFa) and 
Epidermal Growth Factor (EGF). These cytokines are capable of modulating the synthesis 
of collagen by affecting mRNA synthesis, turnover or stability (Mauviel et al, 1988). It 
would appear that the actions of these cytokines are best understood in the context of a 
network, whereby the effect of one cytokine on a target tissue can be altered by the 
presence of another cytokine (Elias et al, 1990). 
In the case of TGF-P, it has been shown that TGF-P stimulates transcription of the human 
a2(I) collagen (COLIA2) promoter by increasing the affinity of an Sp I-containing protein 
complex for its cognate DNA-binding site (Inagaki et al, 1994). A TGF-P-responsive 
element (TbRE) of the COL I A2 promoter has been mapped to a 13 I hp region that 
contains at least two cis-acting elements. DNA binding assays showed that the TbRE 
contains one box (box 3A) occupied by Sp I and the other (box B) occupied by unknown 
factors(s). These results exclude a role for NF-I and implicate Spl in mediating TGF-P 
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stimulation (Inagaki et al, 1994). It is postulated that TNF-a. counteracts the TGF-P-
elicited stimulation of collagen gene expression through overlapping nuclear signaling 
pathways (Inagaki et al, 1995). The one pathway modifies the TGF-P-targeted 
transcriptional complex (possibly by decreasing its stimulatory effect on collagen gene 
expression) and the other pathway acts on the binding of the adjacent factor (possibly by 
increasing its effectiveness in repressing the activity of the collagen promoter). 
1.4.1.3. Regulation by oncogenes 
v-Src, v-Mos, c-Myc, v-Fos and Ras have all been reported to decrease transcription of 
either one or both the a.1 (I) and a.2(I) collagen genes (Slack et al, 1992). In the case of v-
Mos it was postulated that mutations in this gene may alter cellular transcription factors 
which either indirectly or directly control the expression of the collagen gene (Setoyama et 
al, 1985). These oncogenes are members of a network of cellular proteins that play a role 
in the regulation of cell growth and division in normal and neoplastic cells. Functional Ras, 
a member of this network, has been reported to be involved in Src-induced changes in 
gene expression and Src transformation (Cai et al, 1990; Nori et al, 1991 and Smith et al, 
1986). Slack et al, (1992) found that levels of both a.1(1) and a.2(I) collagen mRNAs were 
decreased in Rat 1 fibroblasts overexpressing either the N-rasLYs-Gi or the H-rasvAL-12 
oncogene. Decreased transcription began within 8 hours of Ras induction and it was 
shown for the a.1 (I) gene that the decrease was caused by a decrease in transcription as 
well as by a reduction in stability of the a. I (I) transcript. Oncogenic Ras can therefore 
regulate type I collagen at the transcriptional and post-transcriptional levels and this effect 
(at least for the a.1(1) gene) may perhaps be mediated by sequences located either within 
the body of the gene or in the distal 3 '-flanking region. It has been subsequently shown 
that Ras transformation blocks the function of an intronic AP 1 site in the a. I (I) gene 
(Slack et al, 1995). 
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1.4.1.4. Post-transcriptional Regulation 
The amount of collagen deposited in the ECM could also be regulated by enzymes that 
modify the polypeptide chains. Specific modifications of the peptides include enzymatic 
hydroxylation of certain prolyl and lysyl residues to form peptide-bound hydroxyproline 
and hydroxylysine (Paglia et al, 1979). 
Translational inhibition of procollagen mRNAs by the peptides has been shown to play a 
significant role in the control of collagen biosynthesis. The NH2 and COOH terminal 
peptides of type I procollagen were shown to specifically inhibit the synthesis of collagen 
by affecting polypeptide chain elongation or: termination or both (Aycock et al, 1986; 
Wiestner et al, 1979 and Horlein et al, 1981). This feedback inhibition by these peptides 
may play a role in vivo, but exactly how they accomplish the inhibition remains to be 
elucidated (Bornstein and Sage 1989). 
1.4.2. Degradation of Collagen 
The physical and chemical stability of the collagen triple helix depends on the hydrogen 
bonds between hydroxyproline residues and amino acids on adjacent alpha chains. Intact 
collagen is resistant to attack by most proteases except the specific collagenase. (Pauli et 
al, 1983). 
Collagenase is defined as an enzyme specifically capable of degrading either individual 
. collagen molecules in solution or insoluble collagen fibers under physiological conditions 
(Harris and Krane 1974). The molecular weight of collagenases derived from normal 
tissues range between 33,000 and 80,000 daltons (Liotta et al, 1983). Tumour-derived 
collagenases fall into the same molecular weight range and are also calcium and zinc 
· dependent. Collagenases are members of the metalloproteinase (MMP) family which have 
been found to be involved in the normal processes of tissue remodelling such as wound 
healing, trophoblast implantation and organ morphogenesis. They have also been 
implicated in disease states such as tumour invasion and metastasis, rheumatoid arthritis 
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and osteoporosis (Wilson et al, 1995; Judware and Culp 1996). More than ten MMP's 
have been classified into five major types; the interstitial collagenases, which degrade 
fibrillar collagens; gelatinase/type _IV collagenases which hydrolyse gelatin, type IV and V 
collagen; stromelysins which are active against proteoglycans, laminin, fibronectin, type IV 
collagen and telopeptides of other collagens; matrilysin and macrophage metalloelastase 
and the membrane-bound enzymes (Imai et al, 1995). 
The first vertebrate collagenase was isolated from primary cultures of tadpole tails by 
Gross et al, (1962). The enzyme w~s found to be most active at neutral and/or slightly 
alkaline pH and its activity was inhibited by metal chelating agents such as EDTA. Native 
collagen is cleaved into two :fragments of molecular weight 24,000 daltons (1/4 size) and 
71,000 daltons (3/4 size) at 25°C. These collagen products are thermally unstable and can 
denature at 3 7°C and can be degraded further into smaller :fragments by other proteinases 
such as plasmin or trypsin (Harris and Krane 1974; Liotta et al, 1982; Pauli et al, 1983). 
MMP' s have a cys sulthydryl group in their active site and are produced and secreted from 
cells as inactive zymogens (Judware and Culp 1996). The enzyme is held in an inactive 
state because of its association with zinc, which in the zymogen is associated with the cys 
SH group in the active site. Disruption of this association, probably due to limited 
proteolysis by a serine protease such as plasmin, is a possible mechanism for MMP 
activation (Judware and Culp 1996). 
Natural protease inhibitors which play a significant role in regulating the degradation of 
collagen are present in serum and in the extracellular matrix (Liotta et al, 1983). Matrix-
derived collagenase inhibitors are a family of cationic proteins found in cartilage, and have 
molecular weights between 11,000 and 40,000 daltons. Tissue-derived collagenase 
inhibitors (tissue inhibitor of metalloproteinases or TIMP) are secreted by fibroblasts, 
vascular smooth muscle cells, endothelial cells and chondrocytes (Liotta 1992). TIMPs 
produced in normal tissues, such as cartilage and bone, may guard against excessive 
breakdown of the ECM as well as protecting nerves from injury by preserving the 
·, :,; .· ·., 
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basement membrane that surrounds nerve fibres (Liotta 1992). TIMP-1 is a glycoprotein 
of about 28,500 daltons and has been shown to block the invasion of human amniotic 
membranes by B 16 melanoma cells as well as lung colonisation by the same cells (Alvarez 
et al, 1990). TIMP-2 has been shown to block the formation of new blood vessels required 
by the growing tumour cells. TIMPs have been described as metastasis suppressor 
proteins, implying that TIMP analogues may prevent tumour invasion or metastasis (Liotta 
et al, 1991; Liotta 1992). It has been suggested that a tumour cell's potential to invade the 
ECM is related to the balance between the relative activity of the collagenase and the 
collagenase inhibitor produced by the tumour and obviously a fine balance between the 
two is required (Liotta et al, 1983; Alvarez et al, 1990). 
1.5 STROMAL-EPITHELIAL INTERACTIONS AND CANCER 
Cancer is a multi-faceted disease involving many different cells and their interactions with 
each other and the surrounding environment. There are essentially four types: interactions 
by diffusible factors, cell surface interactions, matrix interactions and direct interactions 
(Haslam 1991 ). It is possible that during the process of tumour invasion, the tumour cell 
interacts with the surrounding environment in a combination of different interactions. 
Collagen is synthesised, predominantly, by fibroblasts even though some studies have 
demonstrated that type I collagen is produced by epithelial cells (Ohtani et al, 1992; Al-
Adanani et al, 197 5; Sakakibara et al, 1982; Roese! et al, 1978). As discussed above the 
· collagen produced by the fibroblasts has to be degraded for metastasis to occur, therefore 
tumour cells interfere with fibroblast function (in some unknown way) to achieve their 
ultimate goal. The connective tissue stroma can modulate epithelial cell growth in such a 
way as to prevent the tumour from growing or to bring about degradation and thus aid 
tumour cell invasion and metastases. This can be done by the secretion of soluble factors 
( either by the tumour cells or the fibroblasts) or by any of the other modes of interactions 
between host cells and the tumour cells. In desmoplasia the excess connective tissue has 
been shown to slow down tumour growth and the mechanism (ie whether the tumour cells 
or fibroblasts secrete factor(s) or whether the cells require direct interaction) is not yet 
known. The possible mechanisms are discussed below. 
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1.5.1 Modification of the ECM by soluble factors 
ECM degradation may be dependent on specific interactions between tumour and host 
cells. Tumour cells may indirectly alter the ECM by interfering with fibroblast functions by 
secreting factor(s) which stimulate(s) the fibroblasts to produce collagenases (Biswas 
1982). Co-culture of rabbit fibroblasts and mouse epithelial tumour cells resulted in 
increased collagenase production, compared to cultures of the individual cells and was 
shown to be dependent on the ratio between normal fibroblasts and tumour cells. 
Increased collagenase production was proposed to be mediated by a soluble factor 
produced by the tumour cells (Biswas 1982). Biswas (1984) and Ellis et al (1989) isolated 
and purified tumour cell-derived collagenase-stimulatory factor (TCSF) or more recently 
extracellular matrix metalloproteinase inducer (EMMPRIN) which is present on the 
surface of several human tumour cells in vitro and in vivo and stimulates production of 
interstitial collagenase in human fibroblasts (Biswas et al, 1995). TCSF was localised in 
human bladder tumours and normal urothelium, suggesting a role in tumour progression 
and invasion in vivo. TCSF was evaluated as a possible tumour marker for bladder 
tumours (Muraoka et al, 1993). Northern blot analysis demonstrated that EMMPRIN 
increases the expression of interstitial collagenase (MMP-1 ), stromelysin and 72 Kd 
gelatinase/type IV collagenase (MMP-2) indicating that this factor could enhance tumour 
invasion (Kataoka et al, 1993). EMMPRIN was also found on the surface of normal 
human keratinocytes, where it is thought to play a role in regulating stromal MMP's 
(Biswas et al, 1995). EMMPRIN has now been identified as a member of the 
immunoglobin superfamily and its sequence is identical to that of the other members of the· 
group, such as gp42 in the mouse, OX-47 or CE-9 in the rat, HT7, neurothelin or 5Al 1 
in the avian system and M6 in the human. Chinese hamster ovary cells were transfected 
with the putative cDNA for EMMPRIN and it was shown that EMMPRIN is extensively 
post-translationally processed and plays a role in tumour cell invasion and ·processes of 
tissue remodelling by regulating the production of interstitial collagenase, stromelysin-1 
and gelatinase A (Guo et al, 1997). The exact physiological role of these members of the 
immunoglobin superfamily are poorly understood and whether they all have EMMPRIN 
activity remains to be assessed. Various roles have however been postulated including cell 
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adhesion or signaling as well as a molecule that stimulates MMP synthesis (Biswas et al, 
1995; Schuster et al, 1996). The rabbit protein was investigated in detail and localised to 
the basal membranes of the tubule epithelia and the papillary surface epithelium in the 
kidney (Schuster et al, 1996). Exactly how these results demonstrate a concise and clear 
cut role for EMMPRIN is not known and whether EMMPRIN is involved in development 
or cell-cell signaling still needs to be determined. 
Other factors which are involved in stromal-epithelial interactions are hormones which 
stimulate the cells to secrete TGFP' s which may affect the regulation of growth and 
differentiation of both tumour cells and fibroblasts either positively or negatively 
(Sakakura 1991). These include TGFa., TGF-P, insulin-like growth factor (IGF), platelet-
derived growth factor (PDGF) and basic fibroblast growth factor. TGF-P is the one 
growth factor which is supposed to play an important role in controlling interactions 
between tumour cells and the surrounding mesenchyme, and can stimulate fibroblasts to 
proliferate while inhibiting the proliferation of epithelial cells (Sakakura 1991 ). TGF-P 
functions could be mediated by the extracellular matrix, for instance TGF-P increases the 
expression of type I collagen, fibronectin and tenascin (Rossi et al, 1988; Ignotz et al, 
1987). 
1.5.2 Direct interactions between fibroblasts and tumour epithelial cells 
This is classified as an interaction mediated by small signal molecules which are 
transported from the epithelium into the stroma, and/or vice versa, through the plasma 
membrane by direct contact (Sakakura 1991 ). It has been noted that cytoplasmic 
processes come from both epithelium and fibroblasts which then make direct contact by 
penetrating the other tissue throught gaps in the basal lamina. At these contact zones, the 
cell plasma membranes are 50-150 nm apart (membrane fusion has not yet been detected) 
and a band of dense material has been found beneath the contact zones. It is thought that 
these contact zones between the cells act as sites for transfer of signal molecules 
(Sakakura 1991 ). Mammary epithelial cell-fibroblast interactions were analysed by their 
response to oestrogen in vivo and cultures containing both epithelial cells and fibroblasts, 
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on exposure to oestrogen, were found to have a three-fold increase in progesterone 
receptor concentration which was associated with the presence ~f mammary stromal 
fibroblasts (Haslam 1991). In this instance, the fibroblasts secreted a ractor which affected 
the epithelial cells which facilitated oestrogen responsiveness. Fibroblasts needed to be in 
close contact with the epithelial cells to promote DNA synthesis. It has been hypothesised 
that cell-cell interactions occur via gap junctions which allow direct transfer of 
informational molecules across cell membranes by specialised channels (Haslam 1991 ). 
1.5.3 Desmoplasia 
Desmoplasia, otherwise known as increased deposition of stromal collagen is found 
around tumour cells or glands (Hewitt et al, 1993). Desmoplasia has been shown to occur 
in cancers such as diffuse infiltrative gastric carcinomas, and in infiltrating ductal 
(scirrhous) carcinomas of the breast (Ohtani et al, 1992). In the desmoplastic stroma of 
scirrhous breast carcinomas, collagen types I, III and V and elastin have all been identified, 
of which collagen type I is the most abundant (Barsky et al, 1982). A common feature of 
the desmoplastic reaction is that the fibroblasts have similar morphological features to 
smooth muscle cells and have therefore been termed myofibroblasts. These cells arise 
during injury and by producing excess collagen participate actively during tissue repair, 
suggesting that desmoplasia might represent an exaggerated response of tissue remodeling 
associated with malignancy (Haslam 1991). The cause of the desmoplastic response is not 
known and controversy exists as to whether the response is a host response to tissue 
injury, similar to wound healing, or that the response is brought about by the tumour 
stimulating the recruitment and proliferation of fibroblasts. The response can benefit the 
host by "walling off'' the tumour, thus preventing it from growing and resulting in 
necrosis. Alternatively, the response can also benefit the tumour by reducing access of 
host lymphocytes, macrophages and other immune cells, in this way protecting the tumour 
from the immune system, until it is ready to invade the host tissue (Barsky and 
Gopalakrishna 1987). To support the hypothesis that the desmoplastic response 1s a 
protective mechanism, Barsky and Gopalakrishna (1987) found that when the 
desmoplastic response was inhibited, there was an increase in spontaneous metastasis from 
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experimental murine melanomas. Studies performed on colorectal carcinomas by Hewitt et 
al (1993) showed the desmoplastic response to occur in carcinomas but absent in non-
,. 
invasive adenomas. Little evidence of a desmoplastic response was detected at the invasive 
edge of the carcinomas, where active invasion was prominent. Active collagen synthesis 
was seen in the tumour centre, whereas very little type I collagen mRNA was evident in 
host tissues ahead of the invasion front. These findings, although on the one hand 
providing evidence that desmoplasia limits tumour invasiveness, also demonstrate that the 
desmoplastic response fails to prevent the spread of colorectal cancer because of its 
absence at the invasive edge (Hewitt et al, 1993). 
Nakanishi et al, (1994) have developed a tumour cell line that secretes a factor(s) which 
causes fibroblasts to produce excess collagen which could be disadvantageous to tumour 
cells by preventing access to the vascular basement membrane, an important step in 
hematogenous metastasis. It has subsequently been found that this stroma-inducing 
tumour cell line expresses a syndecan-like proteoglycan (mouse syndecan-2) which 
exhibits specific binding to fibronectin via its heparan sulphate chains (ltano et al, 1996). 
Mouse syndecan-2 was shown to be phosphorylated at its cytoplasmic domain and was 
hypothesized to be involved in stress-fiber formation. 
It has also been suggested that the desmoplastic response, rather than inhibit invasion of 
scirrhous breast carcinomas, may facilitate their growth by acting as a means of contact 
guidance for malignant cells (Pucci Minafra et al, 1986). Luparello et al (1991) showed 
that ductal infiltrating carcinomas were characterised by the reappearance of "embryonic" 
type I-trimer collagen and an increase in type V collagen content in the matrix. These two 
collagen types were compared with type I collagen as culture substrata for the spreading, 
cytoskeletal organisation and motility of 870 I-BC breast carcinoma cells. Cells grown on 
type I- trimer were found to be motile (whereas on type I collagen, they were stationary) 
indicating that this collagen may favour penetration and scattering of neoplastic cells into 
the surrounding stroma. Type I-trimer collagen is synthesised during embryogenesis, is 
depressed in adult tissues and is restored in cancer (Luparello et al, 1991 ). The breast 
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carcinoma cell line (8701-BC) used by Luparello et al, (1991) was able to produce type I-
trimer and it was therefore hypothesized that the re-deposition of "embryonic" collagen in 
scirrhous carcinomas, produced by the carcinoma cells themselves, may be instrumental in 
providing the tumour cells with stromal pathways allowing them to infiltrate the host 
tissue by acting to guide the tumour cells by contact. This work was refuted by Hewitt et 
al (1993) when no a.1(1) collagen mRNA was detected in the vicinity of neoplastic cells 
showing invasive activity where the type I-trimer collagen was found. Hewitt et al (1993) 
state that due to the fact that collagen-I consists of2 identical a.1(1) chains linked with one 
distinct a.2(1) chain and type-I-trimer is composed of three identical a.1(1) chains, their 
probes and/or antibodr should have recognised the type-trimer molecule. 
The type I trimer found in ductal infiltrating carcinomas has been resolved into three 
distinct 100 Kd chains, where one has an unusual acidic component and the other two 
chains are basic with the same electrophoretic behaviour as a. I (Ill) and a. I (I). The 
collagen was also found to bind laminin and due to this fact as well as its presence in both 
tumour and embryonic-fetal tissues, it was re-named once-fetal laminin-binding collagen 
(OF/LB collagen). The possible presence of OF/LB collagen during development and 
cancer, and its absence in nonnal adult tissues, makes this protein a potential stromal 
marker of malignancy, and could in fact induce tumour promotion (Pucci-Minafra et al, 
1993; Van Den Hooff 1988). Sequence analysis has been perfonned on the trimer chains 
and it has been found that the acidic chain represents a gene product distinct from either 
type I, type III and other known collagen chains. The identity of the other two chains 
remains unknown (Pucci-Minafra et al, 1995). These results do not explain why this 
collagen could not be detected in the work done by Hewitt et al, 1993, taking into account 
that the polyclonal antibody used should have at least detected one basic chain that is 
similar to a.1(1) collagen chain of type I collagen. And as for the collagen mRNA which 
was not detected at the invasive front of the colorectal tumours, it is possible that trimer 
mRNA is rapidly degraded and therefore not detectable. 
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In summary fibroblasts can effect tumour cells by modifying the extracellular matrix (by 
proteolysis), by production of soluble factor(s) as well as by direct c~mtact and transfer of 
molecules via gap junctions or receptors. A combination of these different mechanisms is 
also possible. All aspects of tumour invasion and metastasis are finely balanced and events 
are appropriately timed so that in most instances the host is destroyed, the aim of all 
tumour cells. 
The aim of this thesis was to analyse the interaction between fibroblasts and tumour cells 
in vitro and in vivo and interesting and in some cases novel findings are presented. Firstly, 
fibroblasts (and not tumour cells) produce collagen, secondly; tumour cells as well as the 
tumour cell conditioned media decreased collagen production and finally tumour cells 
need to be in contact with the fibroblasts to bring about a decrease in collagen mRNA. It 
is hypothesized that a decrease in collagen mRNA and therefore collagen protein assists in 
tumour invasion along with the secretion of collagenases by facilitating mov~ment of the 
tumour cells through the ECM. 
CHAPTER TWO 
ANALYSIS OF TYPE I COLLAGEN GENE EXPRESSION IN BREAST AND 
COLORECTAL CANCER 
2.1 INTRODUCTION 
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Collagen gene expression was analysed in two types of cancers (breast and colon 
cancer), both of which are relatively common in certain areas of South Africa and 
therefore tissue is readily available. Breast cancer is a heterogeneous disease, and as 
yet no one specific gene is associated with nonhereditary ("sporadic") breast cancer. It 
is still very much a disease linked to "risk factors" such as family history, age at 
menopause, use of oral contraceptives, hormone replacement therapy and obesity 
(Harris et al, 1992). Genetic factors such as p53 mutations, overexpression or 
mutations in the Ras oncogene and nm23 have all been shown to play a role in breast 
cancer, but whether they are direct causes of the disease still remains to be assessed 
(Varley et al, 1991; Coles et al, 1992; Osborne et al, 1991; Bevilacqua et al, 1989; 
Spandidos 1987; Rochlitz et al, 1989). 
Type I collagen is the most abundant protein in the stroma, how it affects tumour cell 
invasiveness is unknown, an attempt was made in this chapter to obtain a better 
understanding of the relationship between tumour cells and collagen. Once the tumour 
cells have entered the stroma, they then have to travel to other parts of the body and 
they can do so by degrading type I collagen as well as by modulating the functions of 
fibroblasts (such as causing a shut down in mRNA production). 
Total RNA was isolated from breast tumours and the adjacent normal tissue and a 
stage-specific correlation was identified; stage I breast tumours had increased collagen 
gene expression, whereas stages II and III breast tumours had decreased expression. 
These results were confirmed by in situ hybridisation analysis. Colon cancer tissue was 
subsequently analysed in order to ascertain whether the breast cancer stage-specific 
relationship was unique to breast cancer or whether it occurred in other cancers. 
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Similarily, early stages of colon cancer were characterised by high levels of collagen 
mRNA, whereas the more advanced stages had very little collagen ~A. Due to the 
fact that mutations in the Ras oncogene have been shown to occur frequently in 
colorectal cancer and transfecting cells with mutagenic Ras have been known to cause 
decreased collagen gene expression, Ras mutations could indirectly or directly affect 
collagen gene expression in colon cancer. Therefore the colon cancer samples were 
analysed for Ras gene mutations by means of SSCP analysis and direct sequencing. 
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2.2 RESULTS 
2.2.1 Collagen mRNA in cancer tissues 
Type I collagen mRNA was quantitated by Northern blot hybridisation of RNA and 
then localised in collagen synthesising cells by non-radioactive in situ hybridisation. 
2.2.1.1 Northern Analysis 
In order to analyse the levels of collagen mRNA in breast cancer tissue, total RNA 
from breast tumour samples and the adjacent normal tissue was subjected to Northern 
blot analysis. The breast tumours in this study were obtained from the Breast Clinic at 
Groote Schuur Hospital. They were staged according to the TNM system, where T= 
tumour size; N= lymph node involvement and M= presence of distant metastases 
(Harris et al, 1992). In this study stage I tumours were< 2cm, stage II tumours were> 
2cm but < 5cm and stage III tumours were > 5cm. · The tumours were all of the 
invasive ductal type, specifically infiltrating ductal whereby tumour cells are in direct 
contact with the extracellular matrix ( consisting predominantly of type I collagen), and 
may exert an effect on the surrounding fibroblasts. Total RNA was extracted from 
each tissue sample (section 6.1 ), electrophoresed on I% agarose gels containing 8% 
formaldehyde and transferred onto nylon membranes. The membranes were first 
probed with a 32P-labelled a.I (I) collagen cDNA probe (Chu et al, 1982), stripped and 
reprobed with a 32P-labelled a.2(1) collagen probe (Meyers et al, 1981) as described in 
section 6.2. 
Analysis of a.l(I) and a.2(1) collagen mRNA in stage I breast tumours indicated an 
increase in the level of these mRNAs when compared to ·the adjacent normal tissue. f3-
actin was used as an internal control to correct for loading of RNA samples (figure 
2.1 ). From the f3-actin signal, it can be seen that equal amounts of RNA were loaded 
onto the gel and that the transfer to the nylon membrane was even. Figure 2.1 (C) and 
(D) shows the collagen signal relative to f3-actin for several stage I breast tumours .. 
Similarily, stage II breast tumours were analysed for a.1(1) and a.2(1) collagen mRNA 
as shown in figure 2.2. These results indicated that in stage II breast tumours, the 
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levels of al(I) and a2(I) collagen mRNAs were decreased relative to the adjacent 
normal tissue. 13-actin was again used in order to monitor loading of the RNA. Figure 
2.2(D) and (E) summarises the data for several stage II breast tumours relative to 13-
actin. 
RNA from stage III breast tumours was analysed in the same way for al{I) and a2(I) 
collagen mRNA (figure 2.3). As for stage II breast tumours, the stage III tumours also 
had decreased levels of al{I) and a2(I) collagen mRNA. The amount of 13-actin RNA 
between the normal and tumour samples remained relatively unchanged, indicating that 
the decrease in collagen RNA within each patient was specific and not due to 
fluctuations in total RNA. Expression of the results relative to 13-actin is shown in 
figure 2.3(D) and (E). These results indicated that the level of collagen rnRNA was 
increased in stage I breast tumours compared to the adjacent normal mRNA, whereas 
in stages II and III breast tumours there was a decrease in the level of collagen rnRNA 
when compared to the adjacent normal mRNA. 
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Analysis of collagen mRNA in stage I breast tumours and adjacent normal tissue 
Total RNA was extracted from breast tumour (T) and the adjacent normal (N) tissue 
of each patient. 5µg of RNA was resolved on a 1% agarose gel containing 8% 
formaldehyde, blotted onto nylon membranes and hybridised to 32p_Jabelled cDNA 
probes as discussed in section 6.2 of Materials and Methods. The sizes of the 
hybridising bands, in kilobases, are shown on the right. The nylon membrane was first 
hybridised with nick-translated Hf677 containing the full length a 1 (I) collagen cDNA 
probe (A), stripped and hybridised with nick-translated Hf32 containing the full length 
a2(I) collagen cDNA (B) . Both membranes were stripped and hybridised with a nick-
translated 13-actin cDNA probe. The duration of exposure to X-ray film was 18-24 
hours. The expression of a2(1) and a I (I) collagen mRN A relative to 13-actin in some 
samples are shown in (C) and (D), respectively. 
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Analysis of collagen mRNA in stage II breast tumours and adjacent normal 
tissue Total RNA was extracted from breast tumour (T) and adjacent normal (N) 
tissue of which 5 µg was resolved on a 1 % agarose gel containing 8% formaldehyde . 
The RNA was blotted onto nylon membranes and hybridised to 32P-labelled cDNA 
probes as discussed in section 6.2 of Materials and Methods. The membrane was 
hybridised with the al(I) collagen probe (A) as described in the legend to figure 2.1, 
stripped and hybridised with the a2(I) collagen probe (B) . After autoradiography, the 
filter was stripped and hybridised with the 13-actin probe. The expression of a2(I) and 
a 1 (I) collagen mRNA relative to the 13-actin signal in some samples are shown in (C) 
and (D), respectively. 
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Analysis of collagen mRNA in stage ill breast tumours and adjacent normal 
tissue Total RNA was extracted from stage III breast tumours (T) and the adjacent 
normal tissue (N). Sµg RNA was resolved on a 1% agarose gel containing 8% 
formaldehyde, blotted onto a nylon membrane and subsequently hybridised with 32P-
labelled cDNA probes (as described in section 6.2 of Materials and Methods) . (A) 
represents the membrane hybridised with the a I (I) collagen probe (Hf677), as 
described in the legend to figure 2.1, and (B) represents the a2(I) collagen probe 
(HD2). Both membranes were stripped and hybridised with a nick-translated ~-actin 
cDNA probe. The corrected results for a2(I) and al(I) collagen mRNA relative to B-
actin is shown in (C) and (D), respectively. 
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2.2.1.2 In Situ Hybridisation 
Northern blot analysis is not only limited by the problem of ~eterogenous cell 
populations in solid tumours, but also by different proportions of tumour to normal 
cells in the tissues which can cause under or over estimation of RNA transcripts. In 
situ hybridisation circumvents this problem, providing a correlation between gene 
expression and histological data. This technique allows for the direct localisation of 
specific mRNA species in tissue sections. In this study non-radioactive in situ 
hybridisation was used to identify cells specifically producing collagen mRNA. Non-
radioactive in situ hybridisation (Ohtani et al, 1992) has an advantage over radioactive 
in situ hybridisation (Hewitt et al, 1993) in that it is safer and allows morphological 
preservation of tissue structure, enabling better resolution of cell types. Radioactive in 
situ hybridisation, however is more sensitive and quantitative, in that it allows 
quantitation of radioactive "spots" compared to the non-radioactive assay which is 
based on a colour reaction. In this· study, the digoxigenin non-radioactive labelling 
system from Boehringer Mannheim was used. It has to be emphasised that non-
radioactive in situ hybridisation is not a quantitative technique,· in fact it is an empirical 
method and was used to detect the absence or presence of collagen mRNA. A positive 
signal was demonstrated by a blue-purple colour only, other colours such as a faint 
brown or green was caused by the different chemical reagents used. 
In order to confirm the stage specific collagen gene expression observed by Northern 
blot analysis (section 2.2.1.1 ), 10 tissue samples from each stage of breast tumours and 
the adjacent normals were subjected to non-radioactive in situ hybridisation (section 
6.3). In order to ascertain whether this stage specific gene expression occurred in other 
cancers, 32 colorectal carcinoma samples were also subjected to in situ hybridisation. 
All tissue sections were hybridised with digoxigenin labelled RNA probes. A 160 base 
pair XbaI-SacI fragment was released from Hf32 (c:x.2(1) cDNA) and cloned into the 
vector pGEM3. A 581 base pair EcoRI-XhoI fragment was released from Hf677 
(c:x.1(1) cDNA) and cloned into the EcoRI-Sall sites of pGEM3 (refer to Appendix A 
for cloning details). 13-actin, which had already been cloned into pGEM3, was released 
by digestion with restriction enzymes Pvull and Sall. The DNA fragments were eluted 
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from agarose gels using the Qiaex kit from Qiagen as described in section 6.3 .2. DNA 
fragments, as well as the a.2(1) and a.1(1) collagen clones (after linearisation or 
releasing of the appropriate fragment) and the vector pGEM3 were used as templates 
to transcribe digoxigenin-Iabelled RNA using T7 RNA polymerase (section 6.3). B-
actin was used as a positive control since it should be present in all cells, whereas only 
fibroblasts have been shown to produce a.I(I) and a.2(1) collagen RNA The vector 
pGEM3 was used as a negative control to ensure that the collagen signal was specific 
and not due to non-specific hybridisation. 
Figure 2.4 shows consecutive sections of a stage I tumour and its adjacent normal 
tissue probed with an a.2(1) collagen riboprobe. Sequential sections were probed with a 
B-actin riboprobe (positive control). Figures 2.4(A) and (D) were stained with 
haemotoxylin and eosin (H+E), which allows for the identification of the different cell 
types. This stain also differentiates between normal and tumour tissue. Eosin stains the 
cytoplasm pink and haemotoxylin stains the nuclei purple thus allowing the 
identification of multinucleated cells in tumours. The normal tissue, figure 2.4(A), was 
classified as histologically normal clearly depicting intact mammary ducts containing 
two different types of epithelial cells; epithelial cells on the inside of the duct and 
myoepithelial cells on the periphery. The tumour tissue, figure 2.4(D) is characterised 
by a fragmented extracellular matrix (stroma) consisting of collagen fibrils and a 
· number of fibroblasts (also present in normal tissue, but not shown here). The stroma 
also contains numerous multinucleated tumour cells. Figures 2.4(B) and (E) represent 
sections hybridised with an a.2(1) collagen riboprobe. The normal section, 2.4(B) 
shows non-specific binding of the collagen riboprobe which tended to stick to the 
edges of the epithelial cells because of the slightly greater thickness of this section. The 
majority of fibroblasts within the stroma, figure 2.4(E) surrounding the tumour cells 
were positive for a.2(1) collagen mRNA as seen by the blue staining within the 
fibroblasts (arrowheads). The tumour cells (t) on the other hand, were not positive for 
a.2(1) collagen mRNA. Figures 2.4(C) and (F) represent sections hybridised with the 8-
actin riboprobe and as can be seen, the epitheliai cells, fibroblasts (arrowheads) and 
tumour cells (t) all stained positive for 8-actin mRNA: These in situ hybridisation 
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in situ hybridisation results indicate that the staining for collagen mRNA was specific 
to the fibroblasts in the stroma and not the epithelial cells. 
Staining of consecutive sections of a stage II tumour and its adjacent normal tissue 
with H+E clearly showing fibroblasts (f) between intact collagen fibrils in the normal 
tissue (figure 2.5A). The tumour section, figure 2.5(D) contained many tumour cells 
(t) within the stroma as well as numerous fibroblasts ( of which one is shown by an 
arrow). Upon hybridisation of adjacent normal and tumour sections with an a2(I) 
collagen riboprobe the fibroblasts present in_ the normal stroma were shown to be 
positive for a2(I) collagen mRNA, whereas those fibroblasts and tumour cells p·resent 
l 
in the tumour section were negative, a negative fibroblast is indicated by an arrow 
(figures 2.58 and E respectively). Figures 2.5(C) and (F) represent adjacent normal 
and tumour sections hybridised with a B-actin probe. All cells (tumour cells and 
fibroblasts) were positive for f3-actin mRNA, indicating that those fibroblasts present in 
the tumour tissue were producing B-actin mRNA but not collagen mRNA and that the 
absence of a collagen signal in the tumour section was riot due to degradation of the 
RNA in these sections. An arrow represents one of the many fibroblasts present which 
was positive for B-actin mRNA. I. 
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FIGURE 2.4 
Collagen mRNA in a section of a stage I breast tumour and adjacent normal 
tissue. Five micron sections were cut from wax blocks using a microtome. (A) and 
(D); sections stained with haemotoxylin and eosin (H+E). (A) is characterised by 
several normal mammary ducts (nm) as well as intact collagen fibres ( cf) containing 
numerous stromal fibroblasts (f). (D) is characterised by tumour cells (t) which have 
infiltrated the stroma which also contain stromal fibroblasts (arrows). There is a blood 
capillary (be) in the left hand corner of the section. (B) and (E); sections hybridised 
with a digoxigenin-labelled a2(1) collagen riboprobe (section 6.3). The stromal 
fibroblasts stained blue-purple, (arrows) indicating a positive result for collagen 
mRNA. The tumour cells (t) in section (E) were not positive for collagen mRNA. (C) 
and (F); sections hybridised with a digoxigenin-labelled 13-actin riboprobe. The tumour 
cells (t) and stromal fibroblasts (arrows) were positive for 13-actin as detected by blue-
purple staining. Those tumour cells in section (E) which were negative for a2(1) 
collagen were clearly positive for 13-actin. Total magnification for each section was 
1 OOX except for section (E) which was 200X. These are consecutive sections and were 
cut from the same block. 
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FIGURE 2.5 
Collagen mRNA in a section of a stage II breast tumour and adjacent normal 
tissue. (A) and (D); sections stained with H+E. (A) shows intact collagen fibres (cf) 
interspersed with numerous fibroblasts (f) . The tumour cells (t) in (D) have infiltrated 
the collagen stroma and an arrow indicates one fibroblast in this section. (B) and (E); 
sections hybridised with a digoxigenin-labelled a2(1) collagen riboprobe (section 6.3). 
The normal section (B) shows a few blue-purple stained fibroblasts (f) positive for 
collagen mRNA amongst the intact collagen fibres. The fibroblasts (of which one is 
indicated with an arrow) and the tumour cells (t) in section (E) are negative for 
collagen mRNA. (C) and (F); sections hybridised with a digoxigenin-labelled 8-actin 
riboprobe. Section (C) shows fibroblasts (arrow) positive for 8-actin as indicated by 
the blue stain. Both tumour cells (t) and fibroblasts are blue-purple in the tumour 
section when hybridised with 8-actin. Total magnification for each section was 1 OOX 
except for sections (D) and (F) which were 200X. These sections are consecutive and 
were cut from the same block. 
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Haemotoxylin and eosm staining of a stage III tumour showed a stroma with 
infiltrating tumour cells (t), lymphocytes (l) and some fibroblasts (arrows) (figure 
2.6D). The normal section contained collagen fibrils and fibroblasts (f) in the stroma 
(figure 2.6A). The mammary duct (md) in figure 2.6(D) is filled with tumour cells. The 
fibroblasts (f) in the adjacent normal tissue figure 2.6(B) were positive for a2(1) 
collagen mRNA whereas those present in the tumour (arrows), figure 2.6(E), did not 
produce a2(1) collagen mRNA. The fibroblasts (arrows) and tumour cells (t) did 
produce B-actin mRNA, (figure 2.6C and F) including the fibroblasts (arrows) that did 
not produce collagen mRNA. There is clearly no staining of collagen mRNA (2 .6E) 
when compared to the signal obtained with the ~-actin probe (2.4F). The staining also 
shows definitive cells within the stroma as well as the tumour cells which cannot be 
seen in 2.6(E). 
A summary of the in situ hybridisation results is shown in Table I. The majority of 
normal fibroblasts in the tumour tissue of all 10 stage I patients were positive for a 1 (I) 
and a2(1) mRNA as compared to sections from stages II and III patients which were 
negative. 
TABLE I: Summary of the in situ hybridisation results in hr.east tumours. 
TUMOUR NO.OF COLLAGEN GENE 
STAGE PATIENTS EXPRESSION 
I 10 +++ 
II 10 + 
III 10 + 
Where intensity of signal by visualisation is shown as: 
+++ strong; + weak 
~-ACTIN GENE 
EXPRESSION 
+++ 
+++ 
+++ 
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FIGURE 2.6 
Collagen mRNA in a section of a stage ill breast tumour and adjacent normal 
tissue. (A) and (D); sections stained with H+E. Intact collagen fibres ( cf) as well as 
fragmented tissue (ft) due to processing are indicated in (A). Amongst the collagen 
fibres are several fibroblasts (f). Section (D) consists primarily of tumour cells (t) and 
lymphocytes (1) . A region of intact stroma (s) is present next to the mammary duct 
(md), which is filled with tumour cells. Several fibroblasts (arrows) occur in this 
stroma. (B) and (E); sections hybridised with a digoxigenin-labelled a2(1) collagen 
riboprobe (section 6.3) . Section (B) is characterised by blue-purple staining fibroblasts, 
(f) positive for collagen mRNA. The fibroblasts (arrows) on the periphery of the 
mammary duct filled with tumour cells in section (E) were negative for collagen 
mRNA. The tumour cells (t) in the same section were also negative. (C) and (F); 
sections were hybridised with a digoxigenin-labelled 13-actin riboprobe. Section (C) 
shows fibroblasts (f) positive for 13-actin and that the tumour cells (t) and fibroblasts 
(arrows) which were negative for collagen mRNA in section (E) do produce 13-actin 
mRNA as shown in (F) .Total magnification for each section was lOOX. These are 
consecutive sections and were cut from the same block. 
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2.2.2 Collagen Gene Expression in Colon Cancer 
Collagen mRNA levels in 32 colorectal carcinoma samples were .. analysed by non 
radioactive in situ hybridisation as described in Materials and Methods (section 6.3). In 
this study colon tumours were staged according to the Dukes system of staging (Basic 
Pathology 1992). The four main stages are described as follows: Dukes A, the 
neoplasm is located to the mucosa; Dukes B 1, the neoplasm has extended into the 
muscularis propria but has not penetrated it, lymph nodes are not involved; Dukes B2, 
the tumour has penetrated through the entire wall, but without lymph node 
involvement. In Dukes C 1 the tumour is limited to the wall with lymph node 
involvement; Dukes C2, the tumour has extended through all layers of the wall, also 
with lymph node involvement. Dukes D involves distant metastases. Consecutive 
paraffin embedded sections, consisting mostly of normal colon tissue, from each 
sample were analysed for collagen and B-actin mRNA's using digoxigenin labelled 
riboprobes as described in section 2.2.1.2. Only two Dukes A samples were available, 
and both were found to be positive for a. I (I) and a.2(1) collagen as well as B-actin 
mRNA (results not shown). 
An example of a Dukes B colon carcinoma sample is shown in figure 2. 7, stained with 
H+E. The sections consisted of a serosa containing stroma (s) in which is a 
diverticulum ( d) and an elongated blood vessel (bv) (figure 2. 7 A). The fibroblasts are 
indicated by arrowheads and are located within the stroma. Sections were hybridised to 
· an a.I (I) collagen riboprobe which produced an intense blue signal in the majority of 
fibroblasts (figure 2. 7B). The same fibroblasts were positive when the section was 
hybridised to a B-actin riboprobe (figure 2. 7C). A riboprobe was produced from the 
vector pGEM3 as a negative control and, no signal was detected, showing no non-
specific binding of the riboprobes (data not shown). The fibroblasts in Dukes B 
tumours therefore clearly were producing type I collagen mRNA. 
A Dukes C carcinoma, stained with H+E, was found to consist of a layer of muscle 
(m), called the muscularis propria, in which is situated a colon crypt (c) as indicated in 
figure 2.8(A). This layer of muscle is surrounded by the submucosa (s), which is 
interspersed with several fibroblasts, marked with arrowheads, as well as individual 
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tumour cells (t) and lymphocytes (I). The section hybridised to an a I (I) collagen 
riboprobe, produced no blue signal, indicating that the fibroblas~s present in this 
section did not produce any al(I) collagen mRNA (figure 2.8B). These fibroblasts, 
however, stained positive for B-actin (figure 2.8C) demonstrating that the fibroblasts 
were still intact and that there had been no general RNA degradation. The vector 
pGEM3 riboprobe showed negative staining, indicating no non-specific hybridisation 
(data not shown). 
Analysis of Dukes D colon carcinoma samples are shown in figure 2.9. The serosa 
consisted of fragmented collagen. fibres ( cf) as well as numerous elongated fibroblasts 
(arrowheads) and rounded darkly stained lymphocytes (I) and a blood vessel (bv) 
(figure 2.9A). This section was negative for al(I) collagen mRNA (figure 2.9B), while 
the B-actin hybridisation signal was positive (figure 2.9C). The negative control 
showed no non-specific hybridisation (data not shown). All in situ hybridisation 
analyses were also performed with the a2(I) collagen riboprobe and the results were 
identical to those shown for the al(I) collagen mRNA. 
These in situ hybridisation results suggest that although the fibroblasts were viable, 
that they no longer produced type I collagen mRNA as the tumour progressed from a 
Dukes A through to a Dukes D (Table II). This decrease in collagen mRNA could 
facilitate growth of the tumour as well as eventual metastatic spread. Possible 
mechanisms for this modulation of collagen mRNA will be discussed in chapters three 
and four. 
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Table II: Summary of the in situ hybridisation results in colorectal tumours 
TUMOUR STAGE NO.OF COLLAGEN GENE 
PATIENTS EXPRESSION 
DUKES A 2 ++ 
DUKESB 10 +++ 
DUKES C 10. + 
DUKESD 10 -
Where intensity of signal by visualisation is shown as: 
+++ strong; ++ moderate; + weak; - no signal 
2.2.3. Analysis of Ras Gene Mutations 
f3-ACTIN GENE 
EXPRESSION 
+++ 
+++ 
+++ 
+++ 
Mutations in the Ras gene are commonly associated with various cancers (Barbacid 
1.987; Forrester et al, 1987). In particular specific mutations in codons 12, 13 and 61 
have been shown to be prevalent (Bos et al, 1987). Mutations in the Ki-Ras gene have 
been found to occur in the adenoma stage of colorectal cancer patients, this mutation 
therefore could be the initiating event leading to the formation of a carcinoma (Fearon 
and Vogelstein 1990). It is also possible that the mutation in the Ras gene affects the 
synthesis of collagen mRNA in colon cancer, because cells transfected with mutagenic 
Ras have been shown to decrease collagen gene expression (Slack et al, 1992). A 
possible correlation between Ras mutations and collagen gene expression was 
subsequently addressed to ascertain whether mutations in the Ras gene could cause a 
decrease in collagen mRNA levels. 32 carcinoma samples of different stages were 
therefore analysed for Ras mutations, the breast carcinoma cell line T47D was used as 
a positive control for mutations in the Ha-Ras gene. 
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FIGURE 2.7 
Analysis of collagen mRNA in sections of a Dukes B colorectal carcinoma Section 
(A) was stained with haemotoxylin and eosin (H+E), depicting a diverticulum ( d) and 
an elongated blood vessel (bv) within the dense collagen stroma (s). There are 
numerous fibroblasts, some of which are indicated by arrows. Section (B) was 
hybridised with a digoxigenin-labelled al(I) collagen riboprobe (section 6.3) which 
bound to the fibroblasts indicating a positive result for collagen mRNA. Section (C) 
was hybridised with the digoxigenin-labelled 8-actin riboprobe (positive control) which 
bound to tumour cells and fibroblasts. All sections were photographed at a final 
magnification of 1 OOX. These are consecutive sections. 
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B 
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FIGURE 2.8 
Analysis of collagen mRNA in a Dukes C colon carcinoma by in situ 
hybridisation The H+E section (A) contains a typical colon crypt (c) within a layer of 
muscle (m), on top of which are several individual tumour cells (t), lymphocytes (I) as 
well as fibroblasts (arrowheads) . These are all contained within the submucosa layer 
(s). (B) and (C) were hybridised with the digoxigenin-labelled al(I) collagen and 13-
actin riboprobes respectively (as described in figure 2.7). The fibroblasts in section (B) 
are negative for al(I) collagen mRNA but positive for 13-actin mRNA section (C) 
indicating a specific down regulation of collagen mRNA synthesis. All sections were 
photographed at a final magnification of 1 OOX. These are consecutive sections. 
Dukes C 
' 
C 
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FIGURE 2.9 
Analysis of collagen mRNA in sections of a Dukes D colorectal carcinoma Section 
(A) stained with H+E consists of the serosa containing fragmented collagen fibres (cf), 
several lymphocytes (I) and fibroblasts (arrowheads) as well as a blood vessel (bv) . 
Section (B) was hybridised with the digoxigenin-labelled a 1 (I) collagen riboprobe 
which did not bind to the fibroblasts clearly shown in section (A) indicating that these 
fibroblasts did not produce type I collagen mRNA. The fibroblasts upon hybridisation 
with the digoxigenin-labelled f3-actin riboprobe, synthesised B-actin demonstrating that 
the down regulation of mRNA was specific for collagen (C). All sections were 
photographed at a final magnification of 1 OOX. These are consecutive sections. 
DultesD 
C 
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2.2.3.1. Ha-Ras Gene Mutations 
DNA from 32 colon carcinoma samples (these were the same samples used for in situ 
hybridisation and contained a mixture of normal and tumour cells, of which· the 
majority were normal) was extracted from paraffin-embedded sections as described in 
section 6.12.1. PCR conditions were optimised using primers flanking Ha-Ras exon 1 
and 2 (which contains codons 12 and 13). PCR fragments were amplified from 
genomic DNA in the presence of 32P-dCTP, denatured and electrophoresed on 6% 
polyacrylamide gels with or without glycerol at 4°C or room temperature (see sections 
6.12.2 and 6.12.3). All samples were subjected to all four SSCP conditions and Ha-
Ras 12/13 mutations were detected in the T47D cell line (indicated as number 1) and 
patient number 9 with both missing the top band (figure 2.1 OA). Patient numbers 34, 
44, 43, 39 and 45 were shown to lack either the top, bottom or middle bands and these 
mutations were presumed different from each other as judged from their different 
electrophoretic mobility patterns (figure 2.1 OB). No Ha-Ras 61 mutations were found 
using any of the SSC:P conditions, an example of gels electrophoresed at room 
temperature with or without 5% glycerol is shown in figure 2.11. 
DNA from those colon samples that appeared positive for Ha-Ras 12/13 mutations by 
SSCP analysis were amplified by PCR and cloned into pUC 19 for subsequent 
sequencing. PCR products were also sequenced directly as described in section 6.12.5. 
In total, 9 out of the 32 colon carcinoma samples were found to have Ha-Ras 12/13 
mutations; the breast tumour cell line T47D was found to have a mutation in codon 27 
(CAT to CAC), which does not cause an amino acid change. Five colon samples, of 
different Dukes stages, had the same mutation as T47D. Four other colon samples 
were found to have Ha-Ras mutations, 2 in codon 8 changing the amino acid valine 
(GTG) to Ieucine (TTG) and 2 having a deletion of a guanine in the intron. Due to the 
fact that the colon samples consisted of a mixture of normal and tumour cells, the 
mutations in the tumour cells were diluted and thus did not photograph well. Therefore 
the sequencing data is not shown. The data is summarised in Table III. 
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2.2.3.2. Ki-Ras Gene Mutations 
DNA from the 32 colon carcinoma samples were also used for PC~ amplification of 
the Ki-Ras exons 1 and 2 as described in section 6.12.2. Ki-Ras 12/13 mutations were 
analysed under the four different electrophoretic conditions described for Ha-Ras and 
no mutations were detected. Due to the fact that a known Ki-Ras 12/13 mutation (cell 
line MDA-l'vffi-231) did not separate under any of the conditions, other methods of 
SSCP analysis were attempted such as varymg the concentrations of 
bisacrylamide/acrylamide, longer electrophoretic times as well as "cold" or non-
isotopic SSCP analysis, based on the results of Hongyo et al, (1993) (see section 
6.12.4 of Materials and Methods). These all proved unsucessful and all samples were 
therefore subjected to direct sequence analysis. 
Of the 32 samples analysed, 10 were positive for Ki-Ras 12/13 mutations, 4 were in 
Dukes B, 4 in Dukes C and 2 in Dukes D. There were nine codon 12 mutations; four 
changed glycine (GGT) to valine (GTT), three changed glycine (GGT) to aspartate 
(GAT), o·ne altered the glycine (GGT) to alanine (GCT) and one changed glycine 
(GGT) to arginine (CGT). There was only one codon 13 change, from glycine (GGC) 
to aspartate (GAC). A summary of all these mutations is shown in Table III. 
Due to the fact that the SSCP analysis technique proved unreliable for the detection of 
codon 12/13 mutations in the Ki-Ras gene, codon 61 PCR products were also 
subjected to direct sequence analysis. PCR conditions were optimised for the primers 
flanking exon 2 of the Ki-Ras gene, as decribed in section 6.12.2, the samples were 
sequenced directly and no mutations were detected. Other mutations in the Ki-Ras 
gene were detected, for instance a mutation in codon 16 of Ki-Ras in a Dukes D colon 
sample changed serine (AGT) to arginine (CGT). This mutation has not been 
documented in the literature and is not known whether it will impair the GTPase 
activity of p21ras (Polakis and McCormick 1993; Boguski and McCormick 1993). 
There were also three mutations in the untranslated region, two occurring in Dukes C 
colon samples and one in Dukes D. These mutations consisted of a·G-C transversion, 
an A-C transversion and a GA-CC double transversion. These results are summarised 
in Table III. It is unlikely that the mutations in the untranslated region will have an 
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effect on Ras function, however, it may be possible that they affect the initiation of 
translation by altering the ribosome binding site. 
TABLE III: Ras gene mutations in colorectal tumours 
RAS CODON SAMPLE BASE AMINO ACID DUKES 
GENE NO. CHANGE CHANGE STAGE 
Ha-Ras 8 12 GTG~TTG Val~Leu C 
23 GTG~TTG " D 
27 6 CAT~CAC His~His D 
9 " " D 
34 
" " 
B 
41 
" " 
B 
55 
" " 
C 
Untranslated 4 AG - A 
region 20 I " - B 
Ki-Ras 12 8 GGT~GAT Gly~Asp C 
23 " " D 
58 
" " 
B 
25 GGT~GTT Gly~Val C 
29 
" " 
C 
44 
" " 
D 
46 
" " 
B 
17 GGT~GCT Gly~Ala C 
18 GGT~CGT Gly~Arg B 
13 32 GGC~GAC Gly~Asp B 
16 50 AGT~CGT Ser~Arg D 
Untranslated 45 G~C - D 
Region 49 I A~C C ! -
55 I GA~CC - C 
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FIGURE 2.10 
SSCP analysis of colon samples for Ha-Ras 12/13 mutations at room temperature 
(A) DNA from 14 colorectal carcinoma samples was extracted from paraffin-
embedded sections. PCR was performed using 32P-dCTP with primers for exons 1 and 
2 of Ha-Ras 12/13. The products were electrophoresed on a 6% polyacrylamide gel for 
4 hours in IX TBE at 30 watts at room temperature (see section 6.12.3). DNA from 
the tumour cell line T47D (1) and patient number 9 lack the top bands, indicated by the 
arrows. 
(B) 15 different samples, after PCR amplification and labelling with 32P-dCTP were 
electrophoresed on a 6% polyacrylarnide gel at room temperature containing 5% 
glycerol for 6 hours at 30 watts in IX TBE buffer. The dried gels were exposed for 
16-18 hours to X-ray film. Three different mutations are illustrated. Patient number 45 
misses the top band, patients 39, 43 and 44 lack the bottom band and patient number 
34 missed the middle band. All differences are indicated with arrows. (N) represents 
normal DNA and (H) (PCR water blank containing no DNA) was used as a negative 
control. 
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FIGURE2.11 
SSCP Analysis of colon samples for Ha-Ras 61 mutations at room temperature 
DNA from 14 colorectal carcinoma samples was extracted, PCR amplified with 
primers for Ha-Ras 61 (section 6.12.2) and analysed by SSCP on a 6% polyacrylamide 
gel at room temperature for 4 hours (A) or electrophoresed on a 6% gel containing 5% 
glycerol at room temperature (B), for 4-6 hours at 30 watts in IX TBE buffer (section 
6.12.3). The gels were dried and exposed to X-ray film for 16-18 hours. (H) is the 
water blank containing no DNA and (N) is normal DNA These gel conditions failed to 
detect any mutations. 
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2.3 DISCUSSION 
The stage-specific cha~ges in collagen gene expression detected in infiltrating ductal 
breast carcinoma and colorectal carcinoma are probably due to a series of events 
triggered by the onset of the invasive/metastatic process. The stimulation of collagen 
mRNA production in stage I breast tumours and Dukes A and B colon tumours can be 
explained by the desmoplastic effect (Noel et al, 1992). Desmoplasia is described as 
excess production of collagen in the stroma resulting in "hardening" and 
"encapsulation" of the tumour (Pucci Minafra et al, 1986; Basic Pathology 1992). 
There is and has been considerable controversy . as to whether the tumour cells 
themselves synthesize collagen (AI-Adnani et al, 1975; Niitsu et al, 1988) or whether 
fibroblasts around the tumour produce collagen (Ohtani et al, 1992; Barsky et al, 
1992). Yoshida et al (1989) showed that gastric carcinoma cell lines produced pro 
a.l(I) mRNA, whereas the breast and colon tumour cells analysed in our study did not 
produce collagen mRNA. Also, the in situ hybridisation results presented in this study 
clearly demonstrate that the host fibroblasts were responsible for the production of 
collagen and not the tumour cells. 
A study by Nakanishi et al (1994), using cloned mouse Lewis-lung-carcinoma-derived 
cell lines with different metastatic potential, found an inverse relationship between the 
host stromal response and spontaneous lung metastasis. The authors speculate that the 
host stromal response is disadvantageous to tumour cells by preventing their access to 
the vascular basement membrane (Nakanishi et al, 1992 and 1994). This work is in 
agreement with the results presented in this study: stage I breast tumours and Dukes A 
and B colorectal cancers synthesised increased amounts of type I collagen mRNA 
which is similar to the low-metastatic P29 tumour with high collagen protein levels. 
Similarly, stages II and III breast tumours and Dukes C and D colorectal cancers are 
can be compared with the highly metastatic Lewis carcinomas (which contained 
smaller amounts, if any, of type I collagen). Although Nakanishi et al, (1994) analysed 
collagen protein levels, whereas this study concentrated on collagen mRNA, it is 
reasonable to assume that the rnRNA levels would determine the protein content. The 
authors speculate that the host stromal response is disadvantageous to tumour cells by 
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preventing their access to the vascular basement membrane (Nakanishi et al, 1992 and 
1994). In this study, collagen mRNA was localised by in situ hybridisation to the 
.. 
fibroblasts, which is in agreement with Nakanishi et al ( 1994) where they showed that 
the cells positive for type I collagen and fibronectin were not tumour cells but host 
stromal cells, probably derived from fibroblasts. Our study found that the fibroblasts 
were present and normal in the more advanced stages of breast and colon cancers, but 
were not producing collagen, indicating that the tumour cells modulated collagen 
mRNA production. This process would allow the tumour to invade the stroma and 
metastasize. The results in this study suggest that desmoplasia correlates with early 
stages of disease (stage I for breast cancer and Dukes A and B for colorectal cancer) 
and that collagen mRNA is down regulated in the later stages which more than likely 
aids in tumour cell invasion. Hewitt et al (1993) have also reported the absence of type 
I collagen mRNA at the invasive edge of colorectal tumours, which is in agreement 
with the data presented in this chapter. They also refute the work of Luparello et al 
(1991) who found a type-I collagen trimer variant deposited close to the neoplastic 
cells and speculated that the type-I collagen trimer may provide the tumour cells with 
contact guidance for invasive spread. The in situ hybridisation analysis performed in 
this chapter showed no cx.l(I) or cx.2(I) collagen mRNA in fibroblasts in the later, more 
invasive stages of disease. 
Whether the increased collagen present in the early stages of the disease. were of 
benefit to the tumour or "protecting" the host is impossible to say, but both options are 
feasible. It is possible that desmoplasia, in certain tumours, could be part of the process 
of tumour invasion and metastasis. The exact nature of the desmoplastic response is 
still unknown, and even though studies have shown· that growth of tumour cells from 
early lesions is repressed in the presence of fibroblasts, whereas metastatic cells are 
stimulated to grow (Cami! et al, 1991 ), it is possible that tumour cells utilize the 
desmoplastic response so that they can survive and grow. It is possible that interstitial 
collagen, due to its abundance, in the early stages of disease can either protect the host 
or facilitate tumour invasion. This will depend on the tumour type (as not all. tumours 
exhibit the desmoplastic response) as well as the tumour ECM environment. In the 
more advanced stages of disease, the tumour cells may degrade the collagen by 
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producing collagenases as well as switch off collagen mRNA synthesis which facilitates 
and aids in the progression of tumour invasion and eventually metastasis. 
The decreased collagen gene expression in stage II and III breast carcinomas as well as 
the Dukes C and D colon cancers can be linked to any of the many factors involved in 
tumour cell invasion and metastasis. In order for the process of tumour invasion and 
metastasis to occur, the tumour cells must penetrate the extracellular matrix (Liotta et 
al, 1983). It is now well accepted that matrix metalloproteinases (MMPs) are 
responsible for the degradation of the ECM and thus aid in the processes of tumour 
cell invasion and metastasis. These MMPs can be secreted by the tumour cells 
themselves or can be produced by the host fibroblasts in response to factors secreted 
by the tumour cells (Liotta et al, 1983; Biswas 1984). The factors involved in 
modulating collagen production in fibroblasts (ie collagen mRNA levels), however, 
have not been identified and it is not known whether the factor(s) is secreted by the 
tumour cells, macrophages or fibroblasts themselves. This will be addressed in chapters 
three and four. 
One of the factors known to inhibit collagen gene expression is transformation of cells 
with oncogenic Ras (Slack et al, 1992). Since these tu~ours ~re all of epithelial origin, 
while the fibroblasts are normal, the effect on collagen synthesis by the fibroblasts 
would be indirect, and possibly via some signaling pathway. It has been found that 
cytoplasmic Raf and mitogen-activated protein kinases (MAPK) _differentially regulate 
a.1(1) collagen gene expression in activated stellate cells (Davis et al, 1996). A MAPK-
stimulatory signal was mapped to the most proximal NF-I and Sp-I binding domains 
of the collagen promoter whereas a Raf-inhibitory signal was mapped to a further 
upstream binding domain involving a novel 60 Kd DNA-binding protein (p60) (Davis 
. et al, 1996). Since co-culture of oncogenic Ras transformed cells with normal Rat-I 
fibroblasts results in decreased collagen synthesis in the normal cells (Geyp and Parker, 
unpublished data), it is possible that tumours containing mutant Ha-Ras may be 
indirectly responsible for the decrease in collagen mRNA detected in this chapter. 
Since colorectal cancer, shows involvement of Ki-Ras mutations as a late to middle 
event it is possible that these mutations could affect the synthesis of collagen and allow 
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progression to the invasive stage to occur. The exact reason for the mutation remains 
unknown, it could be an initiating event, allowing for the transition from adenoma to 
carcinoma, or those adenomas containing Ras mutations may be more predisposed to 
progress to carcinomas. It cannot be ruled out, however, that the mutations may just 
be coincidental. Ras mutations occur with a very low frequency in breast cancer (less 
than 10%) but overexpression of Ras has been reported as fairly common in breast 
cancer (Rochlitz et al, 1989; Going et al, 1992). If mutant Ras is indeed involved in 
invasion in colon cancer, then these results imply that a different mechanism confers 
invasive properties on the colon cancer cells. 
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CHAPTER THREE 
TUMOUR CELLS ALTER COLLAGEN PRODUCTION IN NORMAL 
FIBROBLASTS 
3.1. INTRODUCTION 
This chapter attempts to address the aberrant collagen gene expression detected in 
breast and colorectal tumours in chapter 2. Tumours are heterogeneous in nature and 
the exact mechanism(s) involved in the modulation of extracellular matrix (ECM) 
deposition is therefore not easily studied. The modulation of ECM deposition is vital 
for tumour cell invasion and metastasis and the effectors can function in a negative or 
positive manner. Negative modulation can be transcriptional, ie due to a shutdown of 
collagen gene expression, unstable mRNA, or translational inhibition of collagen 
synthesis. Alternatively the protein can be degraded which would cause a decrease in 
the amount of collagen protein. 
The degradation of the ECM is thought to lead eventually to metastasis. The exact 
mechanism for modulating the ECM may be different. for different tumour types. 
Tumour cells can secrete proteolytic enzymes to degrade the ECM directly or the 
tumour cells may induce the production of proteolytic enzymes by the surrounding 
normal cells such as macrophages, lymphocytes or fibroblasts. This interaction between 
cells could not only bring about the production of collagenases to degrade the ECM, 
but also factors which could switch off collagen gene transcription (which would aid 
the tumour in its ability to invade and metastasize). It is also possible that this process 
does not involve a single mechanism, but a combination of the above mechanisms. 
There were two major findings in chapter two; (i) increased collagen gene expression 
(desmoplasia) in the early stages of cancer and (ii) decreased collagen gene expression 
in the later stages. The aberrant collagen gene expression may be brought about by the 
tumour cells (which secrete factors) or by the fibroblasts in response to the tumour 
cells. Tumour cells have been shown to directly alter the ECM by secreting proteolytic 
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enzymes such as collagenases. In fact, Liotta et al (1979) identified a type IV 
collagenase in the culture medium of a highly metastatic murine tumour which 
preferentially digested type IV collagen in basement membranes. Few, if any, 
inflammatory cells were observed in the vicinity of the tumour and it was deduced that 
the enzyme is produced by the tumour cells themselves. Alternatively ECM modulation 
may be dependent on specific interactions between tumour and host cells. Tumour cells 
may indirectly alter the ECM by interfering with fibroblast functions by secreting 
factor(s) which stimulate(s) · the fibroblasts to produce collagenases and thus cause 
degradation of the matrix (Biswas 1982 and 1984 ). 
In order to obtain a better understanding of the way in which tumour cells modulate 
type I and III collagen synthesised by normal fibroblasts, we developed a tissue culture 
system. A normal breast fibroblast cell line was established and the influence of breast 
tumour cells on the production of collagen by fibroblasts was analysed using 
conditioned media as well as co-culture. Tumour cell conditioned media and the 
tumour cells themselves caused a decrease in the collagen produced by the fibroblasts. 
This was investigated further by attempting to look for the presence of collagenases 
within the system. A collagenase could be secreted by the tumour cells themselves or 
the tumour cells could induce the fibroblasts to produce it. The tissue culture system 
indicated that tumour cells secrete factor(s) which stimulate normal fibroblasts to 
produce collagenases. 
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3.2. RESULTS 
3.2.1. Preparation of Normal Primary Breast Fibroblasts 
Breast tissue was obtained from a 55 year old female undergoing a mastectomy at the 
Breast Clinic at Groote Schuur Hospital. The tissue was excised at a distance from the 
infiltrating ductal tumour, sliced into small pieces, placed in several 30mm petri dishes, 
covered with a coverslip (see section 6.4) and cultured in 1ml of Eagle's minimal 
essential medium supplemented with 10% fetal calf serum and antibiotics. After 3 
weeks, fibroblasts began to grow out of the tissue and gradually protruded from under 
the coverslips. After 4 weeks the coverslips were removed and the fibroblasts were 
allowed to grow to confluence at which stage they were transferred into 60mm petri 
dishes. Their morphology was similar to that of other normal fibroblasts, having 
spindle-shaped structures (figure 3.1). To ensure that the fibroblasts were in fact 
normal, they were subjected to karyotype analysis. 
3.2.1.1. Karyotype analysis of Normal Breast Fibroblasts 
The breast fibroblasts (BRF fibroblasts) were seeded onto 4 individual coverslips and 
grown to 80% confluence. They were then treated with colcimid, swollen in a 
hypotonic solution and fixed with methanol:acetic acid (3:1) (as described in section 
6.5). After the cells were air dried, the 4 coverslips were stained with Giemsa for 
conventional examination and counting of chromosomes. The chromosomes in several 
cells on all 4 coverslips were counted and found to be 46 in each case (figure 3.2). 
There were no chromosomal abnormalities and the two X chromosomes could also be 
seen. 
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FIGURE3.1 
Establishment of normal primary breast fibroblasts. Breast tissue was sliced into small 
pieces, placed in 30 mm dishes (as described in section 6.4) and covered with a 
coverslip to allow attachment of the cells. Fibroblasts eventually grew out of the tissue 
pieces, under the coverslips and were allowed to grow to con.fluency. The cells shown 
in the figure were at their 8th passage, showing spindle-shaped morphology. The cells 
were photographed at a total magnification of 1 OOX. 
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FIGURE3.2 
Karyotype analysis of breast fibroblasts. Breast fibroblasts were seeded onto coverslips 
in 30 mm dishes and allowed to grow to 80% confluence, prior to treatment with 
colcimid (see section 6.5). The cells were subsequently fixed in acetic acid:methanol 
(1:4), after which the coverslip was removed from the dish and allowed to dry. The 
coverslip was stained with Giemsa, once again allowed to dry after which the 
chromosomes were examined. These fibroblasts were characterised in their 9th passage 
and show 46 normal chromosomes. The chromosomes were shown to be intact, with 
no breaks or deletions. The two X chromosomes are indicated by arrows. 
I 
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3.2.1.2. Analysis of Breast Fibroblast Collagens 
Breast fibroblasts (6th passage) were allowed to grow to 80% confluence in 6-well (24 
mm diameter) dishes prior to the addition of 3H-proline (see section. 6.6). 3H-proline 
was used as a label, because of the high pro line content in collagen. After 16 hours the 
cells were harvested by trypsinisation and the number of cells determined in a Coulter 
Counter. Collagen was harvested from the medium, precipitated in 96% ethanol, 
washed twice with 70% ethanol, vacuum dried and digested with pepsin to remove the 
propeptides. Radioactive collagen corresponding to equal numbers of cells per sample 
was electrophoresed on 6% polyacrylamide SDS gels. The fluorogram shown in figure 
3.3 clearly shows the product of a.2(1) and a.1(1) chains of type I collagen by these 
cells. As a positive control normal WI-38 lung fibroblast cells were treated in the same 
way as the BRF fibroblasts. BRF fibroblasts produced normal type I collagen, except 
that the levels were much higher than in WI-38 fibroblasts. This could be due to the 
fact that BRF fibroblasts were used in their 6th passage, whereas WI-38 fibroblasts 
were used in their 21st passage. 
3.2.2. Modulation of Type I Collagen by Tumour Cells 
These experiments were performed in order to determine whether the tumour cells 
affected type I collagen produced by normal breast fibroblasts. The following breast 
cancer cell lines were used in this study: MCF-7 (Soule et al, 1973); IvIDA-MB-231 
(Cailleau et al, 1974); ZR-75-2 (Engel et al, 1978) and T47D (Keydar et al, 1979). 
Conditioned media were prepared from each of the breast cancer cell lines as well as 
BRF and WI-38 fibroblasts as described in section 6. 7. 
As a first step, the breast tumour cell lines were assayed to confirm that .they do not 
produce type I collagen. Cells were plated in 6-well dishes at a density of 300 000 cells 
per dish and allowed to reach confluency. 3H-proline, ascorbate and l3APN were 
added 16 hours prior to harvesting, (see section 6.6). After removal of the medium, the 
cells were harvested and counted in a Coulter Counter. Radioactively-labelled collagen 
equivalent to 1 o5 cells for each cell line was electrophoresed on a 6% polyacrylamide 
SDS gel, and the results (figure 3 .4) clearly show that the tumour cell lines used in this 
study did not produce any type I collagen. 
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The effect of tumour cells on type I collagen produced by the fibroblasts were 
investigated by two approaches: 1) the addition of tumour cell conditioned medium 
and 2) co-culture of tumour cells and normal fibroblasts. 
3.2.2.1. Conditioned Medium Experiments 
Normal breast fibroblasts were incubated with IX conditioned medium for 2 days 
before the addition of 3H-proline. The medium was harvested 16-18 hours later and 
the total collagen determined using the collagenase assay. The collagenase assay allows 
for quantitative measurement of collagen in the presence of large amounts of other 
proteins. Bacterial collagenase possesses a specificity for the amino acid sequence R-
Pro-X-Gly-Pro-, cleaving between X and Gly. This sequence is found almost 
exclusively, and with great frequency, in collagen, therefore bacterial collagenase 
cleaves collagen into acid-soluble peptides (Peterkofsky and Diegelmann 1971 ). Figure 
3.5 shows type I collagen in the medium and the cells taking into consideration the 
excess proline in collagen compared to other proteins (see section 6.8.1 in Materials 
and Methods). All the breast cancer conditioned media caused a decrease in type I 
collagen produced by the breast fibroblasts. BRF conditioned medium on BRF 
fibroblasts was used as a control. Conditioned media from MDA-MB-231, MCF-7 and 
T47D cells resulted in approximately 50% reduction of type I collagen production, 
whereas ZR-75-2 conditioned medium resulted in a smaller decrease of approximately 
20% (figure 3 .SA). These results suggested that the breast cancer cell lines -secrete a 
factor(s), such as cytokines or even collagenases, into the medium resulting in a 
reduction in the amount of collagen. Intracellular type I collagen levels varied, but the 
changes were small (by 7-10%) for all the breast cancer cell lines used (figure 3.5B). It 
is possible that a type I collagenase was responsible for the degradation of type I 
collagen in the medium. Alternatively, the breast cancer cells may secrete a factor into 
their medium which stimulates the fibroblasts to produce collagenases which degr~de 
type I collagen. Other possible explanations are that the decrease in collagen is due to a 
decrease in collagen gene transcription, decrease stability of mRNA or decreased 
translation. 
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3.2.2.2. Co-Culture Experiments 
In order to confirm the conditioned medium experiments tumour cells were co-
cultured with BRF fibroblasts, or with normal lung and skin fibrobiasts to ascertain 
whether fibroblasts from different origins responded to tumour cells in the same way. 
Equal numbers of BRF fibroblasts and tumour cells (3 0 000) were co-cultured in 24-
well dishes for 48 hours at 37°C (see section 6.8.2 in Materials and Methods). 3H-
proline, was added to the medium 16 hours prior to harvesting and total collagen was 
measured in the medium and cell fractions using the collagenase assay. 
Co-culturing ofBRF fibroblasts with the breast tumour cell lines resulted in a decrease 
(ranging between 51% and 56%) in the amount of collagen produced by the BRF 
fibroblasts, compared to when BRF fibroblasts were cultured on their own (figure 
3.6A). In each case the decrease was greater in the co-culture experiments than in the 
tumour cell conditioned medium experiments (figure 3.5). The most pronounced effect 
was observed in the tumour cell line ZR-75-2, where a decrease of 50% was observed 
in the co-culture experiments, but a decrease of only 20% in the conditioned media 
experiments. The levels of intracellular type I collagen, for all the tumour cell lines, 
was decreased or unchanged as would be expected since the collagen is secreted fairly 
rapidly into the medium (figure 3.6B). The co-culture results were in agreement with 
the conditioned medium experiments and confirmed the hypothesis that breast tumour 
cells can in fact modulate the production of type I collagen by normal breast 
fibroblasts. 
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Analysis of type I collagen in BRF and WI-38 fibroblasts. 300 000 BRF (passage 
6) and WI-38 (passage 21) fibroblasts were plated in 6-well dishes in 2ml medium and 
allowed to grow to confluence. 3H-proline was added and the cells labelled for 16 
hours. The cells were harvested by trypsinisation, counted in a Coulter Counter and 
collagen extracted from the medium. Radioactivity corresponding to 1 o5 cells was 
dried (see section 6.6), resuspended in 2X treatment buffer, denatured for 5 minutes at 
95°C and electrophoresed on a 6% polyacrylamide SOS gel for 2 hours at 100 volts. 
The gel was placed in Enhance TM solution, dried and exposed to X-ray film for 2 
days. The sizes of the protein molecular weight standards, are shown on the left. The 
a 1 (I) and a2(I) collagen chains are indicated by the arrows. The experiment was 
performed in duplicate for each cell line. 
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FIGURE3.4 
Analysis of type I collagen in Breast Tumour Cell Lines. 300 000 epithelial cells 
from the 4 breast tumour cell lines as well as normal WI-38 fibroblasts were plated in 
6-well dishes in 2ml medium as described in the legend to figure 3.3 . Radioactivity 
corresponding to 105 cells was analysed on a 6% polyacrylamide SDS gel (see section 
6.6). The gel was electrophoresed at 100 volts for 2 hours, placed in Enhance™ 
solution for 1 hour, rinsed in distilled H20 for another hour, dried at 70°C and exposed 
to X-ray film for 2 days. Lane l ; WI-38 cells, lane 2; MDA-MB-231, lane 3; MCF-7, 
lane 4; T47D and lane 5; ZR-75-2. The sizes of the protein molecular weight marker 
are indicated on the left hand side of the gel. 
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The effect of tumour cell conditioned media on type I collagen production in 
normal breast fibroblasts. Conditioned media from BRF fibroblasts and the different 
breast tumour cell lines (MDA-MB-231, MCF-7, T47D and ZR-75-2) were prepared 
as described in section 6. 7 of Materials and Methods. 500µ1 of conditioned medium 
was incubated with 40 000 BRF fibroblasts for a total of 48 hours (see section 6.8). 
Total type I collagen was determined using the collagenase assay, as described in 
section 6.9. The results are expressed as the amount of type I collagen upon incubation 
of BRF fibroblasts in BRF conditioned medium as 100%. The conditioned media 
experiments were performed in triplicate. Values · indicate means and standard 
deviations. (A) represents the amount of type I collagen harvested from the medium 
and (B) within the cells. 
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FIGURE 3.6 
Type I collagen production in Breast fibroblasts co-cultured with Breast tumour cells. 30 
000 breast tumour cells (MDA-IvIB-231, MCF-7, T47D or ZR-75-2) and 30 000 
normal breast fibroblasts were co-cultured for 2 days in 24 well dishes in 500µ1 
medium (see section 6.8.2) and labelled for 16 hours with 3H-proline, p~or to 
quantitation of type I collagen using the collagenase assay (see section 6.9). 30 000 
BRF fibroblasts incubated on their own were set as a 100%. Values indicate means and 
standard deviations. (A) represents the amount of type I collagen harvested from the 
medium and (B) within the cells. 
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The co-culture experiments were repeated with the normal embryonic lung fibroblast 
cell line (WI-38) or a skin fibroblast cell line (FGo) in order to detern:iine whether skin, 
lung and breast fibroblasts respond in the same way (figure 3.7). 30 000 cells of each 
cell type were co-cultured in 24-well dishes for 48 hours, as described ·for BRF 
fibroblasts. WI-38 fibroblasts in monoculture was used as a control. Co-culture with all 
the tumour cell lines caused a decrease in the amount of collagen produced by WI-38 
fibroblasts (figure 3. 7(A)), whereas when co-culturing the tumour cells with normal 
skin fibroblasts (FGo's) a different response was observed (figure 3.7(B)). The tumour 
cell line MDA-MB-231 had no effect on type I collagen by skin fibroblasts, whereas 
co-culture with MCF-7, T47D and ZR-75-2 actually resulted in increased type I 
collagen (45%, 12% and 23% respectively). These results are in agreement with 
studies by Noel et al (1992~ 1993) and also suggest that fibroblasts of different origins 
do not respond in the same manner. 
3.2.2.3. EfTect of Tumour Cells on Type m Collagen 
Type III collagen is often produced in conjunction with type I collagen, and in order to 
ascertain whether the effect was specific for type I collagen, samples were analysed for 
type III collagen on SDS polyacrylamide gels containing 10% P-mercaptoethanol (see 
section 6.6 in Materials and Methods). Type III collagen in WI-38 fibroblasts 
incubated with tumour cell conditioned media (MDA-MB-231, MCF-7 and ZR-75-2) 
were also decreased when compared to the fibroblasts incubated with .WI-38 
conditioned medium (figure 3.8(A)). Type III collagen from fibroblasts incubated with 
MDA-MB-231 conditioned medium was decreased by 95%, MCF-7 by 75% and ZR-
75-2 by 69% (figure 3.8(B)). There clearly was no change in the proportion ·of type I 
to type III collagen. These results show that when WI-38 fibroblasts were incubated 
with tumour cell conditioned media there was a decrease in the levels of both types I 
and III collagens. 
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Type I collagen production in lung and skin fibroblasts co-cultured with breast tumour 
cells. Equal numbers (30 000) of the breast tumour cells MDA-MB-231, MCF-7, 
T47D or ZR-75-2 were incubated with normal WI-38 lung :fibroblasts (A) or normal 
FGo skin fibroblasts (B) for 2 days at 37°C and labelled ~ith 3H-proline for 16 hours 
prior to performing the collagenase assay (see section 6.9 of Materials and Methods). 
WI-38 or FGo fibroblasts incubated on their own were set as 100%. All experiments 
were performed in triplicate. Values are the means and standard deviations.· 
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FIGURE 3.8 
Analysis of Type ID Collagen in WI-38 fibroblasts after incubation with. tumour 
cell conditioned media. 300 000 WI-38 fibroblasts were grown to confluence in 6-
well dishes . Tumour cell conditioned media was added 32 hours prior to the addition 
of 3H-pr6line, ~APN and ascorbate (see section 6.6). After labelling for a further 16 
hours, the collagen was harvested from the medium, the cells counted and radioactivity 
corresponding to 105 cells was electrophoresed on a 6% polyacrylamide SDS gel 
containing 10% ~-mercaptoethanol (section 6.6). (A), lane 1; cells labelled in WI-38 
conditioned medium, lanes 2, 3 and 4, cells labelled in MDA-MB-231 , MCF-7 and ZR-
75-2 tumour cell conditioned media respectively. The top band represents type III 
collagen and the lower bands are the al(I) and a2(I) chains of type I collagen. The 
intensity of the bands were determined by densitometric scanning and the type III 
collagen in the tumour cell conditioned media was expressed as a % of the type III 
collagen in cells grown in WI-38 conditioned medium (B). 
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3.2.3. Tumour cell conditioned media contains collagenase stimulatory activity 
The tumour cell conditioned medium on its own and after incubation with normal 
breast or lung fibroblasts was analysed for type I collagenase activity. The medium was 
also analysed by Western blotting for the presence of the tumour cell collagenase 
stimulatory factor (TCSF/EMMPRIN) which has been shown to stimulate interstitial 
collagenase (Biswas 1984). 
3.2.3.1. Detection of collagenase activity 
Type I collagen was extracted from WI-38 cells after labelling with 3H-proline (see 
section 6.6). 10 000 dpm of labelled collagen substrate was incubated overnight at 
25°C with the different tumour cell conditioned media. After digestion, the products 
were analysed on SDS polyacrylamide gels (section 6.6). The tumour cell conditioned 
media (figure 3.9) did not contain any collagenase activity, as was also the case with 
the BRF fibroblast conditioned medium. The positive control was completely digested 
; 
by the bacterial collagenase. Densitometric analysis of the fluorogram showed slight 
decreases in the intensity of the bands, but these·decreases were not significant. 
The tumour cell conditioned media clearly did not contain any collagenase activity 
(figure 3. 9) but it is possible that collagenase activity can be induced in normal 
fibroblasts. The breast fibroblasts were therefore incubated in tumour cell conditioned 
medium for 48 hours before the assay in order to determine whether the tumour cell 
conditioned media could induce collagenase production by the fibroblasts (section 
6.10). The results in figure 3. IO clearly show that tumour cell conditioned medium was 
capable of inducing collagenase activity in breast fibroblasts. ZR-75-2 tumour cells 
caused the highest stimulation of collagenase as can be seen from the total absence of 
collagen after the incubation period, whereas MCF-7 tumour cells caused the least 
stimulation. The 83 Kd and 27 Kd digested fragments of type I collagen were not 
detected, possibly due to further degradation by other proteolytic activities ( eg 
gelatinase). The same results were obtained with WI-38 fibroblasts (data not shown). 
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3.2.3.2. Identification of the collagenase stimulatory factor 
In an attempt to identify the factor secreted by the tumour cells, the tumour cell 
conditioned medium was subjected to Western blot analysis using the tumour cell 
collagenase stimulatory factor (TCSF) mouse antibody (see section 6.11 of Materials 
and Methods). This antibody was kindly provided by Professor Toole (Tufts 
University, Boston, Massachusetts). 20µ1 tumour cell conditioned media from MDA-
:MB-231, MCF-7, T47D, ZR-75-2, BE and Ht-29 tumour cell lines (see section 3.22 
and 6. 7) were electrophoresed on a 10% polyacrylamide SOS gel for 1 hour. The 
proteins were electroblotted onto Hybond C membranes (Amersham), · blocked 
overnight, hybridised with the TCSF antibody as described in section 6. 7 of Materials 
and Methods. A specific protein band of approximately 66 Kd, (figure 3 .11) which is in 
agreement with the size of TCSF, was detected in the tumour cell conditioned media 
which suggested that the factor which stimulates collagenase in this system could very 
well be the TCSF discovered and isolated by Biswas and colleagues (Biswas 1982, 
1984; Ellis et al, 1989). 
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FIGURE3.9 
Absence of collagenase activity in tumour cell conditioned media. (A) 3H-labelled 
type I collagen (10 000 dpm) was incubated with the indicated tumour cell conditioned 
media at 25°C for 16 hours (see section 6.10), after which the samples were 
electrophoresed on a 6% polyacrylamide SDS gel at 150 volts for 2 hours. The gel was 
soaked in Enhance™ for 1 hour, rinsed in distilled H20 for another hour and exposed 
to X-ray film for 2 days. Lane l; undigested collagen, lane 2; collagen digested with 2 
units of bacterial collagenase, lane 3; collagen digested with breast fibroblast 
conditioned medium, lanes 4, 5, 6 and 7; collagen digested with MDA-MB-231 , MCF-
7, T47D and ZR-75-2 tumour cell conditioned media respectively. The sizes of the 
protein molecular weight markers are indicated on the left hand side of the gel. (B) 
shows the densitometric analysis of the gel in (A). 
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FIGURE3.10 
Stimulation of collagenase activity in breast fibroblasts by tumour cell 
conditioned media. (A) Tumour cell conditioned media was incubated with normal 
breast fibroblasts for 48 hours, and incubated with 10 000 dpm 3H-labelled collagen at 
25°C for 16 hours (section 6.10). Samples were analysed on a 6% polyacrylamide SDS 
gels and processed as described in the legend to figure 3. 9. Lane 1; undigested 
collagen, lane 2; collagen digested with 2 units of bacterial collagenase, lane 3; 
collagen digested with BRF fibroblast conditioned medium, lanes 4, 5, 6 and 7; 
collagen digested with MDA-MB-231 , MCF-7, T47D and ZR-75-2 respectively. The 
sizes of the protein marker is shown on the left hand side of the gel. The gels were 
scanned densitometrically and the results are shown in (B). 
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4 5 6 
Detection of a Tumour Cell Collagenase Stimulatory Factor. Tumour cell 
conditioned media was electrophoresed on a 10% polyacrylamide SDS gel for 1 hour, 
electroblotted and hybridised to the TCSF antibody as described in section 6.11 of 
Materials and Methods. Lanes 1, 2, 3, 4, 5 and 6; tumour cell conditioned media from 
the tumour cell lines: MDA-I\.1B-231, MCF-7, T47D, ZR-75-2, BE and Ht-29 
respectively. A 66 Kd sized protein is shown which is of similar size to the 
TCSF/EM1\.1PRIN. Protein molecular markers are shown on the left hand size of the 
gel. 
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3.3 DISCUSSION 
The studies described in this chapter analysed the relationship between normal 
fibroblasts and breast tumour cells. Specifically, whether tumour cells can modulate the 
production of collagen in fibroblasts, and also whether this modulation is unique to 
breast fibroblasts. In attempting to analyse the complex relationship between tumour 
cells and host fibroblasts, we developed a normal breast fibroblast cell line which 
would be more appropriate than using fibroblasts of another origin. Primary breast 
fibroblast cultures were established and shown to be normal by karyotype analysis 
which was necessary because the tissue had been obtained from a ductal infiltrating 
carcinoma, excised at a distance from the tumour which consisted predominantly of 
fatty tissue. These fibroblasts were shown to produce type I collagen consisting of 
al (I) and a.2(1) collagen chains, in contrast to the breast tumour cells which did not 
produce any type I collagen. 
It is uncertain why the particular breast cancer cells used in this study did not produce 
oncofetal/laminin binding (OF/LB) collagen, it might be due to the environment from 
which the tumour cells were originally excised. If the breast tumour cells (MDA-MB-
231, ZR-75-2, T47D and MCF-7) did produce OF/LB collagen, our gel systems 
should have identified it because our system is the same as that utilised by Pucci-
Minafra et al, {1993). The human breast carcinoma cell line (8701-BC) that produces 
OF/LB collagen was derived from a primary infiltrating ductal carcinoma, unlike the 
breast carcinoma cell lines utilised in this study where the epithelial cells were obtained 
from either ascite fluids or pleural effusions (Minafra et al, 1995; Soule et al, 1973 and 
Cailleau et al, 1974). This demonstrates the importance of variations in tissue culture 
systems and also questions the exact nature of the breast cancer cell line 8701-BC as to 
whether it is epithelial or perhaps it is a transformed fibroblast cell line. The fact that 
none of the epithelial cells (normal and tumour) in the in situ hybridisation studies 
( chapter two) produced type I collagen mRNA would substantiate the theory that 
epithelial cells are not meant to produce collagen and it is possible that when they are 
cultured in vitro, genes become switched on which in vivo are actually not activated. 
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Both the co-culture and conditioned media experiments showed that tumour cells were 
able to inhibit type I collagen in normal fibroblasts. One of the explanations, for the 
decrease in collagen, is that the tumour cells secrete a collagena·se or induce the 
secretion of collagenases by fibroblasts. The stimulation of fibroblasts to produce 
collagenases by secreted tumour factors was initially demonstrated by Bauer et al 
(1979) and then by Biswas (1982; 1984). Ellis et al, 1989 called their factor the 
Tumour Cell Collagenase Stimulatory Factor which is now termed EMMPRIN 
(Biswas et al, 1995). 
Tumour cell conditioned media incubated with breast fibroblasts generally caused a 
reduction in type I collagen in the medium. However, a larger decrease was observed 
when ZR-75-2 cells were in direct contact with breast fibroblasts, unlike the other 
tumour cell lines which did not require such interaction. This suggested that different 
tumour cells modulate collagen synthesis via different mechanisms, with some 
requiring direct interaction with fibroblasts for any significant effect to be achieved. 
Co-culture experiments with the lung fibroblast cell line (Wl-38) and the different 
tumour cell lines yielded results similar to those obtained with BRF fibroblasts. 
Tumour cell conditioned media incubated with WI-38 fibroblasts also resulted in a 
significant reduction in type III collagen levels. This was not totally unexpected since 
these two collagens are co-ordinately expressed as well as co-ordinately regulated in 
many cells (Noel et al, 1992). 
In the FGo skin fibroblast cell line, however, co-culture of the MCF-7, T47D or ZR-
75-2 tumour cell lines caused an increase in collagen synthesis, whereas MDA-MA-
231 had no effect. These results are in agreement with those published by Noel et al, 
(1992 and 1993) who used the same cell lines to show that the stimulation in collagen 
synthesis was not related to the fibroblast proliferation rate and that the ·levels of 
steady-state collagen mRNA paralled that of the protein. The fact that fibroblasts of 
lung and breast origin were responsive to the tumour cells and produce collagenase, 
whereas skin fibroblasts were not, is in agreement with the work done by Biswas 
(1982) who showed that certain mouse fibroblasts are refractory to stimulatory agents 
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to produce collagenase and therefore cannot respond to the tumour cells . as other 
fibroblasts ( of rabbit and rat origin). These results indicate that "responsive" fibroblasts 
may not necessarily be species specific but tissue specific. 
The intricate relationship between normal fibroblasts and breast tumour cells was 
assessed in order to gain better insight into the complicated process of tumourigenesis. 
In vivo studies, discussed in chapter two, demonstrated that cancer growth or 
progression is associated with decreased collagen gene expression. An in vitro system 
was therefore developed which allowed analysis of collagen by breast fibroblasts co-
cultured with tumour cells. None of the tumour cells or tumour cell conditioned media 
resulted in an increase in collagen synthesis by breast fibroblasts ( correlating with 
desmoplasia), an increase in collagen was only detected when skin fibroblasts (FGo's) 
were used, but the reason for this is unknown at this stage. The decrease in collagen 
· types I and III (by conditioned medium and in the co-culture system) was thus shown 
to be due to induction of collagenase production by the fibroblasts and not because of 
increased secretion of collagenases by the tumour cells. It is possible that the decrease 
in collagen could be contributed to by a decrease in collagen mRNA, this is further 
investigated in chapter four. 
CHAPTER FOUR 
_TUMOUR CELLS CAN MODULA TE TYPE I AND III COLLAGEN mRNA IN 
NORMAL FIBROBLASTS 
4.1 INTRODUCTION 
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Investigation into the interaction between normal breast fibroblasts and tumour cells, 
showed that tumour cells, either in co-culture with fibroblasts or by the addition of tumour 
cell conditioned media to normal fibroblasts, caused a decrease in collagen by the 
fibroblasts. Chapter three showed that nonnal fibroblasts were stimulated to secrete 
collagenases which resulted in degradation of collagen. It is also possible that the breast 
tumour cells, used in this study, also secrete the tumour cell collagenase stimulatory factor 
(TCSF or now tenned EMMPRIN) into their medium, which upregulates the expression 
of the collagenase gene which then secretes excess collagenases to degrade the collagen 
(Prescott et al, 1989; Biswas et al, 1995). It has been postulated that EMMPRIN is an 
important regulator of tissue destruction during tumour cell invasion of the ECM (Biswas 
et al, 1995). What is not known is whether EMMPRIN affects the collagen gene itself 
causing a decrease in collagen mRNA levels which would also explain the decreased 
collagen synthesis. Understanding the modulation of collagen gene expression during the 
process of tumour cell invasion and metastasis would provide new insights into these 
complex processes. In situ hybridisation analysis ( chapter two) suggested that the 
fibroblasts most affected during tumourigenesis were those in the vicinity of the tumour 
cells, whether fibroblasts have to be in physical contact with each other or whether factors 
are secreted which affect the collagen gene are discussed in this chapter. · 
The in vitro system established in our laboratory enabled us to investigate the levels of 
type I and III collagen mRNA when nonnal fibroblasts were incubated with tumour cells 
as well as with tumour cell conditioned media. When tumour cell conditioned media was 
added to the fibroblasts, type I collagen mRNA was shown to be increased or unaffected, 
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whereas type III collagen was either decreased or slightly increased. When the cells were 
co-cultured, both types I and III collagen mRNAs were decreased. This demonstrated that 
either the fibroblasts and the tumour cells required direct interaction ·in order to exert an 
. . 
effect on collagen mRNA or the "factor" that affected the collagen gene was lost during 
the preparation of the tumour cell conditioned media. To further analyse this "factor" the 
tumour cells and fibroblasts were cultured in the same medium but separated by a 
membrane to prevent direct interaction between the cells but still allowing for the 
exchange of any factors. In most cases types I and III collagen mRNA levels were 
unaffected, demonstrating that tumour cells require direct contact with the fibroblasts in 
order to affect collagen mRNA. 
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4.2RESULTS 
4.2.1 The Effect of Tumour Cells on Collagen Gene Expression in·Normal fibroblasts 
The modulation of collagen synthesis in BRF and WI-38 fibroblasts could involve a 
transcriptional mechanism, as there are many factors, such as cytokines, which are known 
to affect collagen gene expression. TGF-f3 l is known to stimulate the production of 
collagen mRNA in cultured fibroblasts, whereas tumour necrosis factor-a (TNF-a.) 
decreases the level of a.l(I) collagen mRNA (Bornstein and Sage 1989). The question 
was presented as to whether tumour cells. either indirectly (by secreting factors into the 
medium) or directly (being in contact with fibroblasts) modulate collagen mRNA 
production by normal fibroblasts. MDA-MB-231, MCF-7 and ZR-75-2 breast cancer cell 
lines, normal lung fibroblasts (WI-38), and the colorectal cancer cell lines BE and HT-29 
were used to prepare conditioned media as described in section 6. 7. 
The modulation of collagen mRNA by tumour cells was analysed using three approaches: 
I) conditioned media, 2) co-culture experiments and 3) culturing the cells in the same 
medium but separating them by a permeable membrane. 
4.2.1.1. The effect of tumour cell conditioned media on type I and ID collagen 
mRNA 
Monolayer cultures containing breast or WI-38 fibroblasts (2XI06 cells/lOOmm dish) were 
incubated with conditioned medium for 48 hours, followed by extraction of the RNA (see 
section 6.1.2). 5µg of total RNA was electrophoresed on a 1% agarose gel containing 8% 
formaldehyde, transferred to nylon membranes and hybridised with a mixture of either 32P-
labelled a2(I), al(I) or al(III) collagen (Hf 934, Chu et al, 1985) and f3-actin cDNA 
probes. Breast or Wl-38 fibroblasts cultured in fibroblast conditioned medium was used as 
a control. The addition of MDA-MB-231 and ZR-75-2 tumour cell media resulted in a 
45% and by 55% increase in a2(I) collagen mRNA, while no effect was observed with 
MCF-7 conditioned medium (figure 4.lA). Type III collagen was found to be affected 
differently, MDA-MB-231 conditioned medium caused a decrease of 16%, ZR-75-2 
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conditioned medium a 31% decrease whereas MCF-7 increased cxl(III) collagen mRNA 
by 14% (figure 4. IB). The membranes were scanned densitometricall_y using ~-actin as the 
internal standard and the results for type I and III collagen are shown in figure 4. IC and D 
respectively. 
This increase in type I collagen mRNA in the conditioned media experiments 1s m 
contradiction to the decrease observed at the protein level (chapter three). A possible 
explanation for this observation include the existence of a positive feedback loop whereby 
the synthesis of collagen mRNA is stimulated in response to the decrease in protein. As to 
why type III collagen mRNA is not affected in the same way as type I collagen mRNA is 
not easily addressed. These two interstitial collagens are often regulated in the same way 
for many different diseases (eg breast cancer, specifically desmoplasia) although they are 
situated on two different genes (Vuorio and de Crombrugghe 1990). 
4.2.1.2. The effect of tumour cells on types I and ID collagen mRNA production in 
normal fibroblasts 
Tumour cell conditioned medium was shown to increase or have no effect on collagen 
gene expression (section 4.2.1.1) whilst the level of collagen protein produced by the 
fibroblasts incubated with the tumour cell conditioned media was decreased ( chapter 
three). It is possible that the fibroblasts require contact with the tumour cells for the levels 
of collagen mRNA to be decreased and therefore WI-38 fibroblasts were co-cultured with 
breast or colon tumour cells. After 48 hours the cells were harvested for RNA extraction 
as described in section 6.1.2 of Materials and Methods. Sµg of total RNA was 
electrophoresed on an 1 % agarose gel containing 8% fonnaldehyde, transferred to a nylon 
membrane and hybridised with all three collagen probes as well as ~-actin. WI-38 
fibroblasts incubated on their own was used as a control and as can be seen the a.2(1) 
collagen mRNA was decreased when co-cultured with MDA-MB-231, MCF-7, T47D, 
ZR-75-2, BE and HT-29 tumour cell lines (decreases of 80%, 52%, 66%, 75%, 78% and 
60% respectively) whereas co-cultured with the normal breast epithelial cell line (MCF-
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I2F) did not change the levels of type I or type III collagen mRNA (figure 4.2A). Type III 
collagen mRNA was also found to be decreased; MDA-MB-23 I (75%), MCF-7 (66%), 
T47D (63%), ZR-75-2 (75%), BE (75%) and HT-29 (33%) in line with the decreases 
observed for type I collagen mRNA (figure 4.2B). The levels of J3-actin rnRNA, remained 
unchanged, demonstrating that that the effect was specific for collagen. All northern blots 
were hybridised with an cx.I(I) collagen cDNA probe and the same results were found as 
that for cx.2(1) collagen mRNA (data not shown). 
These results showed that the tumour cells either needed to be in direct contact with the 
fibroblasts for collagen mRNA to be decreased, or that the "factor" that affected collagen 
gene expression was lost during preparation of the conditioned media. 
4.2.1.3. Search for a diffusible factor affecting types I and ID collagen gene 
expression 
In order to investigate whether tumour cells required specific contact with the fibroblasts 
to modulate collagen gene expression, Transwell dishes (Costar) were used. These dishes 
allowed the cells to share the same medium without actually being in contact with each 
other. 300 000 WI-38 fibroblasts were plated in the dish and 300 000 tumour cells were 
plated on top of the fibroblasts on a permeable membrane in the same well, so that the 
tumour cells were not in physical contact with the fibroblasts. After 48 hours, the 
fibroblasts were washed ·with PBS and the RNA extracted as described in section 6.1.2. 
WI-38 fibroblasts plated with WI-38 fibroblasts were used as a positive control. 5µg of 
total RNA was electrophoresed on a I% agarose gel containing 8% formaldehyde, 
transferred to a nylon membrane and hybridised with a mixture of ex.I (I), cx.2(1) or ex.I (III) 
collagen probes and J3-actin. ex. I (I) collagen mRNA results were the same as those for 
cx.2(1) collagen mRNA (data not shown). The breast tumour cell line T47D affected the 
fibroblasts the most, causing a 30% decrease on cx.2(1) collagen mRNA, MDA-MB-23 I 
decreased cx.2(1) collagen mRNA by 8% (figure 4.3A). ZR-75-2 and the colon tumour cell 
line HT-29 had no effect on type I collagen mRNA. The breast tumour cell lines MDA-
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:MB-231 and ZR-75-2 increased type III collagen mRNA by 11 % and 27% respectively, 
whereas T47D and HT-29 tumour cells decreased the collagen mRNA by 23% and 15% 
respectively (figure 4.3B). These results indicate that different tumour cell lines are 
capable of modulating collagen mRNA in different ways. A summary of these results is 
presented in Table IV. 
TABLE IV: Summary of the interactions between tumour cells or tumour cell conditioned 
media and fibroblasts on collagen mRNA levels. 
CELL LINE CONDITIONED CO-CULTURE DIFFUSIBLE 
MEDIUM ME:MBRANE 
Type I Type III Type I Type III Type I Type III 
MDA-:MB-231 t45% ,l. 16% ,l. 80% J.. 75% J.. 8% t 11% 
MCF-7 no change t 14% J.. 52% J.. 66% ND ND 
T47D ND ND J.. 66% J.. 63% J.. 30% J.. 23% 
ZR-75-2 t 55% ,l.31% J.. 75% J.. 75% no change t27% 
BE ND ND J.. 78% J.. 75% ND ND 
HT-29 ND ND J.. 60% J.. 33% no change J.. 15% 
Where ND = not done 
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FIGURE 4.1. 
Analysis of a.2(1) and a.1(111) collagen mRNA in fibroblasts incubated with tumour cell 
conditioned media. Total RNA was extracted from 2Xl06 WI-38 fibroblasts in~ubated with 
tumour cell conditioned media for 48 hours (section 6.1.2). 5µg of total RNA was 
electrophoresed on a I% agarose gel containing 8% formaldehyde, transferred to nylon 
membranes and hybridised with a.2(1) collagen and !3-actin cDNA probes (A) . Lane I is 
RNA from WI-38 conditioned medium, lane 2 'MDA-l'vffi-231 , lane 3 MCF-7 and lane 4 
ZR-75-2. The membrane was stripped and reprobed with !3-actin and a. I (III) collagen 
probes as shown in (B). Both membranes were scanned densitometrically and these results 
are shown in (C) and (D). All experiments were performed in triplicate. 
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Analysis of a2(1) and al (Ill) collagen mRNA in fibroblasts co-cultured with tumour cells. 
2XI06 WI-38 fibroblasts were co-cultured with 1XI06 breast or colon cancer cells, total 
RNA was extracted and electrophoresed on a 1 % agarose gel containing 8% 
formaldehyde, transferred to nylon membranes and hybridised with 32P-labelled a2(I) or 
al(III) collagen and J3-actin cDNA probes as described in the legend to figure 4.1 and 
sections 6.1.2 and 6.2 [(A) a2(I) collagen mRNA and (B) al(III)]. Lane 1; Wl-38 
fibroblasts co-cultured with WI-38 fibroblasts, lanes 2, 3, 4, 5 is RNA from WI-38 
fibroblasts co-cultured with the breast tumour cell lines (MDA-rvffi-231, MCF-7, T47D 
and ZR-75-2 respectively); lane 6; RNA from fibroblasts co-cultured with the normal 
breast epithelial cell line MCF-I2F while lanes 7 and 8 contain RNA from fibroblasts co-
cultured with the colon cancer cell lines BE and HT-29. The gels were exposed to X-ray 
film for 8 hours after which they were scanned densitometrically [(C) and (D)]. All 
experiments were performed in triplicate. 
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Analysis of a.2(1) and a.1 (Ill) collagen mRNA in fibroblasts co-cultured but physically 
separated from tumour cells. 300 000 WI-38 fibroblasts were plated in Transwell tissue 
culture dishes (Costar) and incubated with breast or colon tumour cells for 48 hours (as 
described in section). Total RNA was extracted (section 6.1.2), of which 5µg was 
electrophoresed on a I% agarose gel containing 8% formaldehyde, transferred to nylon 
membranes and hybridised with a mixture of 32P-labelled a2(I) or a I (III) collagen and f3-
actin cDNA probes; [(A) and (B)]. Lane I; WI-38 fibroblasts cultured with WI-38 
fibroblasts; lanes 2, 3, 4 and 5 is RNA from the tumour cell lines MDA-MB-231, T47D, 
ZR-75-2 and HT-29 incubated with WI-38 fibroblasts . The gels were exposed to X-ray 
film for 8 hours after which they were scanned densitometrically [(C) and (D)]. All 
experiments were performed in triplicate. 
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4.3 DISCUSSION 
As m~ntioned previously, the decrease in collagen (chapter three), apart from degradation 
by collagenases, could also be due to a decrease in collagen mRNA levels. Addition of 
tumour cell conditioned media to fibroblasts did not cause the expected decrease in type I 
collagen mRNA levels, in fact an increase was detected with the breast tumour cell lines 
MDA-1vffi-231 and ZR-75-2. This effect was totally unexpected, not only because there 
had been a decrease in collagen protein (which admittedly could be explained by 
collagenases) but also from work done by Noel et al (1992) who found an increase in 
types I and III collagen in conditioned media when skin fibroblasts were co-cultured with 
the tumour cell lines MCF-7, SA52 and T47D with a concomitant increase in the levels of 
types I and III collagen mRNA. It is possible that the fibroblasts of breast and lung origin 
responded differently to skin fibroblasts. It could also be that the breast or Jung fibroblasts 
require direct interaction with the breast tumour cells or that another factor was involved 
( other than EMMPRIN) that had been lost in the preparation of the conditioned media. 
Why collagen mRNA from fibroblasts of different origins were regulated in a different 
manner is not clear at this stage. 
Type III collagen mRNA, on the other hand, was shown to be either decreased (by MDA-
MB-231 and ZR-75-2) or increased (by MCF-7) which agrees with the work done by 
Noel et al, 1992. Both studies demonstrated that the different collagens were regulated 
differently, furthermore, other factors (such as the heterodimeric CCAAT factor) have 
also been shown to control the al(III) gene but not the type I collagen gene (Vuorio and 
de Crombrugghe 1990). Studies have shown that there is often a co-ordinate decrease in 
the levels of a2(I) and a 1 (III) collagen RNA in transformed cells (Liau et al, 1985). 
However, in one mouse cell line, transformed by Rous sarcoma virus, a 1 (III) collagen 
mRNA showed a 4-fold increase while the a2(I) collagen mRNA was decreased 7-fold. 
These results demonstrated that, in most cases types I and III collagen mRNA is often co-
ordinately expressed, but there are certain circumstances where this is not the case (Liau 
et al, 1985). Three mechanisms were suggested to explain this inhibition of type I collagen 
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gene transcription, they included the existence or presence of a repressor, an inactive 
activator and thirdly a change in the conformation of chromatin around the genes that are 
inhibited in transformed cells, preventing the activation of these genes {Liau et al, 1985). 
When the fibroblasts were co-cultured with the breast or colon tumour cells, types I and 
III collagen rnRNA were decreased by all the tumour cell lines. These results indicated, 
that the cells required either direct interaction or alternatively, the factor. that affects 
collagen gene expression was lost during preparation of the tumour cell conditioned 
media. To answer this question, the cells were separated from each other by a membrane 
such that any diffusible factor(s) secreted by the tumour cells would be able to act on the 
fibroblasts. In this instance, type I collagen rnRNA was decreased by tumour cell lines 
MDA-MB-231 (8%) and T47D (30%), compared to 80% and 66% respectively when the 
cells were co-cultured with the fibroblasts. ZR-75-2 and HT-29 had no effect on type I 
collagen mRNA, whereas decreases of 75% and 60% were obtained upon co-culture. 
MDA-MB-231 and ZR-75-2 breast tumour cell lines, when cultured separately from the 
fibroblasts, increased type III collagen mRNA by 11 % and 27% respectively, whereas 
decreases were obtained when the cells were cocultured (75% and 75%). T47D and HT-
29 had no effect on type III collagen mRNA but decreases of 63% and 33% were detected 
in co-culture. These results demonstrate that, in most cases, a difusible factor was not 
involved but that the tumour cells required contact with the fibroblasts to decrease 
collagen mRNA. 
It was therefore shown that a) types I and III collagen mRNAs were affected differently 
even though type I collagen and III was affected in the same way; b) different tumour cells 
(breast and colon) affect collagen mRNA differently and c) tumour cells modulate type I 
collagen using two different mechanisms; one causing the degradation of collagen and the 
other affecting collagen mRNA steady state levels, both of which would aid in tumour cell 
invasion and metastasis. The one mechanism involved secretion of factors which caused 
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the degradation of collagen whereas the other mechanism required direct interaction of 
fibroblasts and tumour cells. 
It has been shown that skin fibroblasts, when cultured in a three-dimensional environment 
consisting mainly of collagen I fibrils, synthesize reduced levels of types I and III collagen 
as well as reduced levels of steady-state collagen mRNA (Mauch et al, 1988). The 
reduced steady-state levels were found to be partly d_ue to reduced de novo transcription 
of the collagen I gene and in part to a reduction in pro a I (I) collagen mRN A stability 
(Eckes et al, 1993). There was also an increase in collagenase gene expression and all this 
data was found to be dependent on the contact of fibroblasts in a three-dimensional 
collagenous matrix (Mauch et al, 1989). This interaction between fibroblasts and the 
three-dimensional lattice has subsequently been shown to trigger tyrosine phosphorylation 
of pp 120 which is identical to pp 125FAK , a novel tyrosine kinase localised in focal 
adhesions (Roeckel and Krieg 1994). This phosphorylation has been shown to be mediated 
by the integrin a 2P1 which presumably provides the structural link between the ECM and 
the cytoskeleton or in this case the fibroblasts and the collagen lattice (Klein et al, 1991 ~ 
Schiro et al, 1991 ). It has been suggested that the phosphorylation event promotes 
alterations in cellular morphology, including formation and maintenance of focal contacts 
and cell spreading, all of which might influence gene expression (Roeckel and Krieg 
1994). Recent data have shown that the integrin a 1P1 is involved in the down regulation of 
collagen gene expression, whereas the a 2P I integrin mediates induction of collagenase 
(MMP-1). With the use of signal transduction inhibitors, it was shown that different 
signaling pathways are involved in the decrease in collagen mRNA and MMP-1. It was 
shown that induction of MMP-1 is mediated by tyrosine-specific protein kinases, the 
mechanism of down regulating type I collagen mRNA still needs to be elucidated 
(Langholz et al, 1995). 
Data from this chapter, specifically the fact that tumour cells directly interact with 
fibroblasts to affect gene expression, implies that tumour cells may mimic the environment 
created by the three-dimensional collagen gel system and in binding to the fibroblasts via 
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specific receptors (possibly integrin(s)), certain signal transduction pathways are activated 
causing a reduction in collagen gene expression and an increase in collagen degradation. 
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CHAPTER FIVE 
CONCLUSION 
Tumour cell invasion and metastasis depend on the degradation of the collagen matrix 
which would normally maintain the integrity of the tissue or organ. The degradation of the 
extracellular matrix (ECM) in highly metastatic tumours is associated with high levels of 
collagenases (Stetler-Stevenson et al, 1993). Not much is known about collagen gene 
expression in fibroblasts present in the ECM surrounding the tumours. Type I collagen 
mRNA levels were therefore analysed in various stages of breast and colon cancer tissue 
since the disease is relatively common in the South African population and tissue is readily 
available. 
Analysis of RNA levels in breast tumours and the adjacent normal tissue by Northern 
hybridisation indicated that stage I breast tumours had increased collagen mRNA 
compared to the adjacent normal tissue, while in stages II and III breast tumours it was 
decreased. These results were confirmed by non-radioactive in situ hybridisation which 
showed that stage I breast tumour cells had increased collagen mRNA levels, whereas 
stage II and III tumour cells had decreased expression (when compared to the adjacent 
normal cells).· This stage-specific phenomenon was found not only to occur in breast 
cancer but also in colorectal cancer. These results showed high levels of collagen mRNA 
in the early stages of cancer and decreased or negligible expressi~n as the tumours 
advanced to the later stages. This study showed that the stromal fibroblasts and not the 
tumour cells, were producing excess collagen mRNA ( correlates with desmoplasia) in the 
early stages of the disease whereas fibroblasts in the later disease stages were synthesising 
collagen mRNA at reduced rates. One can hypothesize that excess collagen acts as a 
barrier against tumour cell invasion (in this way protecting the host) in the early stages of 
cancer but as the tumour progresses and becomes more aggressive, collagen mRNA 
production is switched off, enabling the tumour cells to migrate and metastasize. In situ 
hybridisation analysis also indicated that fibroblasts in the direct vicinity of the tumour 
cells were most affected, suggesting that tumour cells can modulate or control collagen 
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mRNA production by the fibroblasts to aid the process of tumour cell mvaston and 
metastasis. 
In order to analyse the relationship between normal fibroblasts and breast tumour cells, 
primary breast fibroblasts were co-cultured with ivtDA-MB-231, MCF-7, T47D or ZR-75-
2 breast tumour cells, and as additional endeavor, normal cells were incubated with 
tumour cell conditioned media. The tumour cells ·and the tumour cell conditioned media 
caused a decrease in collagen protein levels and moreover type III collagen was found to 
be regulated in the same way as type I collagen (also decreased as demonstrated by 
interrupted gel electrophoresis). Fibroblasts of different origins responded differently to 
tumour cells; in this study skin fibroblasts when co-cultured with various tumour cell lines 
produced excess collagen, on the other hand, breast and lung fibroblasts produced less 
collagen. This indicated that collagen production in fibroblasts depends on the tissue of 
ongm. 
The decrease in collagen levels was analysed at two levels: degradation (by the production 
of collagenases) and decreased collagen mRNA production. Tumour cell conditioned 
media was found to be incapable of degrading type I collagen, demonstrating that the 
tumour cells themselves were not responsible for degrading type I collagen (ie that they 
did not secrete interstitial collagenases). When tumour cell conditioned media was 
incubated with normal fibroblasts, however, type I collagen was digested, indicating that 
the tumour cells secreted a factor(s) that stimulated the fibroblasts to produce 
collagenases. The collagenase could then degrade the collagen secreted by the fibroblasts. 
This factor was shown by Western blotting to be of similar molecular weight to the 
. already known TCSF or EM:MPRIN discovered by Biswas (1982, 1984), Ellis et al (1989) 
and Biswas et al ( 1995). 
Collagen mRNA levels were also analysed in order to ascertain whether the decrease in 
collagen was also due to a decrease in mRNA. In these studies, normal fibroblasts were 
incubated with breast tumour cell conditioned media which resulted in an increase in a.2(1) 
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collagen mRNA with MDA-MB-231 conditioned medium of 45% and ZR-75-2 
conditioned medium of 55%, conditioned medium from MCF-7 cells .~ad no effect. Similar 
results were obtained for al(I) collagen rnRNA. For type III collagen rnRNA, however, 
MDA-l\ffi-231 and ZR-75-2 conditioned media caused a decrease whilst MCF-7 
conditioned medium had no effect. The reason for the difference in types I and III collagen 
mRNA levels is unknown, but it could be that the factor(s) in the tumour cell conditioned 
media also ablates co-ordinate regulation of these genes. Such lack of co-ordinate 
regulation of the types I and III collagen genes has been documented (Vuorio and de 
Crombrugghe 1990). It is also important to point out that even though types I and III 
collagen are often produced in the same tissue, they are not produced at the same levels 
for example, type III collagen is not present in bone whereas type I collagen is the most 
abundant protein. 
The increase in type I collagen rnRNA, especially when a decrease in type I .collagen had 
already been demonstrated, was surprising. If EMMPRIN was involved in the down 
regulation of type I collagen, a decrease rather tha~ an increase in collagen rnRNA would 
have been detected. It is quite conceivable therefore that there was another factor involved 
in the down regulation of coHagen mRNA and that it was lost during preparation of the 
conditioned media or that cell-cell contact was required. All the tumour cells were shown 
to decrease type I and III collagen mRNA production in co-culture experiments. Culture 
of the tumour cells with the fibroblasts in the medium separated by a membrane confirmed 
that the cells required some form of contact in order to decrease collagen gene expression. 
As to why the different tumour cells affected collagen mRNA levels in different ways is 
not quite clear, but this phenomenon has also been shown in other studies_ (Noel et al, 
1992 and 1993). These tissue culture results indicated that fibroblasts require direct 
contact with tumour cells for there to be a substantial decrease in collagen gene 
expression, which would then explain the decrease in collagen detected by the collagenase 
assay. These results also support the in situ hybridisation data presented in this thesis 
which indicated that collagen gene expression was shut down only in the fibroblasts in the 
direct vicinity of the tumour cells. 
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How tumour cells interact with fibroblasts (ie via integrins or cadherins) and how they 
bring about a decrease in collagen gene expression is unknown at t~s stage. The increase 
in collagen, in the early stages of disease, possibly acts as a barrier for tumour progression 
and invasion and could be a host response to increased cell mass. The tumour cells then 
respond to this increase in two ways; first secretion of collagenases and secondly ( or 
concurrently) by switching off collagen mRNA production in the fibroblasts. Being 
capable of modulating normal fibroblast functions, such as increasing the production of 
collagenases or switching off collagen gene expression, must surely aid in the process of 
tumour cell invasion and metastasis. This ability of tumour cells to shutdown type I 
collagen gene expression opens up a vast area of research which can be exploited from a 
potential therapy point of view. For instance, if tumour cells could be prevented from 
switching off collagen mRNA, the process of invasion and metastasis may be slowed down 
or inhibited. What now needs to be established is the signal transduction pathway which is 
utilised by the tumour cells in order to exert their effect on collagen production by the 
fibroblasts. 
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CHAPTER SIX 
MATERIALS AND METHODS 
6.1 ISOLATION OF RNA 
6.1.1 Extraction of RNA from Tissue 
RNA was extracted essentially as described by Choinczynski and Sacchi (1978). lg of 
breast tissue was homogenised with 1 ml of solution D (section 6.15) using an ultra 
turrex. The homogenate was transferred to a 10ml falcon tube, to which 100µ1 of 2M 
Na acetate pH 4, 1ml H20 saturated phenol and 200µ1 chloroform:isoamyl alcohol 
( 49: 1) was added. This was followed by thorough mixing and placed on ice for 15 
minutes. After centrifugation at 10 000 rpm in a JA 20. l rotor for 20 minutes at 4°C, 
the aqueous phase was removed and transferred to a fresh tube. I ml of isopropanol 
was added and the RNA was left to precipitate at -20°C overnight. The RNA was 
pelleted by centrifugation at 10 000 rpm for 20 minutes, the supernatant discarded and 
the pellet resuspended· in 300µ1 of solution D. The RNA was again precipitated by 
addition of an equal volume of isopropanol and left at -20°C for I hour. The RNA was 
pelleted at 10 000 rpm for 10 minutes at 4°C, washed twice with 70% ethanol, dried 
under vacuum and resuspended in 50µ1 diethyl pyrocarbonate (DEPC) treated water 
(section 6.15). 
The RNA concentration was determined spectrophotometerically and an aliquot of the 
sample was electrophoresed on a 1 % agarose gel containing 8% formaldehyde to 
check the quality of the RNA. 
6.1.2. Extraction of RNA from Cultured Cells 
Wl-38, FGo's or breast fibroblasts and MDA-MB-231, MCF-7, T47D, ZR-75-2, BE 
or HT-29's tumour epithelial cells were cultured in 6 well dishes in Minimal Essential 
Medium (MEM) supplemented with 10% heat inactivated foetal calf serum, 100 µg/ml 
penicillin and 100 units/ml streptomycin at 37°C. To harvest the cells, the culture 
medium was removed, the cell layer rinsed with Phosphate Buffered Saline Solution 
(section 6.15) and 1ml of solution D was added to the cells followed by mixing with 
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gentle circular movements for about 2 minutes. The solution became thick and viscous 
and was transferred to 10ml plastic falcon tubes to which was added. 100µ1 of 2M Na 
acetate (pH 4.0), 1ml water saturated phenol and 200µ1 chloroform:isoamyl alcohol 
( 49: 1 ). This mixture was shaken for 10 seconds and placed on ice for 15 minutes. After 
centrifugation at 10 000 rpm in a JA 20.1 rotor for 20 minutes at 4°C, the aqueous 
layer was removed and transferred to a fresh tube, to which an equal volume of 
isopropanol was added. The RNA was precipitated at -20°C overnight and pelleted by 
centrifugation at 10 000 rpm for 20 minutes. The pellet was washed twice with 70% 
ethanol, dried under vacuum for 5 minutes and resuspended in 20-50µ1 DEPC treated 
water. The concentration and quality of the RNA was determined 
spectrophotometrically whereby 1A26o = 40µg RNA. 
6.2. NORTHERN BLOTTING AND HYBRIDISATION 
5-IOµg ofRNA was added to 16.5µ1 RNA loading buffer (section 6.15) and heated for 
10 minutes at 55°C. The RNA was electrophoresed on a 1 % agarose gel containing 
8% formaldehyde at 30mA for 2-3 hours in RNA running ~uffer (section 6.15). The 
RNA was blotted onto Hybond N membranes (Amersham) for 16-18 hours. After 
blotting the gel was stained with ethidium bromide to check for transfer of RNA onto 
the membrane. The membrane was rinsed briefly in 6X SSC (section 6.15) and 
crosslinked using a UV crosslinker (Spectro-linker, Spectronics corporation) at 
optimal crosslinking conditions before placing it in a sterile glass bottle for 
prehybridisation. 
The membrane was prehybridised for 4 hours at 42°C in prehybridisation buffer 
(section 6.15) in a Hybaid rotary oven. The probe was labelled by nick-translation as 
specified by the suppliers (Boehringer Mannheim). Prior to use, the probe was 
denatured at 95°C for 10 minutes and placed on ice for 5 minutes. 1-2 million cpm 
probe was added per ml of prehybridisation mixture and allowed to hybridise for 16-18 
hours at 42°C. After hybridisation, the membrane was washed twice for 15 minutes at 
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room temperature in 2X SSC, 0.1 % SDS followed by two washes for 15 minutes each 
at 65°C in O.IX SSC, 0.1% SDS. The membrane was placed in a plastic bag, sealed 
and exposed to X-ray film at -70°C for 16-18 hours. 
6.3. IN SITU HYBRIDISATION 
Slides were soaked overnight in 250ml chromic acid (section 6.15), rinsed 5 times in 
distilled water, and then placed in distilled water for 30 minutes. The water was 
decanted and the slides left in 250ml acetone for 30 minutes. 5ml of 3-
aminopropyltriethoxy-silane was added to 250ml fresh acetone which was then poured 
onto the slides and stirred for 30 minutes. The solution was decanted and the slides 
were placed at 80°C for 30 minutes. The slides were rinsed, left in DEPC treated water 
for 2 hours and placed at 80°C overnight to dry. The slides were then placed in a 
plastic packet with silicon crystals and sealed until further use. 
Formalin fixed tissue sections were cut into 4 micron sections using a microtome, 
placed on slides and allowed to dry overnight at 65°C. The sections were stored in 
plastic packets until further use. 
Fragments to be used as riboprobes, as well as the cloning vector pGEM3, were 
digested overnight with the appropriate restriction enzymes at 37°C. The digested 
samples were heated at 60°C for 10 minutes and subsequently electrophoresed on a 
0.8-1% low melting agarose gel in TAE buffer (section 6.15) at 30mA for 3-4 hours. 
The desired fragment and pGEM3 were excised from the gel and and the agarose 
melted at 70°C for 10 minutes (Current Protocols in Molecular Biology 1995). 
Various amounts of insert and vector slices were combined in fresh microfuge tubes 
(total volume of 9µ1) and placed at 37°C for an additional 10 minutes. 2 units T4 DNA 
ligase and 2µ1 of 1 OX ligase buffer (section 6.15) were added to each tube and 
incubated at 15°C for 16-18 hours. After the ligation reaction was completed the 
ligated products were heated at 73°C for 10 minutes, and 5µ1 was added to 200µ1 
competent E. coli cells (prepared as described in section 6.14). Transformants were 
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selected by plating the cells on bacterial agar plates (section 6.15) containing 0.5 
mg/ml ampicillin. The plasmid DNA from several selected transformants was purifi~d 
using the rapid miniprep procedure (section 6.14.). Restriction enzyme analysis was 
used to confirm the presence of the insert DNA, which was then further purified using 
the Qiagen Maxi plasmid preparation procedure. As confirmation, the insert was 
sequenced using the Sanger dideoxy method (Sanger et al, 1977) as described by the 
manufacturers of Sequenase TM (United States Biochemical Corporation, Cleveland, 
Ohio). 
T7 RNA polymerase was used to produce digoxigenin-labelled (dig-labelled) RNA 
Approximately I Oµg of dig-labelled RNA was obtained from I µg of linear template 
DNA This reaction was carried out at 37°C for 2 hours, as recommended by the 
suppliers (Boehringer Mannheim). Briefly, 40 units of T7 RNA polymerase was added 
to lµg of linearised plasmid DNA (pGEM3 containing B-Actin, al(I) or a.2(1) 
collagen inserts or pGEM3 alone) in transcription buffer (section 6.15) in a final 
volume of 20µ1 containing lOmM each of ATP, CTP, GTP, 6.5mM UTP and 3.5mM 
DIG-UTP. 20 units RNasin was added to inhibit any possible contaminating RNases. 
The reaction mixture was incubated at 37°C for 2 hours after which 50mM EDTA (pH 
8.0) was added to stop the reaction. The RNA was precipitated overnight at -20°C by 
the addition of 2µ1 of 5M LiCI and 75µ1 of 96% ethanol. The RNA was pelleted by 
· centrifugation for 30 minutes at 10 000 rpm, washed twice with 70% ethanol, dried 
under vacuum and resuspended in 100µ1 DEPC treated water. To facilitate 
resuspension, the RNA was incubated at 37°C for 30 minutes prior to storage at -
20°C. In order to check the quality of the labelled probe 5 to 1 Oµl of the probe was 
electrophoresed on a 1 % agarose gel containing 8% formaldehyde and transferred 
overnight to a Hybond N membrane. The membrane was washed· for 5 minutes in 
buffer B (section 6.15) at room temperature and blocked with 2% normal sheep serum 
in buffer B at 3 7°C for 20 minutes. The membrane was then placed in buffer B 
containing 0.5% Tween for 5 minutes at room temperature, followed by the addition of 
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a 1: 100 dilution of sheep anti-digoxigenin antibody conjugated with alkaline 
phosphatase. The membrane was placed in buffer C (section 6.15}.for 5 minutes at_ 
room temperature after which the substrate was added to detect the blue-purple colour 
(the membrane was placed in the dark for this detection). Nitro-Blue-Tetrazolium 
Chloride (NBT) and 5-Bromo-4-Chloro-3-indolyl-phosphate (X-Phosphate) were used 
as substrates of which 4.5µ1 of NBT and 3.5µ1 of X-Phosphate were added to 1ml 
buffer C. Buffer C contains MgCl2 which is required for alkaline phosphatase activity 
(as described by Boehringer Mannheim). 
Paraffin embedded colon and breast tissue sections were dewaxed in 250ml xylene at 
65°C for 30 minutes and washed twice in 250ml xylene for 10 minutes each. This was 
followed by rehydrating the sections in decreasing concentrations of 250ml ethanol 
(100%, 90% and 70%) for 2 minutes each. The slides were rinsed in 250ml DEPC 
treated water for 5 minutes, and transferred to 250ml PBS for 5 minutes. 
Depending on the size of the section, 200-500µ1 proteinase K at a concentration of 1 
to 10 µg/ml in buffer A (section 6.15) was placed onto each slide and incubated for 
between 15 and 45 minutes at 37°C in a humidified chamber. As a negative control 
RNase A ( 40 µg/µI) was added together with the proteinase K in some samples. 
The slides were placed in 250ml PBS for 5 minutes. 500µ1 of 0.4% paraformaldehyde 
diluted in PBS (to refix the sections to the slides) was placed onto each section and the 
slides were left at room temperature for 5 minutes in a humidified chamber. The slides 
were transferred to a rack, and submerged in 250ml DEPC treated water for 2-3 
minutes. O. IM triethanolamine and 0.25% acetic anhydride (v/v) was added to the 
DEPC treated H20, while stirring continuously at room temperature. The solution was 
stirred for IO minutes, decanted, and the slides placed in 250ml PBS for 5 minutes. 
After acetylation the slides were dehydrated in increasing concentrations of 250ml 
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ethanol (50%, 70%, 90% and twice in 100%) for 2 minutes each, and allowed to air 
dry. 
Before use both the prehybridisation and hybridisation mixtures (section 6.15) were 
diluted with an equal volume of deionised formamide. 50µ1 of the prehybridisation 
mixture was placed onto each section, covered with parafilm and incubated in a 
humidified container at 50°C for 1-2 hours. The parafilm was removed and 25µ1 of 
hybridisation mixture containing the appropriate dig-labelled probe was added to each 
section. The sections were covered with parafilm and incubated in a humidified 
chamber at 50°C overnight. 
After hybridisation the slides were washed twice in 250ml of 2X SSC for 15 minutes, 
with constant stirring at room temperature. This was followed by two 1 S minute 
washes at 43°C in 250ml of O. IX SSC with gentle shaking. The slides were incubated 
at room temperature in 250ml of buffer B (section 6.15) for 5 minutes and blocked 
with 150µ1 blocking solution containing 2% normal sheep serum in buffer B. Each 
section was covered with parafilm and placed at 37°C for 20 minutes in a humidified 
chamber. The parafilm was removed and the slides were placed in 250ml of buffer B 
containing 0.5% Tween-20 for 5 minutes at room temperature. I 00µ1 of a I: I 00 
dilution of anti-digoxigenin antibody were added to each slide and incubated at 3 7°C 
for between 30 minutes and 2 hours. 
After incubation with the anti-digoxigenin antibody, the sections were washed twice in 
buffer B for 15 minutes each at room temperature, followed by 5 minutes in buffer C 
(section 6.15). The substrates (4.5µ1 NBT and 3.5µ1 X-P into 1ml of buffer C) were 
diluted prior to use and 100µ1 of this solution was placed onto each slide and the slides 
incubated in the dark until a blue-purple colour appeared (between 30 minutes and 
overnight). After the appearance of the blue-purple colour the reaction was stopped by 
placing the slides in 250ml of buffer D (section 6.15). The slides were finally 
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dehydrated in 250ml of increasing concentrations of ethanol (50%, 70%, 90% and 
twice in 100%) for 2 minutes each, followed by 2 or 3 washes in -250ml xylene (to 
remove any traces of water) after which they were mounted with entellen (Merck) and 
covered with a glass coverslip. 
Each in situ hybridisation run included a negative control (pGEM-3), to control for 
non-specific binding and a positive control (/3-actin). 
6.4 PREPARATION OF NORMAL PRIMARY BREAST FIBROBLASTS 
Normal breast tissue was obtained from Groote Schuur Hospital (GSH) and cut into 
very fine pieces. These pieces were placed in 30mm sterile petri dishes and overlayered 
with a coverslip to ensure that the tissue remained fim:ly fixed to the dish. 1 ml MEM 
containing I 0% foetal calf serum, I 00 µg/ml penicillin and l 00 units/ml streptomycin 
was added to each dish and placed at 37°C. Every 3 days the medium was changed and 
replaced with fresh medium. After 10 days the fibroblasts from the tissue had anchored 
to the dish. The area under the coverslip was allowed to become confluent before the 
coverslip was removed. The fibroblasts were rinsed with PBS, trypsinised and placed 
into a 60mm sterile petri dish. The cells were allowed to become confluent after which 
an aliquot was frozen in MEM containing I 0% foetal calf serum, I 00 µg/ml penicillin 
and 100 units/ml strptomycin and 10% DMSO. 
6.5. KARYOTYPE ANALYSIS 
Breast fibroblasts were plated on a coverslip in a 30mm petri dish and left to grow at 
37°C for 5-7 days in 2-3ml MEM supplemented with 10% foetal calf serum and 
antibiotics. Once the cells had become 80% confluent, 150µ1 of 10 µg/ml colcimid was 
added and incubated for 5 hours at 37°C. The medium was decanted, 2ml of 0.075M 
KCI was added to the dish and left for 1 hour at 37°C. 1 ml of fixative solution (20ml 
acetic acid in 80ml cold methanol) was added to the cells and left for 45 minutes at 
37°C. The fixative was decanted, the cells immersed in 2ml of fresh fixative and 
incubated at room temperature for a further 30 minutes. The coverslip was gently 
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removed from the dish and placed onto the lid of the petri dish and left overnight at 
60°C to dry. The coverslip was stained with 2ml Giemsa for 2 minutes, washed with 
distilled water and placed at 60°C to dry for 30 minutes. The coverslip was fixed onto 
a glass slide and the chromosomes counted. 
6.6. ANALYSIS OF TYPES I AND III COLLAGEN IN CULTURED CELLS 
Approximately 150 000 to 200 000 fibroblasts or tumour epithelial cells were plated in 
6-well plates in 2ml of MEM containing either 10% or 5% foetal calf serum 
respectively, 100 µg/ml penicillin and 100 units/ml streptomycin. When the cells were 
confluent (1-2 days) they were rinsed with PBS and 2ml of fresh serum free medium 
containing 20µ1 of 5 mg/ml ascorbate, 20µ1 of 5 mg/ml B aminopropionitrile (BAPN) 
and 20µ1 of 3tt-proline (44 Ci/ml) was added to the cells. The cells were incubated at 
3 7°C for 16 hours, after which the medium was harvested. The medium was placed in 
10ml falcon tubes (on ice), containing 200µ1 of lOX N-ethylmaleimide (NEM), SM 
phenylmethylsulphonylfluoride (PMSF) and 50 µI rat tail collagen. The dishes were 
rinsed with 200µ1 of PBS which was subsequently combined with the medium fraction. 
1.2ml of 96% ethanol was added to the medium fraction and incubated overnight at -
20°C. 1ml of trypsin was added to the cell layer, followed by incubation at 37°C for 2-
3 minutes to detach the cells. 100µ1 of the cell suspension was counted in 9.9ml 
isotone in a coulter counter to determine the number of cells per dish. 
The precipitate was pelleted at 10 000 rpm in a JA20. l rotor for 30 minutes at 4°C. 
The supernatant was decanted, the pellet washed twice in 70% ethanol, dried under 
vacuum and dissolved in 0.5M acetic acid by vortexing. The protein was incubated in 
0.05 mg/ml pepsin at 12-15°C for 16 hours. 5µ1 of the sample was pipetted onto 
Whatmann # 1 paper discs which were pre-soaked in 10% trichloroacetic acid, (TCA) 
and allowed to air dry. The discs were rinsed twice in ice cold 10% TCA, boiled in 
10% TCA for 5 minutes, followed by washing in 10% TCA then 70% ethanol and 
ether. The discs were dried and counted in a scintillation counter. 
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The calculated amount oflabelled protein ( either constant dpm or radioactivity per 105 
cells) was dried, resuspended in 10-12µ1 of 2X treatment buffer (sect1on 6.15) heated 
at 95°C for 5 minutes and electrophoresed on a 6% polyacrylamide SDS minigel (0.4M 
tris/HCI pH8.8, 0.1% SDS, 6% acrylamide:bisacrylamide (29:1), 0.05% ammonium 
persulphate and 1% TEMED) with a 3% stacking gel (0.125M tris/HCI pH6.8, 0.1% 
SDS, 3% acrylamide:bisacrylamide (29:1), 0.05% ammonium persulphate and 1% 
TEMED). The gels were electrophoresed in a Biorad minigel apparatus, at 100 volts 
for 1-2 hours in SDS running buffer (section 6.15) until the bromophenol-blue reached 
the bottom of the gel. The gels were incubated in Enhance™ solution (Dupont) with 
gentle shaking for 1 hour, followed by another hour in distilled water, dried under 
vacuum at 70°C for 1 hour and exposed to X-ray film for 1-2 days. 
Type III collagen was analysed essentially as described for Type I collagen. Labelled 
protein was calculated (as constant dpm), vacuum dried, resuspended in 12µ1 of 2X 
Treatment Buffer (section 6.15) without f3-mercaptoethanol heated at 95°C for 5 
minutes and electrophoresed on a 6% polyacrylamide SDS gel with a 3% stacking gel 
(as described above). Electrophoresis was for 1 hour at 100 volts in SDS running 
buffer (section 6.15) after which the current was switched off and the sample wells 
were filled with 10% v\v f3-mercaptoethanol (in SDS running buffer). This was allowed 
to diffuse into the gel for 1 hour before the current was switched back on and the gel 
was electrophoresed for another hour (Sykes et al, 1976). The gel was incubated in 
Enhance™ solution for I hour (with shaking), followed by another hour in distilled 
water, dried under vacuum at 70°C and exposed to X-ray fiI for 2-3 days. 
6.7. PREPARATION OF CONDITIONED MEDIA 
IOX conditioned media was prepared from MDA-MB-231, T47D, MCF-7 and ZR-75-
2 breast cancer cell lines as well as from the colon cancer cell lines BE and HT-29. 
The cancer and normal breast fibroblast cell Jines were grown in Minimal Essential 
Medium (MEM) containing 5 or I 0% foetal calf serum respectively, supplemented 
with 100 µg/ml penicillin and 100 units/ml streptomycin. After 2 days the medium was 
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removed, the cell layers rinsed twice with PBS and serum free MEM was added. After 
2 days the medium was removed and centrifuged at 4000 rpm· in a bench-top 
centrifuge (Beckman TJ-6) for 1 hour to remove any cellular debris. The medium was 
transferred to dialysis tubing (which had been previously boiled in 1 mM EDT A. then 
boiled in distilled water and allowed to cool to 4°C) and dialysed overnight at 4°C 
against distilled H20. The medium was lyophillised and reconstituted in 1/10th the 
original volume of sterile water, making the medium 1 OX concentrated. The medium 
was filter sterilised through 0.2µm millipore filters. 
6.8. CONDITIONED MEDIUM AND CO-CULTURE EXPERIMENTS 
6.8.1. Conditioned Medium Experiments 
Breast fibroblasts were plated at a density of 40 000 cells per well in 24-well dishes in 
MEM containing 10% foetal calf serum and antibiotics (section 6. 7) and allowed to 
grow until they were 80% confluent. The medium was removed and the cell layer 
rinsed with PBS. IOX conditioned medium (described in section 6.7) was diluted to the 
desired concentration in fresh serum free MEM containing antibiotics and added to the 
cells. The cells were incubated at 37°C for 32 hours and for a further 16 hours in the 
presence of 50 µg/ml ascorbate, 50 µg/ml f3APN and 2 µCi/ml 3H-proline (44 Ci/ml) 
to label the proteins. 
After the labelling period, the medium and cell layers were harvested. The medium was 
added to a cocktail containing 50µ1 NEM and PMSF and 0.025 mg/ml bovine serum 
albumin (BSA) in 1.5ml microfuge tubes. Each well was washed with 50µ1 PBS which 
was added to the medium fraction. 500µ1 of 96% ethanol was added to the medium 
fraction and the proteins precipitated overnight at -20°C. 
After removmg the medium fraction, the cells were rinsed with 500µ1 -PBS and 
harvested by adding 200µ1 trypsin to each well. After 2 minutes the cells were 
transferred to microfuge tubes and pelleted by centrifugation at IO 000 rpm for 2 
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minutes. The supernatant was discarded and the pellet dissolved in 500µ1 0. 05M 
tris/HCl pH 7.2 and O.OlM CaCl2. The cells were lysed by 3 cycles of freeze-thawing 
and the cellular debris removed by centrifugation at 10 000 rpm for 2-5 minutes. The 
supernatant was transferred to fresh microfuge tubes containing a cocktail of 50µ1 
NEM and PMSF and 0.025 mg/ml BSA, to which 500µ1 of 96% ethanol was added. 
The proteins were precipitated overnight at -20°C. 
The precipitate was pelleted by centrifugation at 10 000 rpm for 3 0 minutes at 4 °C 
followed by 2 washes with 70% ethanol. The pellets were dried under vacuum for 10 
minutes and resuspended in 500µ1 ofO.lN NaOH and stored at 4°C until further use. 
6.8.2 Co-Culture Experiments 
A total of 40 000 cells were plated per dish (20 000 fibroblasts and 20 000 tumour 
cells) as described for the conditioned medium experiments ·(section 6.8.1 ). The cells 
were incubated in MEM containing 10% foetal calf serum and antibiotics. After 24 
hours, the medium was removed, the cell layer rinsed with PBS and fresh medium was 
added. The cells were incubated for 8 hours at 37°C, prior to the addition of 50 µg/ml 
ascorbate, 50 µg/ml f3APN and 2 µCi/ml 3H-proline (44 Ci/ml). After 16 hours, the 
protein was harvested as described in section 6.8.1. 
6.9. ESTIMATION OF COLLAGEN USING THE COLLAGENASE ASSAY · 
100µ1 of 3H-labelled protein (sections 6.8.1 and 6.8.2) was added to 100µ1 of 0.08N 
HCI and 50µ1 collagenase digestion buffer (120mM tris/HCI pH 7.2, 0.5mM CaCl2 
containing 0.5 units bacterial collagenase) and incubated at 37°C for 2-3 hours 
(Hendriks et al, 1993). 100µ1 of the digest was removed for determination of total 
radioactivity (T). 100µ1 of 50% TCA was added to the remaining solution which was 
incubated on ice for 1 hour to precipitate the undigested proteins. The precipitate was 
pelleted by centrifugation at 10 000 rpm for 5 minutes at room temperature and 400µ1 
of the supernatant was removed for determining the collagenase sensitive digested 
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·protein (S). Subtraction of the radioactivity in the collagenase sensitive protein fraction 
(S) from that in the total protein (T) yields the non-collagenous protein fraction (T-S). 
The % collagen synthesis was calculated using the formula of Peterofsky and 
Diegelmann (1971) which also takes into account the enrichment of pro line in collagen 
compared with other proteins: 
(S) 
%C= X 100 
5.4 (T-S) + S 
Where S = Collagenase Sensitive Protein, T = Total Protein and %C = 
%Collagen Present 
6.10. DETECTION OF COLLAGENASES 
Labelled collagen from WI-38 cells was prepared as described (section 6.6). 10 000 
dpm aliquots of protein were dried down in 1.5ml microfuge tubes and resuspended in 
50µ1 of 0. lN acetic acid and neutralised with 50µ1 of O. lM NaoH. 50µ1 collagenase 
digestion buffer (120mM tris/HCI pH 7.2 and 0.5mM CaCl2) and either 50µ1 of 
tumour cell conditioned medium (section 6. 7) or 50µ1 of tumour cell conditioned 
medium pre-incubated with breast fibroblasts was added to each tube. The digestion 
was allowed to occur at 25°C for 15 hours, after which the samples were dried under 
vacuum, resuspended in 20µ1 2X treatment buffer (section 6.15), denatured at 95°C 
for 5 minutes and electrophoresed .on 6% polyacrylamide SOS gels in SDS running 
buffer (section 6.15) for 2 hours at 100 volts, as described in section 6.7. The gels 
were dried and exposed to X-ray film for 1-2 days. 
6.11 WESTERN BLOT ANAL YSJS 
20µ1 of 1 OX tumour cell conditioned media (prepared as described in section 6. 7) was 
boiled in 2X Treatment Buffer (section 6.15) for 5 minutes before electrophoresis on 
10% SDS polyacrylamide gels for 1 hour at 100 volts. The proteins on the gel were 
transferred to Hybond C in an electroblotting apparatus, after which the membrane was 
removed and blocked overnight in 10% fat free milk powder in PBS+0.1 % Tween. 
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The membrane was washed and incubated with the monoclonal mouse EMMPRIN 
antibody for 1 hour with shaking at room temperature. The EMMPRIN antibody was 
removed and the membrane was washed for 25 minutes in PBS/Tween after which a 
1: 10 000 dilution of the secondary antibody (goat anti-mouse conjugated with horse 
radish peroxidase, Caltag) was added and left for 1 hour, with shaking at room 
temperature. The membrane was washed for 30 minutes with PBS/Tween and then 
incubated for 1 minute in ECL detection (Amersham) before overnight exposure to X-
ray film. 
6.12. SINGLE STRAND CONFORMATION POLYMORPHISM (SSCP) ANALYSIS 
6.12.1 Extraction of DNA from paraffin embedded tissue sections 
Paraffin embedded colon sections were placed into microfuge tubes containing 1 ml of 
xylene. The tubes were inverted several times and the tissue pelleted by centrifugation 
at 10 000 rpm for 5-10 minutes. The xylene was removed with a pasteur pipette and 
the procedure repeated. 500µ1_ of 100% ethanol was added to the tubes which were 
shaken well before centrifugation for 5-10 minutes at 10 000 rpm. The ethanol was 
removed with a pasteur pipette and the wash repeated with another 500µ1 of ethanol. 
The samples were dried under vacuum and the pellet dissolved in 200µ1 digestion 
buffer (50mM tris/HCI, pH 8.5, lmM EDTA and 0.5% Tween 20) containing 200 
µg/ml proteinase K and incubated for 3 hours at 55°C, or overnight at 37°C. The 
proteinase K was inactivated by incubation at 95°C for 8-10 minutes. The samples 
were centrifuged briefly in order to remove any residual paraffin or remaining tissue. 
The supernatant containing the DNA was transferred to a clean, sterile tube and 
between 1 and I OµI was used in PCR reactions. 
6.i2.2. Polymerase Chain Reaction (PCR) 
The DNA isolated in 6.12.1 was used in the amplification of specific regions of the ras 
genes by the polymerase chain reaction (PCR). 0.5-1 units Tag polymerase was added 
to 50-IOOng DNA in Tag polymerase buffer (section 6.15) containing 0.2mM each. of 
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dATP, dGTP, dCTP and dTTP and 5pmol of each primer specific for the various 
exons of the Ki-Ras and Ha-Ras genes in a final volume of 50µ1. Amplifications were 
carried out in a Hybaid thermal cycler with the following PCR cycle: denaturation at 
94°C for I minute, annealing at 54-68°C for 2 minutes (see various primer sets) and 
extension at 72°C for 2 minutes. 
PRIMER SEQUENCES ARE AS FOLLOWS: 
GENE EXON PRIMER ANNEALING 
TEMPERATURE 
Ha-Ras 1: FORWARD 5'-GGGCCCTCCTTGGCAGGTGG-3' 68°C 
1: REVERSE 5'-CACCTGGACGGCGGCGCT AG-3' 
Ha-Ras 2: FORWARD 5'-GGAGAGGCTGGCTGTGTGAA-3' 56°C 
2: REVERSE 5'-AAAAGACTTGGTGTTGTTGA-3' 
Ki-Ras I: FORWARD 5'-ACATGTTCTAATATAGTCAC-3' 59°c 
I: REVERSE 5'-CT ATTGTTGGATCAT ATTCG-3' 
1: REVERSE 5'-TCAAAGAA TGGTCCTGCACC-3' · 54°c 
Ki-Ras 2: FORWARD 5'-TTGAGTTGTATATAACACCT-3' 58°C 
2: REVERSE 5'-CATGGCATTAGCAAAGACTC-3' 
The PCR products were heated at 65°C for 5 minutes prior to electrophoresis on 8% 
polyacrylamide gels (acrylamide:bisacrylamide (39:1], 0.2% ammonium persulphate 
and I% TEMED) to check for specificity of the PCR reaction. The gels were 
electrophoresed in IX TBE for 1.5 hours at 150 volts or until the bromophenol blue 
reached the bottom. The gels were stained in I mg/ml ethidium bromide and 
photographed. 
6.12.3. Radioactive SSCP Analysis 
The PCR was performed as described above, except with the addition of 2.5 µCi of 
32P-dCTP (3000 Ci/mmol) to each reaction mixture. 3µ1 of the PCR product was 
diluted with an equal volume of formamide loading buffer (section 6.15) ·containing 
20rnM NaOH. The samples were denatured at 95°C for 10 minutes, placed directly 
onto ice and loaded on a 6% polyacrylamide SSCP gel with or without 5% (v/v) 
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glycerol. The gels were electrophoresed at room temperature or 4°C in 1 X TBE. The 
samples were electrophoresed at 70 watts for the first 10 minutes .and then for 4-5 
hours at 30 watts or until the bromophenol blue reached the bottom of the gel. The gel 
was dried and exposed to X-ray film. Samples with altered mobility compared to 
normal DNA were subjected to direct sequence analysis or cloned into pUC 19 and 
subsequently sequenced. 
6.12.4. Non-Radioactive SSCP Analysis 
PCR samples were prepared as described in section 6.12.2. and 5 µI was added to 0.4µ1 
of IM methylmercury hydroxide, lµI 15% ficoll loading buffer (section 6.15) and 
made up to 20µ1 with IX TBE. The samples were heated at 85°C for 5 minutes and 
placed onto ice prior to loading on a 20% polyacrylamide gel (1.5X TBE, 20% 
acrylamide:bisacrylamide (39:1), 0.05% ammonium persulphate and 1% TEMED) with 
or without 2% (v/v) glycerol. The gels were electrophoresed in 1.5X TBE at 200 volts 
for 1-2 hours at 4°C or room temperature. After electrophoresis the gels were stained 
in 0.5 µg/ml ethidium bromide and photographed. 
Samples were also analysed on discontinous gels as follows: 1 OµI of PCR sample was 
added to 1 µI formamide loading buffer (section 6.15), denatured at 95°C for 5 
minutes, placed on ice and loaded onto a 2 phase discontinuous formamide gel. The 
lower phase or separating gel contained 6% acrylamide:bisacrylamide ( 49: 1 ), 0.5X 
TBE, 0.05% ammonium persulphate, 1 % TEMED, with or without 5% (v/v) glycerol. 
This was overlaid with isopropanol to allow polymerisation to proceed (30 minutes). 
The top phase or stacking gel contained 8% acrylamide:bisacrylamide (39: 1), 0.2X 
TBE, 75% formamide, 0.25% ammonium persulphate, I% TEMED, and was allowed 
to polymerise overnight. These gels were electrophoresed at 4°C or room temperature 
in 0.5X TBE at 200-300 volts for 1-2 hours, after which they were stained with 0.5 
µg/ml ethidium bromide and photographed. 
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6.12.5. Direct Sequencing of PCR Products 
PCR samples showing altered mobilities by SSCP analysis were sequenced directly 
using the USB PCR sequencing kit (Amersham) as recommended by the suppliers 
(United States Biochemical). Colon DNA was amplified as described in section 6.13.2. 
and an aliquot ( 15 µl) was first checked on a I% agarose gel prior to sequence analysis. 
After the sequencing reactions were completed, the samples were heated at 75°C for 2 
minutes, loaded on a 6% polyacrylamide gel. and electrophoresed in 1 X TBE buffer. 
6.13. CLONING OF PCR FRAGMENTS INTO pUC19 
6.13.1. Crush Soak Method for Obtaining PCR Fragments 
DNA fragments for cloning were amplified by PCR and electrophoresed on a 6% 
polyacrylamide gel. The bands of interest were excised from the gel and cut into small 
pieces which were transferred to a microfuge tube, to which an equal volume of DNA 
elution buffer (section 6.15) was added. The tube was incubated overnight at 37°C 
with gentle shaking, after which the buffer was removed and transferred to a fresh 
microfuge tube. An equal volume of phenol/chloroform/isoamyl alcohol (25 :24: 1) was 
added to the DNA solution, mixed well and centrifuged at 10 000 rpm for 5 minutes. 
The aqueous phase was removed and extracted with an equal volume of 
chloroform/isoamyl alcohol (24: 1 ). The solution was centrifuged at IO 000 rpm for 5 
minutes after which the aqueous phase was removed and the DNA precipitated 
overnight at -20°C by the addition of 0.1 volume of 3M Na acetate pH 5.5 and 3 
volumes of 96% ethanol. The DNA was pelleted by centrifugation at 10 000 rpm for 
30 minutes at 4°C, washed twice with 70% ethanol, dried and resuspended in I Oµl TE 
buffer (section 6.15). 
6.13.2. Cloning of PCR Products 
The gel-extracted PCR products were incubated at 37°C for 1 hour with T4 
polynucleotide kinase (I unit per µg of DNA) in buffer containing lmM ATP (section 
6.15) in a final volume of 20µ1. The enzyme was heat inactivated at 65°C for 10 
minutes. 
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20µ1 of phosphorylated DNA was incubated with 2 units Kienow fragment DNA 
polymerase in 1 X Kienow buffer in the absence of deoxynucleotide triphosphates 
(dNTP's) for 5 minutes at room temperature. dNTP's were then added to a final 
concentration of 2.5mM and incubated at room temperature for a further 30 minutes. 
The enzyme was heat inactivated at 65°C for 10 minutes and the PCR product 
electrophoresed on a 1 % low melting temperature agarose gel in IX T AE buffer. The 
DNA bands were excised from the gel and an in-gel ligation was performed with Smal 
digested and alkaline phosphatase treated pUCl 9 (section 6.3). The ligated products 
were transformed into E. coli DK-1 cells (section 6.14). Transformants were selected 
for ampicillin resistance and the plasmid DNA purified using the rapid plasmid prep 
procedure. Plasmid DNA was digested with restriction endonucleases to confirm the 
presence of the insert (section 6.3). Large scale plasmid DNA was prepared using the 
Qiagen Maxi Prep procedure. Inserts were confirmed by sequence analysis using the 
Pharmacia Sequencing Kit as per. manufacturers instructions. 
In order to prevent pUCl 9 from self-ligating (after enzymatic digestion with Smal), 
calf intestinal alkaline phosphatase (CIAP) was used to remove the available 
phosphates at the 5' ends. 1 unit of CIAP was added per pmol of blunt-ended DNA in 
CIAP buffer (section 6.15) and incubated at 50°C for 1 hour. To terminate the 
reaction, I/10th the volume of 500mM EGTA, pH 8.0 was added and the DNA was 
incubated at 65°C for 45 minutes. The enzyme was removed by 
phenol/chloroform/isoamyl alcohol extraction and the DNA precipitated at -70°C for 
30 minutes by the addition of 3 volumes 96% ethanol. The pellet was washed twice 
with 70% ethanol, dried for 5-10 minutes and resuspended in 1 X TE buffer. 
6.14 PREPARATION OF COMPETENT DK-1 CELLS AND TRANSFORMATION 
Competent E. Coli DK-1 cells were prepared by inoculating 10ml of Luria Broth 
(section 6.15) with 20µ1 of DK-I cells from a glycerol stock. The cells were grown 
overnight at 37°C with vigorous shaking. 1ml of this overnight culture was used to 
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inoculate 300ml of Luria Broth in a sterile 2 litre flask. The cells were grown with 
vigorous shaking at 37°C until the OD650 was between 0.2-0.4 (it· should not take 
longer than 3 hours). The cells were pelleted by centrifugation at 5000 rpm in a 
Beckman JA 10 rotor at 4°C. The cells were resuspended in 40ml of ice cold 60mM 
CaCl2, lOmM Pipes, pH 7.2, left on ice for 20 minutes, centrifuged at 5000 rpm for 10 
minutes at 4°C and resuspended in 4ml of 60mM CaCl2, lOmM Pipes, pH 7.2 
containing 15% glycerol. Cells were frozen in 200µ1 aliqouts in a dry ice-ethanol bath 
and stored at -70°C until further use. The transformation efficiency was usually 
between 106 and 107 transformants per microgram of DNA, using supercoiled 
pBR322 (Current Protocols in Molecular Biology). 
Aliquots of competent cells were thawed on ice and 100µ1 were transferred to 10ml 
falcon tubes. 5µ1 of the ligation mixture was added to the cells, incubated for a further 
30 minutes on ice and heat shocked at 42°C for 2-3 minutes. 1ml of prewarmed Luria 
Broth (37°C) was added and incubated for a further hour at 37°C. Aliquots of 20, 50 
and 100µ1 were plated onto agar plates containing 0.5 mg/ml ampicillin and incubated 
at 3 7°C overnight. 
The alkaline lysis procedure (Bimboim and Doly, 1979; Birnboim 1983) was used to 
prepare plasmid DNA for rapid analysis. I 0ml of Luria Broth was inoculated with a 
single bacterial colony and grown overnight at 37°C with shaking. The cells were 
pelleted at 2000 rpm for 10 minutes in a Beckman TJ-6 centrifuge at 4°C. The pellet 
was resuspended in 200µ1 RAPS solution-I (section 6.15), transferred to a microfuge 
tube and incubated for 5 minutes at room temperature. The bacteria were lysed by the 
addition of 400µ1 RAPS solution-2 (section 6.15) and placed on ice for 5 minutes. 
300µ1 RAPS solution-3 (section 6.15) was added and the cells were incubated on ice 
for 10 minutes. The cellular debris was pelleted by centrifugation for 5 minutes at 4°C 
(to remove the chromosomal DNA and bacterial membranes). The supernatant was 
transferred to a fresh tube, re-centrifuged, and transferred to another fresh tube to 
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which was added 600µ1 of ice cold isopropanol to allow the plasmid DNA to 
precipitate at -20°C for 1 hour. The plasmid DNA was recovered by centrifugation, 
washed in 70% ethanol, dried under vacuum for 10 minutes and resuspended in 80µ1 of 
IX TE buffer. The DNA was treated with Rnase A at a concentration of 1 mg/ml at 
3 7°C for 10 minutes and an aliquot electrophoresed on a 1 % agarose gel to ensure that 
the plasmid DNA was free of contaminating RNA. Restriction enzyme analysis 
confirmed the identity of the plasmid. 
6.15. BUFFERS AND SOLUTIONS 
30% ACRYLAMIDE STOCK SOLUTION (29:1) 
29% Acrylamide 
1 % Bisacrylamide 
40% ACRYLAMIDE STOCK SOLUTION (38:2) 
38% Acrylamide 
2% Bisacrylamide 
40% ACRYLAMIDE STOCK SOLUTION (39:1) 
39% Acrylamide 
1 % Bisacrylamide 
50% ACRYLAMIDE STOCK SOLUTION (49:1) 
49% Acrylamide 
1 % Bisacrylamide 
CHROMIC ACID 
100, g K)Cr207 
250 ml H2S04 made up to 1 litre with H20 
lOX CIAP BUFFER 
3 MNaCI 
30 mM Triethanolamine (pH 7.6) 
100 mM MgCl2 . 
100 mMZnCl2 
lOOX DENHARDTS SOLUTION 
2% (w/v)BSA 
2% (w/v) Ficoll 
2% (w/v) Polyvinylpyrolidone (PVP) 
DEPC TREATED H20 
Add DEPC to 0.1% (v/v), stir at room temperature and autoclave 
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IN SITU HYBRIDISATION BUFFER B 
100 mM Tris-Cl (pH 7.5) 
150 mMNaCl 
IN SITU HYBRIDISATION BUFFER C 
100 mM Tris-Cl (pH 9.5) 
50 mMMgCl2 
100 mMNaCI 
IN SITU HYBRIDISATION BUFFER D 
10 mM Tris-Cl (pH 8.0) 
1 mMEDTA 
IN SITU HYBRIDISATION MIXTURE 
0.25% Dextran Sulphate 
12.5 mM Tris-Cl (pH 8.0) 
12.5X Denhardts Solution 
1.25 mM EDTA 
12.5 mM DTT 
2.5X SSC 
0.005 mg/ml Herring Sperm DNA 
0.005 mg/ml tRNA 
IN SITU PRE-HYBRIDISATION MIXTURE 
0.25% Dextran Sulphate 
25mM Tris-Cl (pH 8.0) 
25X Denhardts Solution 
2.5 mMEDTA 
25 mMDTT 
1.25 mg/ml Herring Sperm DNA 
0.125 mg/ml tRNA 
lOX KLENOW BUFFER 
100 mM Tris-Cl (pH 7.5) 
100 mMMgCl2 
500 mMNaCI 
lOmMDTE 
123 
LURIA AGAR 
10 g/1 Tryptone 
5 g/l Yeast Extract 
5 g/1 NaCl 
15 g/1 Agar 
LURIA BROTH 
IO g/l Tryptone 
5 g/1 Yeast Extract 
5 g/1 NaCl 
NORTHERN BLOT PRE-HYBRIDISATION MIXTURE 
· I 0% Dextran Sulphate 
5X SSC 
50 mM Sodium Pyrophosphate 
5X Denhardts Solution 
50% Formarnide 
0.1. mg/ml Herring Sperm DNA 
0.1% SDS 
PHOSPHATE BUFFERED SALINE 
137 mMNaCI 
2.7 mMKCL 
4.3 mM Na2HP04.7H20 (pH 7.4) 
1.4 mM KH2P04 
RAPS SOLUTION 1 
25 mM Tris-Cl (pH 8.0) 
lOmMEDTA 
50 mM Glucose 
RAPS SOLUTION 2 
200 mMNaOH 
1% SDS 
RAPS SOLUTION 3 
3M Potassium Acetate (pH 4.8) 
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RNA LOADING BUFFER 
IX RNA Running Buffer 
· 45% Deionised Formamide 
6% Formaldehyde 
IX Formaldehyde loading buffer 
lOX RNA RUNNING BUFFER 
41.8g MOPS to 800ml water (pH 7.0) 
16.6rn1 3M Sodium Acetate (pH 5.5) 
20ml o.·5 M EDTA (pH 8.0) 
Make up to 1 litre with water 
SX SDS RUNNING BUFFER 
250 mM Tris-Cl (pH 8.3) 
1. 92 M Glycine 
0.5% SDS 
SOLUTIOND 
· 4.2 M Guanidine (Thiocyanate Salt) 
0.03 M Sodium Citrate (pH 7.0) 
0.5% Sarcosyl 
360µ12-Mercaptoethanol (14. IM) is added per 50ml solution D 
20X SSC 
3 MNaCI 
300 mM Sodium Citrate 
1 OX TAE BUFFER 
40 mM Tris-Acetate (pH 7.8) 
5 mM Sodium Acetate 
1 mMEDTA 
lOX TBE BUFFER 
90 mM Tris-Borate (pH 8.0) 
90 mM Boric Acid 
2.5mMEDTA 
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lOX TE BUFFER 
100 mM Tris-Cl (pH 8.0) 
IOmMEDTA 
lOX TRANSCRIPTION BUFFER 
400 mM Tris-Cl (pH 8.0) 
60 mMMgCl2 
100 mM OTT 
20 mM Spermidine 
100 mMNaCl 
2X TREATMENT BUFFER 
0.125 M Tris-Cl (pH 6.8) 
4%SDS 
20% Glycerol 
5 mMEDTA 
10% 2-Mercaptoethanol 
lOX T4 POLYNUCLEOTIDE KINASE BUFFER 
500 mM Tris-Cl (pH 7.5) 
lOOmMMgCl2 
50mMDTT 
0.5 mg/ml BSA 
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APPENDIX A 
CLONING FRAGMENTS OF THE al(I) AND a2(I) COLLAGEN GENES INTO THE 
VECTOR pGEM3 AS RIBOPROBES FOR IN SITU HYBRIDISATION 
THE al(I) COLLAGEN FRAGMENT 
The vector pGEM3 was digested with restriction enzymes EcoRI and Sall and the plasmid 
Hf677, which contains the full length a.1(1) collagen cDNA, was digested with EcoRI and 
Xhol (producing a fragment size of 581 base pairs). This fragment was eluted from a 1% 
low melting agarose gel, electrophoresed in IX T AE, along with pGEM3, and cloned by 
means of in gel ligation. pGEM3 containing the a. I (I) collagen fragment was terrned 
pGEMa.1. A schematic diagram of the cloning is illustrated on page . For the purpose of 
in situ hybridisation, pGEMa.1 was digested with the restriction enzymes Pvull and BstXI, 
producing a 319 base pair fragment.. This fragment was electrophoresed on a 1 % low 
melting agarose gel and eluted from the gel using Qiaex as per the manufacturers 
instructions, 40 units T7 RNA polymerase was then used to transcribe antisense 
digoxigenin-labelled RNA. 
5' 
Xbal 
3' 
160bp Sacl 
pGEMa2 
3027bp 
Hf32 
6500bp 
1 
+ 
l 
pGEM3 
2867bp 
5' 
I 
Hind Ill 
'1:1 
C 
:. 
140bp 
142 
3' 
~ 
Pvull 
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THE a2(1) COLLAGEN FRAGMENT 
The vector pGEM3 as well as the plasmid Hf322 (which contains the full length a.2(I) 
collagen cDNA) were subjected to restriction analysis using the enzymes Xbal and Sac!. 
Upon digestion, these enzymes produced a 160 base pair fragment from Hf322 which was 
cloned into pGEM3 and termed pGEMa.2. A schematic diagram of the cloning strategy is 
shown on page . For the purposes of in situ hybridisation, pGEMa.2 was digested with 
restriction enzymes Pvull and Hindlll, producing a 140 base pair fragment. This fragment 
after elution and Qiaex was used to transcribe antisense digoxigenin-labelled RNA with T7 
RNA polymerase. 
3' 
I 
EcoRI 
581bp 
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Xhol 
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